{
 "cells": [
  {
   "cell_type": "markdown",
   "id": "e01b7f60",
   "metadata": {
    "slideshow": {
     "slide_type": "slide"
    }
   },
   "source": [
    "# Data preprocessing"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "id": "1b8c71dd",
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "[nltk_data] Downloading package stopwords to\n",
      "[nltk_data]     /Users/luzemok/nltk_data...\n",
      "[nltk_data]   Package stopwords is already up-to-date!\n",
      "[nltk_data] Downloading package vader_lexicon to\n",
      "[nltk_data]     /Users/luzemok/nltk_data...\n",
      "[nltk_data]   Package vader_lexicon is already up-to-date!\n"
     ]
    },
    {
     "data": {
      "text/plain": [
       "True"
      ]
     },
     "execution_count": 3,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "# Import packages\n",
    "import pandas as pd\n",
    "from datetime import datetime\n",
    "from datetime import date\n",
    "import xlrd\n",
    "import numpy as np\n",
    "import re\n",
    "import nltk\n",
    "nltk.download('stopwords')\n",
    "nltk.download('vader_lexicon')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 2,
   "id": "fccabb30",
   "metadata": {},
   "outputs": [],
   "source": [
    "CONTRACTION_MAP = {\n",
    "\"ain't\": \"is not\",\n",
    "\"aren't\": \"are not\",\n",
    "\"can't\": \"cannot\",\n",
    "\"can't've\": \"cannot have\",\n",
    "\"'cause\": \"because\",\n",
    "\"could've\": \"could have\",\n",
    "\"couldn't\": \"could not\",\n",
    "\"couldn't've\": \"could not have\",\n",
    "\"didn't\": \"did not\",\n",
    "\"doesn't\": \"does not\",\n",
    "\"don't\": \"do not\",\n",
    "\"hadn't\": \"had not\",\n",
    "\"hadn't've\": \"had not have\",\n",
    "\"hasn't\": \"has not\",\n",
    "\"haven't\": \"have not\",\n",
    "\"he'd\": \"he would\",\n",
    "\"he'd've\": \"he would have\",\n",
    "\"he'll\": \"he will\",\n",
    "\"he'll've\": \"he will have\",\n",
    "\"he's\": \"he is\",\n",
    "\"how'd\": \"how did\",\n",
    "\"how'd'y\": \"how do you\",\n",
    "\"how'll\": \"how will\",\n",
    "\"how's\": \"how is\",\n",
    "\"I'd\": \"I would\",\n",
    "\"I'd've\": \"I would have\",\n",
    "\"I'll\": \"I will\",\n",
    "\"I'll've\": \"I will have\",\n",
    "\"I'm\": \"I am\",\n",
    "\"I've\": \"I have\",\n",
    "\"i'd\": \"i would\",\n",
    "\"i'd've\": \"i would have\",\n",
    "\"i'll\": \"i will\",\n",
    "\"i'll've\": \"i will have\",\n",
    "\"i'm\": \"i am\",\n",
    "\"i've\": \"i have\",\n",
    "\"isn't\": \"is not\",\n",
    "\"it'd\": \"it would\",\n",
    "\"it'd've\": \"it would have\",\n",
    "\"it'll\": \"it will\",\n",
    "\"it'll've\": \"it will have\",\n",
    "\"it's\": \"it is\",\n",
    "\"let's\": \"let us\",\n",
    "\"ma'am\": \"madam\",\n",
    "\"mayn't\": \"may not\",\n",
    "\"might've\": \"might have\",\n",
    "\"mightn't\": \"might not\",\n",
    "\"mightn't've\": \"might not have\",\n",
    "\"must've\": \"must have\",\n",
    "\"mustn't\": \"must not\",\n",
    "\"mustn't've\": \"must not have\",\n",
    "\"needn't\": \"need not\",\n",
    "\"needn't've\": \"need not have\",\n",
    "\"o'clock\": \"of the clock\",\n",
    "\"oughtn't\": \"ought not\",\n",
    "\"oughtn't've\": \"ought not have\",\n",
    "\"shan't\": \"shall not\",\n",
    "\"sha'n't\": \"shall not\",\n",
    "\"shan't've\": \"shall not have\",\n",
    "\"she'd\": \"she would\",\n",
    "\"she'd've\": \"she would have\",\n",
    "\"she'll\": \"she will\",\n",
    "\"she'll've\": \"she will have\",\n",
    "\"she's\": \"she is\",\n",
    "\"should've\": \"should have\",\n",
    "\"shouldn't\": \"should not\",\n",
    "\"shouldn't've\": \"should not have\",\n",
    "\"so've\": \"so have\",\n",
    "\"so's\": \"so as\",\n",
    "\"that'd\": \"that would\",\n",
    "\"that'd've\": \"that would have\",\n",
    "\"that's\": \"that is\",\n",
    "\"there'd\": \"there would\",\n",
    "\"there'd've\": \"there would have\",\n",
    "\"there's\": \"there is\",\n",
    "\"they'd\": \"they would\",\n",
    "\"they'd've\": \"they would have\",\n",
    "\"they'll\": \"they will\",\n",
    "\"they'll've\": \"they will have\",\n",
    "\"they're\": \"they are\",\n",
    "\"they've\": \"they have\",\n",
    "\"to've\": \"to have\",\n",
    "\"wasn't\": \"was not\",\n",
    "\"we'd\": \"we would\",\n",
    "\"we'd've\": \"we would have\",\n",
    "\"we'll\": \"we will\",\n",
    "\"we'll've\": \"we will have\",\n",
    "\"we're\": \"we are\",\n",
    "\"we've\": \"we have\",\n",
    "\"weren't\": \"were not\",\n",
    "\"what'll\": \"what will\",\n",
    "\"what'll've\": \"what will have\",\n",
    "\"what're\": \"what are\",\n",
    "\"what's\": \"what is\",\n",
    "\"what've\": \"what have\",\n",
    "\"when's\": \"when is\",\n",
    "\"when've\": \"when have\",\n",
    "\"where'd\": \"where did\",\n",
    "\"where's\": \"where is\",\n",
    "\"where've\": \"where have\",\n",
    "\"who'll\": \"who will\",\n",
    "\"who'll've\": \"who will have\",\n",
    "\"who's\": \"who is\",\n",
    "\"who've\": \"who have\",\n",
    "\"why's\": \"why is\",\n",
    "\"why've\": \"why have\",\n",
    "\"will've\": \"will have\",\n",
    "\"won't\": \"will not\",\n",
    "\"won't've\": \"will not have\",\n",
    "\"would've\": \"would have\",\n",
    "\"wouldn't\": \"would not\",\n",
    "\"wouldn't've\": \"would not have\",\n",
    "\"y'all\": \"you all\",\n",
    "\"y'all'd\": \"you all would\",\n",
    "\"y'all'd've\": \"you all would have\",\n",
    "\"y'all're\": \"you all are\",\n",
    "\"y'all've\": \"you all have\",\n",
    "\"you'd\": \"you would\",\n",
    "\"you'd've\": \"you would have\",\n",
    "\"you'll\": \"you will\",\n",
    "\"you'll've\": \"you will have\",\n",
    "\"you're\": \"you are\",\n",
    "\"you've\": \"you have\"\n",
    "}\n",
    "\n",
    "CONTRACTION_MAP = dict((k.lower(),v.lower()) for k,v in CONTRACTION_MAP.items())"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 19,
   "id": "5b54f321",
   "metadata": {
    "slideshow": {
     "slide_type": "slide"
    }
   },
   "outputs": [],
   "source": [
    "import pdfplumber\n",
    "import re\n",
    "\n",
    "def generate_call_content(file_path):\n",
    "    pdf = pdfplumber.open(file_path)\n",
    "\n",
    "    text_list = []\n",
    "    for page in pdf.pages:\n",
    "        cropped = page.crop((0.12*page.width, 0.08*page.height, 0.9*page.width, 0.9*page.height))\n",
    "        text = cropped.extract_text().split('\\n')\n",
    "        for line in text:\n",
    "            if line.startswith('This transcript may not be 100 percent accurate'):\n",
    "                disclaimer = line\n",
    "                index = text.index(disclaimer)\n",
    "                text = text[:index]\n",
    "            else:\n",
    "                text = text\n",
    "\n",
    "        text_list.extend(text)\n",
    "\n",
    "    call_content = ' '.join(text_list)\n",
    "    pdf.close()\n",
    "    \n",
    "    return call_content\n",
    "\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "a844e721",
   "metadata": {
    "scrolled": false,
    "slideshow": {
     "slide_type": "slide"
    }
   },
   "outputs": [],
   "source": [
    "file_path = ['/Users/luzemok/Desktop/Data_Bloomberg/AstraZeneca/20220419_AstraZeneca_PLC-_2018-5-18_SD000000002874132112.pdf',\n",
    "            '/Users/luzemok/Desktop/Data_Bloomberg/Ashtead Group/20220419_Ashtead_Group_PLC-_2017-9-12_SD000000002865840988.pdf',\n",
    "            '/Users/luzemok/Desktop/Data_Bloomberg/Barclays/SD000000002872194039.pdf',\n",
    "            '/Users/luzemok/Desktop/Data_Bloomberg/BP/20220419_BP_PLC-_2018-5-1_SD000000002872768301.pdf',\n",
    "            '/Users/luzemok/Desktop/Data_Bloomberg/BTA/BT Group PLC Earnings Call 2017728 SD000000002903981916.pdf',\n",
    "            '/Users/luzemok/Desktop/Data_Bloomberg/Dutch Shell/20220419_Shell_PLC-_2018-4-26_SD000000002872194459.pdf',\n",
    "            '/Users/luzemok/Desktop/Data_Bloomberg/GSK/GlaxoSmithKline PLC Earnings Call 2018425 SD000000002905307487.pdf',\n",
    "            '/Users/luzemok/Desktop/Data_Bloomberg/HSBC/HSBC Holdings PLC Earnings Call 201854 DN000000002424936894.pdf',\n",
    "            '/Users/luzemok/Desktop/Data_Bloomberg/IAG/20220419_INTL_CONS_AIRLIN-_2018-5-4_SD000000002872781361.pdf',\n",
    "            '/Users/luzemok/Desktop/Data_Bloomberg/IMB/Imperial Brands PLC Earnings Call 201859 SD000000002905331812.pdf',\n",
    "            '/Users/luzemok/Desktop/Data_Bloomberg/Lloyds/20220419_LLOYDS_BANKING-_2018-4-25_SD000000002902660182.pdf',\n",
    "            '/Users/luzemok/Desktop/Data_Bloomberg/Natwest/NatWest Group PLC Guidance Call 2018427 SD000000002905311087.pdf',\n",
    "            '/Users/luzemok/Desktop/Data_Bloomberg/RRS/RANDGOLD RES LTD Earnings Call 2018510 SD000000002874123247.pdf',\n",
    "            '/Users/luzemok/Desktop/Data_Bloomberg/SKY(till2018)/20220419_Sky_Ltd-_2017-10-12_SD000000002866592237.pdf',\n",
    "            '/Users/luzemok/Desktop/Data_Bloomberg/SHP/Shire.pdf',\n",
    "            '/Users/luzemok/Desktop/Data_Bloomberg/SN/SN.pdf',\n",
    "            '/Users/luzemok/Desktop/Data_Bloomberg/TUI/TUI AG Earnings Call 2018213 DN000000002398709321.pdf',\n",
    "            '/Users/luzemok/Desktop/Data_Bloomberg/ENDEAVOUR MINING Earnings Call 2018515 SD000000002874126402.pdf']\n",
    "\n",
    "data = generate_call_content(file_path[0])\n",
    "data1 = generate_call_content(file_path[1])\n",
    "data2 = generate_call_content(file_path[2])\n",
    "data3 = generate_call_content(file_path[3])\n",
    "data4 = generate_call_content(file_path[4])\n",
    "data5 = generate_call_content(file_path[5])\n",
    "data6 = generate_call_content(file_path[6])\n",
    "data7 = generate_call_content(file_path[7])\n",
    "data8 = generate_call_content(file_path[8])\n",
    "data9 = generate_call_content(file_path[9])\n",
    "data10 = generate_call_content(file_path[10])\n",
    "data11 = generate_call_content(file_path[11])\n",
    "data12 = generate_call_content(file_path[12])\n",
    "data13 = generate_call_content(file_path[13])\n",
    "data14 = generate_call_content(file_path[14])\n",
    "data15 = generate_call_content(file_path[15])\n",
    "data16 = generate_call_content(file_path[16])\n",
    "data17 = generate_call_content(file_path[17])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 9,
   "id": "037c436a",
   "metadata": {
    "slideshow": {
     "slide_type": "slide"
    }
   },
   "outputs": [],
   "source": [
    "from collections import defaultdict\n",
    "import itertools\n",
    "import pandas as pd\n",
    "pd.set_option('display.max_colwidth', 400)\n",
    "\n",
    "def simple_clean(data):\n",
    "    data = data.replace('$', '')\n",
    "    data = re.sub('\\s(A|Q)\\s\\-','', data)\n",
    "    return data\n",
    "\n",
    "def remove_punctuation(text):\n",
    "    text = text.lower().strip().split(' ')\n",
    "    text = [word[:-1] if word.endswith(',') or word.endswith('.') else word for word in text]\n",
    "    text = [CONTRACTION_MAP[word].split(' ') if word in CONTRACTION_MAP.keys() else word for word in text]\n",
    "\n",
    "    new_text = []\n",
    "    for item in text:\n",
    "        if isinstance(item, list):\n",
    "            new_text.extend(item)\n",
    "        else:\n",
    "            new_text.append(item)\n",
    "    return ' '.join(new_text)\n",
    "\n",
    "\n",
    "def get_speaker_content(data):\n",
    "    data = simple_clean(data)\n",
    "    management = re.findall('(?<=Company\\sParticipants)(.*)(?=Other\\sParticipants)', data)[0]\n",
    "    speakers = re.findall(\"((\\w+\\s\\w+|\\w+)\\s\\{\\w+\\s\\d+\\s<\\w+>\\})\", data)\n",
    "    iterator = re.finditer(\"((\\w+\\s\\w+|\\w+)\\s\\{\\w+\\s\\d+\\s<\\w+>\\})\", data)\n",
    "    indices = [m.start(0) for m in iterator]\n",
    "    \n",
    "    info = defaultdict(list)\n",
    "\n",
    "    for i in range(len(indices)):\n",
    "\n",
    "        if i != len(indices)-1:\n",
    "            content = data[indices[i]:indices[i+1]]\n",
    "            speaker_bio = re.findall(\"((\\w+\\s\\w+|\\w+)\\s\\{\\w+\\s\\d+\\s<\\w+>\\})\", content)[0]\n",
    "            content = content[len(speaker_bio[0]):]\n",
    "            speaker = speaker_bio[1]\n",
    "            if management.find(speaker) != -1:\n",
    "                position = 'management'\n",
    "            else:\n",
    "                position = 'analyst'\n",
    "        else:\n",
    "            content = data[indices[i]:]\n",
    "            speaker_bio = re.findall(\"((\\w+\\s\\w+|\\w+)\\s\\{\\w+\\s\\d+\\s<\\w+>\\})\", content)[0]\n",
    "            content = content[len(speaker_bio[0]):]\n",
    "            speaker = speaker_bio[1]\n",
    "            if management.find(speaker) != -1:\n",
    "                position = 'management'\n",
    "            else:\n",
    "                position = 'analyst'\n",
    "        info['speaker'].append(speaker)\n",
    "        info['position'].append(position)\n",
    "        info['content'].append(content)\n",
    "    \n",
    "    df = pd.DataFrame(info)\n",
    "    df['content'] = df['content'].apply(remove_punctuation)\n",
    "\n",
    "    return df"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 36,
   "id": "b7287b85",
   "metadata": {
    "scrolled": false
   },
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>speaker</th>\n",
       "      <th>position</th>\n",
       "      <th>content</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>Pascal Soriot</td>\n",
       "      <td>management</td>\n",
       "      <td>hello everyone it is pascal soriot here ceo of astrazeneca welcome to our first quarter results conference call and webcast for investors and analysts we are here in london on a very beautiful day for the annual general meeting this afternoon we have people on the phone and on the webcast the presentation is available to you on astrazeneca.com as always for you to download please turn to slide...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>David Fredrickson</td>\n",
       "      <td>management</td>\n",
       "      <td>great thank you so much pascal and i am really pleased here to be here to update all of you on the performance of our new generation of medicines i will start ﬁrst with oncology and then i will hand it over to mark mallon for a summary of cvrm respiratory and emerging markets if we could turn please to page 12 we are really pleased to announce that total oncology grew by 33% quarter-over-quart...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>Mark Mallon</td>\n",
       "      <td>management</td>\n",
       "      <td>thanks dave now moving to new cvrm which as pascal mentioned is deﬁned as our medicines in cardiovascular renal and metabolic diseases sales were up by 8% despite the intense competition with first quarter sales at 900 million farxiga and brilinta continued to remain strong with double-digit growth across all regions brilinta sales of 293 million with 24% growth driven by the u.s at 32% and em...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>Marc Dunoyer</td>\n",
       "      <td>management</td>\n",
       "      <td>thank you mark and hello everyone i am going to spend the next few minutes taking you through our ﬁnancial performance in the first quarter of the year as well as our unchanged guidance please turn to slide 22 as usual i will begin with the reported p&amp;l before turning to the core numbers as pascal mentioned earlier product sales declined by 2% impacted by the reduced sales of crestor in europe...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>Sean Bohen</td>\n",
       "      <td>management</td>\n",
       "      <td>thank you marc i would now like to run through the late-stage pipeline events since the last results announcement and the highlights of recent data presentations at medical meetings and as usual i will ﬁnish with a look at our upcoming news ﬂow please turn to slide 28 we delivered more good progress in the quarter in oncology lynparza received eu approval for a broad second-line ovarian cancer...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5</th>\n",
       "      <td>Pascal Soriot</td>\n",
       "      <td>management</td>\n",
       "      <td>thank you sean please turn to slide 33 now let me summarize before we end we are really pleased with the ongoing launches and the performance of our newer medicines during the first quarter as they underpin the guidance of growth in product sales in 2018 our ﬁnancials are on track with our performance being weighted towards the second half of the year and with product sales leading the way tot...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6</th>\n",
       "      <td>Pascal Soriot</td>\n",
       "      <td>management</td>\n",
       "      <td>so we have a question here from simon baker at exane simon go ahead simon p</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>7</th>\n",
       "      <td>Baker</td>\n",
       "      <td>analyst</td>\n",
       "      <td>one for sean please if i may we can see from the press release this morning the expanding and evolving parp io combination trials that you are conducting but i was just wondering how much further there is to expand that i am thinking areas like colorectal where there is been some interesting work published this year on the potential applicability of parp in that indication and also therefore p...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>8</th>\n",
       "      <td>Sean Bohen</td>\n",
       "      <td>management</td>\n",
       "      <td>okay so let me -- sort of 2 questions there one is the expansion of i am going to call lynparza io so lynparza imﬁnzi or imﬁnzi plus treme so when we shared our ovarian cancer data we also shared that we have -- we are initiating a trial called duo-o which is looking at that combination speciﬁcally in ovarian cancer then we are looking at other data sets to see where we might expand beyond tha...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9</th>\n",
       "      <td>Pascal Soriot</td>\n",
       "      <td>management</td>\n",
       "      <td>thank you sean there is a question on the webcast that we will read aloud from vincent meunier at morgan stanley so he is trying to understand the potential of tagrisso initiative that were before you and the question is are there countries where the prevalence of the egfr mutations is higher than other countries? what about japan? and also in china what is the breakdown of volumes sales that ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>10</th>\n",
       "      <td>David Fredrickson</td>\n",
       "      <td>management</td>\n",
       "      <td>so thank you for the question so yes there are countries where the prevalence is higher and in asian countries it tends to be the highest around the globe prevalence rates in countries we see it around 30% even as much as 35% japan china korea this would all be the case for those countries as you look through that on the second question in terms of the breakdown of volumes and sales in china t...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>11</th>\n",
       "      <td>Pascal Soriot</td>\n",
       "      <td>management</td>\n",
       "      <td>thank you dave then there is a question from tim anderson at bernstein tim go ahead timothy</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>12</th>\n",
       "      <td>Minton Anderson</td>\n",
       "      <td>analyst</td>\n",
       "      <td>emerging markets and china are a big part of your business and in china your proportion of total sales coming from that region is much higher than peers i usually thought of emerging markets exposure as a good thing but you could argue it is the other way around because proﬁt levels are less markets like china you may get volatility tied to price cuts so with astra investors generally look for...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>13</th>\n",
       "      <td>Pascal Soriot</td>\n",
       "      <td>management</td>\n",
       "      <td>let me just cover the second question tim then mark mallon you might want to cover the china question the second is very simple and straightforward tim we were not approached did not talk to michael cohen so we are totally out of this discussion china mark?</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>14</th>\n",
       "      <td>Mark Mallon</td>\n",
       "      <td>management</td>\n",
       "      <td>so we deﬁnitely see china as a positive and to have such a strong position in there and we see continued growth and future potential of course every country around the globe is wrestling with health care costs and as we have seen in the last week in the u.s. there is risks around pricing actions and i do not think china represents particularly more or less risk than any other countries in fact...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>15</th>\n",
       "      <td>Matthew Weston</td>\n",
       "      <td>analyst</td>\n",
       "      <td>pascal my question's on the cost base really higher sg&amp;a has been one of the key discussion points this morning with investors mark mentioned the low base eﬀects but also the guidance range of low; to mid-single-digit growth is a large window so can you just give us some of the drivers of that range? is it competitors potentially reacting in respiratory that you may need to react to? it does n...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>16</th>\n",
       "      <td>Pascal Soriot</td>\n",
       "      <td>management</td>\n",
       "      <td>yes i mean let me try and mark mallon and marc dunoyer you could also help me but just in terms of the new launches i mean we have talked about quite a number of new launches tagrisso et cetera et cetera for sure now in the second half i think you have got to think of roxa and lokelma but they are like more in the prelaunch mode if you will including in the u.s. lokelma after we get approval w...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>17</th>\n",
       "      <td>Marc Dunoyer</td>\n",
       "      <td>management</td>\n",
       "      <td>no i think we are -- just one word we are obviously launching 8 -- in total 8 new medicine line extensions or new formulation and obviously we are -- this is very -- an important timing for the ﬁnal trajectory so we are closely monitoring the performance of these brands as they are being launched and this is why we try to allocate as much resources as we can dedicate to ensure the ﬁnal success...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>18</th>\n",
       "      <td>Mark Mallon</td>\n",
       "      <td>management</td>\n",
       "      <td>i will just add one (point) again is china and china to your point we have great scope and scale but we still have so much more to penetrate and so we have to continuously -- we are continuously expanding into new hospitals and customers and even cities and also we are doing multiple new launches in china so it is not just the established portfolio we have got many launches occurring at the sa...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>19</th>\n",
       "      <td>Pascal Soriot</td>\n",
       "      <td>management</td>\n",
       "      <td>so as you can hear we are -- yes go ahead matt</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>20</th>\n",
       "      <td>Matthew Weston</td>\n",
       "      <td>analyst</td>\n",
       "      <td>if i could just ask one quick follow-up so i have no question regarding the increased spending in sg&amp;a because clearly you are in full launch mode i understand that everything that everybody seems to have referred to in your answer is events that are known to you or very highly likely to happen with the exception of really declare and roxa my question was really about what about the 5percentag...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>21</th>\n",
       "      <td>Marc Dunoyer</td>\n",
       "      <td>management</td>\n",
       "      <td>matt ﬁrst of all we provide guidance on product sales and eps so these are the 2 variables we obviously closely look at there are obviously several lines in the p&amp;l between product sales and eps but you need to remember we have provided guidance on these 2 and we will be doing our best to meet or exceed this guidance for the year</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>22</th>\n",
       "      <td>Pascal Soriot</td>\n",
       "      <td>management</td>\n",
       "      <td>so we committed to the guidance and in fact the variation matt is really based on what opportunities we see i mean we see a new opportunity somewhere that could drive additional sales and proﬁt and we ﬂex at that point but essentially as marc said we will stick to the guidance so we can move maybe -- maybe the last point i was going to make earlier is that you can see we are in a -- and as you...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>23</th>\n",
       "      <td>Marc Dunoyer</td>\n",
       "      <td>management</td>\n",
       "      <td>so the 5 point reduction is obviously a reduction from quarter one 2017 quarter one 2018 and roughly the 4 factors that have been proposed are more or less equivalent to explain the diﬀerence so the buildout of the biologic manufacturing the lower absorption because we are early in the launch this is about 1/4 of it mix eﬀect on products such as crestor this is another 1/4 of this variance the...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>24</th>\n",
       "      <td>Pascal Soriot</td>\n",
       "      <td>management</td>\n",
       "      <td>thank you marc as far as the capacity build we are kind of almost done with this we are completing our ﬁlling plant in sweden but in terms of manufacturing product substance we are done and then we will start using that capacity over time so we now have a question from andrew baum at citi andrew go ahead andrew</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>25</th>\n",
       "      <td>Simon Baum</td>\n",
       "      <td>analyst</td>\n",
       "      <td>so i suspect astra has received the request for information from the hss following the drug pricing announced could you give us a sense of how much follow-through to expect in relation to this announcement particularly the conversations about removing the protective class? and i am thinking of categories such as parp and maybe just then a quick one for sean could you just outline your plans fo...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>26</th>\n",
       "      <td>Pascal Soriot</td>\n",
       "      <td>management</td>\n",
       "      <td>2 great questions i must say the line was breaking up the second question is clear for sure and the ﬁrst one hopefully mark you got that one okay?</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>27</th>\n",
       "      <td>Mark Mallon</td>\n",
       "      <td>management</td>\n",
       "      <td>yes what i heard andrew and if i am oﬀ track please correct me but you asked about did we get a request to provide information as part of the drug pricing plans that the administration are working on and how much do we expect that to come through the system i think as you know and we all know i mean there were a lot of i think over 50 potential actions highlighted in the administration's plan ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>28</th>\n",
       "      <td>Pascal Soriot</td>\n",
       "      <td>management</td>\n",
       "      <td>yes yes so i mean we have been very successful with some of the outcome-based pricing contracts we have implemented and if we could expand on those as part of a broader policy that the administration would want to put in place i think it would really be very welcomed by us and i am sure by many other companies sean do you want to cover the akt question?</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>29</th>\n",
       "      <td>Sean Bohen</td>\n",
       "      <td>management</td>\n",
       "      <td>sure sure thank you for the question andrew so the question relates to the phase ii data that (you've seen the abstract and) we will present it in more detail at the asco meeting capivasertib our akt inhibitor in triple negative breast cancer metastatic breast cancer we think the data's encouraging we think it is pretty strong indication of activity of the akt pathway in triple negative breast...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>30</th>\n",
       "      <td>Pascal Soriot</td>\n",
       "      <td>management</td>\n",
       "      <td>thank you sean as you can see more to come on this one but certainly very exciting early data with this new agent coming out of cambridge research team so really really good new development we will extend the (tc) by about 10 minutes so that we give everybody a chance to ask a question and the next one on the list here is sachin jain at bank of america sachin go ahead on lynparza similar to th...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>31</th>\n",
       "      <td>Sean Bohen</td>\n",
       "      <td>management</td>\n",
       "      <td>okay so i think -- sachin let me clarify your -- in this case you are referring speciﬁcally the study 8 data in prostate cancer when you say in combination for..</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>32</th>\n",
       "      <td>Sachin Jain</td>\n",
       "      <td>analyst</td>\n",
       "      <td>correct</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>33</th>\n",
       "      <td>Sean Bohen</td>\n",
       "      <td>management</td>\n",
       "      <td>okay okay great well i think the -- i mean i think the answer is not dissimilar to the answer i gave for andrew's question with regard to capivasertib again we do -- we ﬁnd that data encouraging from study 8 again the question is really whether there is a regulatory pathway to bring that forward and that is a discussion with regulators in order to decide whether or not we are going to do that ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>34</th>\n",
       "      <td>Pascal Soriot</td>\n",
       "      <td>management</td>\n",
       "      <td>excellent so there is a question on the webcast by sam fazeli at bloomberg and the question is can you explain the reasoning behind starting pacific 2? so sort of the pacific program sean do you want to cover that?</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>35</th>\n",
       "      <td>Sean Bohen</td>\n",
       "      <td>management</td>\n",
       "      <td>yes sure yes the rationale behind pacific 2 really has to do with the fact that while concurrent administration of chemotherapy and radiation therapy are the well-established standard of care in the united states and europe there are many parts of the world where concurrent is not the standard of care and a lot of that has to do with the challenges of coordinating that radiation therapy and ch...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>36</th>\n",
       "      <td>Pascal Soriot</td>\n",
       "      <td>management</td>\n",
       "      <td>thank you sean i think we have -- maybe we will take another 2 so we have one question</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>37</th>\n",
       "      <td>Alex Arfaei</td>\n",
       "      <td>analyst</td>\n",
       "      <td>great well just looking at your operating margin here i fully appreciate the headwinds you are facing with the patent expirations and the investments the maximum pressure points on launches et cetera but as you step back and look at your business how realistic is it for investors to expect that once things normalize you should have an operating margin that is more in line with your european an...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>38</th>\n",
       "      <td>Pascal Soriot</td>\n",
       "      <td>management</td>\n",
       "      <td>okay so the second question will be -- dave you could take and in the ﬁrst question is about margins when you look at our peers you really have to be careful who you look at because some companies have such a very focused business around say specialty care and sometimes it is even beyond that specialty care u.s with a little bit of european presence so the margins of course reﬂect a little bit...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>39</th>\n",
       "      <td>David Fredrickson</td>\n",
       "      <td>management</td>\n",
       "      <td>yes so on the ﬁrst question of the uptake that we have been seeing with imﬁnzi in stage iii unresectable as i mentioned earlier the lion's share in fact the overwhelming majority of our sales in the first quarter came from that population as you saw earlier in one of the slides from pascal you can see the demand increasing with imﬁnzi within this population we had an estimated 3,500 monthly in...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>40</th>\n",
       "      <td>Pascal Soriot</td>\n",
       "      <td>management</td>\n",
       "      <td>sorry did you want to..</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>41</th>\n",
       "      <td>Sean Bohen</td>\n",
       "      <td>management</td>\n",
       "      <td>yes i believe if i heard you right alex there was a question as well around resectable disease and obviously that is not the indication so that is not something we track i just want to point out that we do have an adjuvant study ongoing which studies that question very speciﬁcally stage ib through iia non-small cell lung cancer post-surgical therapy they do better than unresectable patients bu...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>42</th>\n",
       "      <td>David Fredrickson</td>\n",
       "      <td>management</td>\n",
       "      <td>yes and just so that i am clear and almost -- i mean 100% of our use is in the unresectable population post-crt and in the u.s. that represents about 80% of stage iii in terms of the unresectable population</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>43</th>\n",
       "      <td>Pascal Soriot</td>\n",
       "      <td>management</td>\n",
       "      <td>so we will take the marietta's question on the webcast at primavenue and she is asking a question about farxiga and in china and saying \"i did not realize you could get provincial reimbursement without being on the nrdl.\" and also \"is there a chance to get on the nrdl through negotiations that are outside the oﬃcial window for reviews and additions?\" mark do you want to cover this?</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>44</th>\n",
       "      <td>Mark Mallon</td>\n",
       "      <td>management</td>\n",
       "      <td>yes so thanks marietta it is a great question so yes you can we have done this in the past with other products in fact i should say getting on the nrdl does not guarantee you that you get listed on the province level this is why pascal -- one of the reasons pascal keeps highlighting the importance about the quality of our people and the scale of our business is because we have dedicated market...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>45</th>\n",
       "      <td>Pascal Soriot</td>\n",
       "      <td>management</td>\n",
       "      <td>not only you can get provincial reimbursement you can sometimes get city reimbursement so there are many many diﬀerent sources of access in china and the last question richard parkes of deutsche bank and we will ﬁnish with richard's question go ahead richard richard j</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>46</th>\n",
       "      <td>Parkes</td>\n",
       "      <td>analyst</td>\n",
       "      <td>great so again it is on imﬁnzi and the stage iii in resectable lung cancer setting so if you look at the ims weekly sales it looks like you are annualizing now well north of 400 million i am just wondering if you could give us any kind of sense of where you are in terms of penetration of that unresectable setting in the u.s. and maybe whether that strong launch would make you reevaluate your ﬂ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>47</th>\n",
       "      <td>Pascal Soriot</td>\n",
       "      <td>management</td>\n",
       "      <td>thanks very much richard i appreciate the question that will help us in our discussions with dave actually and the forecast you are absolutely right the last weekly data points are pretty good and dave do you want to cover that one?</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>48</th>\n",
       "      <td>David Fredrickson</td>\n",
       "      <td>management</td>\n",
       "      <td>yes absolutely so i think the ﬁrst place just to comment on in terms of where we see the penetration and i want to ground it just in the crt behavior so again about 80% of stage iii patients are unresectable of those half gets crt and that is not something that has really changed too dramatically in terms of the number of crt patients post that are unable to get unresected so one of our big ed...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>49</th>\n",
       "      <td>Pascal Soriot</td>\n",
       "      <td>management</td>\n",
       "      <td>thanks dave and as you can imagine of course we are also launching in japan and the rest of the world europe et cetera later this year and into early next year so there is a lot more to come as it relates to imﬁnzi but give me a chance before i conclude give me a chance to thank dave and the oncology team in particular in the u.s with the fantastic imﬁnzi launch and also the tagrisso team and ...</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "              speaker    position  \\\n",
       "0       Pascal Soriot  management   \n",
       "1   David Fredrickson  management   \n",
       "2         Mark Mallon  management   \n",
       "3        Marc Dunoyer  management   \n",
       "4          Sean Bohen  management   \n",
       "5       Pascal Soriot  management   \n",
       "6       Pascal Soriot  management   \n",
       "7               Baker     analyst   \n",
       "8          Sean Bohen  management   \n",
       "9       Pascal Soriot  management   \n",
       "10  David Fredrickson  management   \n",
       "11      Pascal Soriot  management   \n",
       "12    Minton Anderson     analyst   \n",
       "13      Pascal Soriot  management   \n",
       "14        Mark Mallon  management   \n",
       "15     Matthew Weston     analyst   \n",
       "16      Pascal Soriot  management   \n",
       "17       Marc Dunoyer  management   \n",
       "18        Mark Mallon  management   \n",
       "19      Pascal Soriot  management   \n",
       "20     Matthew Weston     analyst   \n",
       "21       Marc Dunoyer  management   \n",
       "22      Pascal Soriot  management   \n",
       "23       Marc Dunoyer  management   \n",
       "24      Pascal Soriot  management   \n",
       "25         Simon Baum     analyst   \n",
       "26      Pascal Soriot  management   \n",
       "27        Mark Mallon  management   \n",
       "28      Pascal Soriot  management   \n",
       "29         Sean Bohen  management   \n",
       "30      Pascal Soriot  management   \n",
       "31         Sean Bohen  management   \n",
       "32        Sachin Jain     analyst   \n",
       "33         Sean Bohen  management   \n",
       "34      Pascal Soriot  management   \n",
       "35         Sean Bohen  management   \n",
       "36      Pascal Soriot  management   \n",
       "37        Alex Arfaei     analyst   \n",
       "38      Pascal Soriot  management   \n",
       "39  David Fredrickson  management   \n",
       "40      Pascal Soriot  management   \n",
       "41         Sean Bohen  management   \n",
       "42  David Fredrickson  management   \n",
       "43      Pascal Soriot  management   \n",
       "44        Mark Mallon  management   \n",
       "45      Pascal Soriot  management   \n",
       "46             Parkes     analyst   \n",
       "47      Pascal Soriot  management   \n",
       "48  David Fredrickson  management   \n",
       "49      Pascal Soriot  management   \n",
       "\n",
       "                                                                                                                                                                                                                                                                                                                                                                                                            content  \n",
       "0   hello everyone it is pascal soriot here ceo of astrazeneca welcome to our first quarter results conference call and webcast for investors and analysts we are here in london on a very beautiful day for the annual general meeting this afternoon we have people on the phone and on the webcast the presentation is available to you on astrazeneca.com as always for you to download please turn to slide...  \n",
       "1   great thank you so much pascal and i am really pleased here to be here to update all of you on the performance of our new generation of medicines i will start ﬁrst with oncology and then i will hand it over to mark mallon for a summary of cvrm respiratory and emerging markets if we could turn please to page 12 we are really pleased to announce that total oncology grew by 33% quarter-over-quart...  \n",
       "2   thanks dave now moving to new cvrm which as pascal mentioned is deﬁned as our medicines in cardiovascular renal and metabolic diseases sales were up by 8% despite the intense competition with first quarter sales at 900 million farxiga and brilinta continued to remain strong with double-digit growth across all regions brilinta sales of 293 million with 24% growth driven by the u.s at 32% and em...  \n",
       "3   thank you mark and hello everyone i am going to spend the next few minutes taking you through our ﬁnancial performance in the first quarter of the year as well as our unchanged guidance please turn to slide 22 as usual i will begin with the reported p&l before turning to the core numbers as pascal mentioned earlier product sales declined by 2% impacted by the reduced sales of crestor in europe...  \n",
       "4   thank you marc i would now like to run through the late-stage pipeline events since the last results announcement and the highlights of recent data presentations at medical meetings and as usual i will ﬁnish with a look at our upcoming news ﬂow please turn to slide 28 we delivered more good progress in the quarter in oncology lynparza received eu approval for a broad second-line ovarian cancer...  \n",
       "5   thank you sean please turn to slide 33 now let me summarize before we end we are really pleased with the ongoing launches and the performance of our newer medicines during the first quarter as they underpin the guidance of growth in product sales in 2018 our ﬁnancials are on track with our performance being weighted towards the second half of the year and with product sales leading the way tot...  \n",
       "6                                                                                                                                                                                                                                                                                                                                       so we have a question here from simon baker at exane simon go ahead simon p  \n",
       "7   one for sean please if i may we can see from the press release this morning the expanding and evolving parp io combination trials that you are conducting but i was just wondering how much further there is to expand that i am thinking areas like colorectal where there is been some interesting work published this year on the potential applicability of parp in that indication and also therefore p...  \n",
       "8   okay so let me -- sort of 2 questions there one is the expansion of i am going to call lynparza io so lynparza imﬁnzi or imﬁnzi plus treme so when we shared our ovarian cancer data we also shared that we have -- we are initiating a trial called duo-o which is looking at that combination speciﬁcally in ovarian cancer then we are looking at other data sets to see where we might expand beyond tha...  \n",
       "9   thank you sean there is a question on the webcast that we will read aloud from vincent meunier at morgan stanley so he is trying to understand the potential of tagrisso initiative that were before you and the question is are there countries where the prevalence of the egfr mutations is higher than other countries? what about japan? and also in china what is the breakdown of volumes sales that ...  \n",
       "10  so thank you for the question so yes there are countries where the prevalence is higher and in asian countries it tends to be the highest around the globe prevalence rates in countries we see it around 30% even as much as 35% japan china korea this would all be the case for those countries as you look through that on the second question in terms of the breakdown of volumes and sales in china t...  \n",
       "11                                                                                                                                                                                                                                                                                                                      thank you dave then there is a question from tim anderson at bernstein tim go ahead timothy  \n",
       "12  emerging markets and china are a big part of your business and in china your proportion of total sales coming from that region is much higher than peers i usually thought of emerging markets exposure as a good thing but you could argue it is the other way around because proﬁt levels are less markets like china you may get volatility tied to price cuts so with astra investors generally look for...  \n",
       "13                                                                                                                                                let me just cover the second question tim then mark mallon you might want to cover the china question the second is very simple and straightforward tim we were not approached did not talk to michael cohen so we are totally out of this discussion china mark?  \n",
       "14  so we deﬁnitely see china as a positive and to have such a strong position in there and we see continued growth and future potential of course every country around the globe is wrestling with health care costs and as we have seen in the last week in the u.s. there is risks around pricing actions and i do not think china represents particularly more or less risk than any other countries in fact...  \n",
       "15  pascal my question's on the cost base really higher sg&a has been one of the key discussion points this morning with investors mark mentioned the low base eﬀects but also the guidance range of low; to mid-single-digit growth is a large window so can you just give us some of the drivers of that range? is it competitors potentially reacting in respiratory that you may need to react to? it does n...  \n",
       "16  yes i mean let me try and mark mallon and marc dunoyer you could also help me but just in terms of the new launches i mean we have talked about quite a number of new launches tagrisso et cetera et cetera for sure now in the second half i think you have got to think of roxa and lokelma but they are like more in the prelaunch mode if you will including in the u.s. lokelma after we get approval w...  \n",
       "17  no i think we are -- just one word we are obviously launching 8 -- in total 8 new medicine line extensions or new formulation and obviously we are -- this is very -- an important timing for the ﬁnal trajectory so we are closely monitoring the performance of these brands as they are being launched and this is why we try to allocate as much resources as we can dedicate to ensure the ﬁnal success...  \n",
       "18  i will just add one (point) again is china and china to your point we have great scope and scale but we still have so much more to penetrate and so we have to continuously -- we are continuously expanding into new hospitals and customers and even cities and also we are doing multiple new launches in china so it is not just the established portfolio we have got many launches occurring at the sa...  \n",
       "19                                                                                                                                                                                                                                                                                                                                                                   so as you can hear we are -- yes go ahead matt  \n",
       "20  if i could just ask one quick follow-up so i have no question regarding the increased spending in sg&a because clearly you are in full launch mode i understand that everything that everybody seems to have referred to in your answer is events that are known to you or very highly likely to happen with the exception of really declare and roxa my question was really about what about the 5percentag...  \n",
       "21                                                                      matt ﬁrst of all we provide guidance on product sales and eps so these are the 2 variables we obviously closely look at there are obviously several lines in the p&l between product sales and eps but you need to remember we have provided guidance on these 2 and we will be doing our best to meet or exceed this guidance for the year  \n",
       "22  so we committed to the guidance and in fact the variation matt is really based on what opportunities we see i mean we see a new opportunity somewhere that could drive additional sales and proﬁt and we ﬂex at that point but essentially as marc said we will stick to the guidance so we can move maybe -- maybe the last point i was going to make earlier is that you can see we are in a -- and as you...  \n",
       "23  so the 5 point reduction is obviously a reduction from quarter one 2017 quarter one 2018 and roughly the 4 factors that have been proposed are more or less equivalent to explain the diﬀerence so the buildout of the biologic manufacturing the lower absorption because we are early in the launch this is about 1/4 of it mix eﬀect on products such as crestor this is another 1/4 of this variance the...  \n",
       "24                                                                                         thank you marc as far as the capacity build we are kind of almost done with this we are completing our ﬁlling plant in sweden but in terms of manufacturing product substance we are done and then we will start using that capacity over time so we now have a question from andrew baum at citi andrew go ahead andrew  \n",
       "25  so i suspect astra has received the request for information from the hss following the drug pricing announced could you give us a sense of how much follow-through to expect in relation to this announcement particularly the conversations about removing the protective class? and i am thinking of categories such as parp and maybe just then a quick one for sean could you just outline your plans fo...  \n",
       "26                                                                                                                                                                                                                                                               2 great questions i must say the line was breaking up the second question is clear for sure and the ﬁrst one hopefully mark you got that one okay?  \n",
       "27  yes what i heard andrew and if i am oﬀ track please correct me but you asked about did we get a request to provide information as part of the drug pricing plans that the administration are working on and how much do we expect that to come through the system i think as you know and we all know i mean there were a lot of i think over 50 potential actions highlighted in the administration's plan ...  \n",
       "28                                              yes yes so i mean we have been very successful with some of the outcome-based pricing contracts we have implemented and if we could expand on those as part of a broader policy that the administration would want to put in place i think it would really be very welcomed by us and i am sure by many other companies sean do you want to cover the akt question?  \n",
       "29  sure sure thank you for the question andrew so the question relates to the phase ii data that (you've seen the abstract and) we will present it in more detail at the asco meeting capivasertib our akt inhibitor in triple negative breast cancer metastatic breast cancer we think the data's encouraging we think it is pretty strong indication of activity of the akt pathway in triple negative breast...  \n",
       "30  thank you sean as you can see more to come on this one but certainly very exciting early data with this new agent coming out of cambridge research team so really really good new development we will extend the (tc) by about 10 minutes so that we give everybody a chance to ask a question and the next one on the list here is sachin jain at bank of america sachin go ahead on lynparza similar to th...  \n",
       "31                                                                                                                                                                                                                                                okay so i think -- sachin let me clarify your -- in this case you are referring speciﬁcally the study 8 data in prostate cancer when you say in combination for..  \n",
       "32                                                                                                                                                                                                                                                                                                                                                                                                          correct  \n",
       "33  okay okay great well i think the -- i mean i think the answer is not dissimilar to the answer i gave for andrew's question with regard to capivasertib again we do -- we ﬁnd that data encouraging from study 8 again the question is really whether there is a regulatory pathway to bring that forward and that is a discussion with regulators in order to decide whether or not we are going to do that ...  \n",
       "34                                                                                                                                                                                           excellent so there is a question on the webcast by sam fazeli at bloomberg and the question is can you explain the reasoning behind starting pacific 2? so sort of the pacific program sean do you want to cover that?  \n",
       "35  yes sure yes the rationale behind pacific 2 really has to do with the fact that while concurrent administration of chemotherapy and radiation therapy are the well-established standard of care in the united states and europe there are many parts of the world where concurrent is not the standard of care and a lot of that has to do with the challenges of coordinating that radiation therapy and ch...  \n",
       "36                                                                                                                                                                                                                                                                                                                           thank you sean i think we have -- maybe we will take another 2 so we have one question  \n",
       "37  great well just looking at your operating margin here i fully appreciate the headwinds you are facing with the patent expirations and the investments the maximum pressure points on launches et cetera but as you step back and look at your business how realistic is it for investors to expect that once things normalize you should have an operating margin that is more in line with your european an...  \n",
       "38  okay so the second question will be -- dave you could take and in the ﬁrst question is about margins when you look at our peers you really have to be careful who you look at because some companies have such a very focused business around say specialty care and sometimes it is even beyond that specialty care u.s with a little bit of european presence so the margins of course reﬂect a little bit...  \n",
       "39  yes so on the ﬁrst question of the uptake that we have been seeing with imﬁnzi in stage iii unresectable as i mentioned earlier the lion's share in fact the overwhelming majority of our sales in the first quarter came from that population as you saw earlier in one of the slides from pascal you can see the demand increasing with imﬁnzi within this population we had an estimated 3,500 monthly in...  \n",
       "40                                                                                                                                                                                                                                                                                                                                                                                          sorry did you want to..  \n",
       "41  yes i believe if i heard you right alex there was a question as well around resectable disease and obviously that is not the indication so that is not something we track i just want to point out that we do have an adjuvant study ongoing which studies that question very speciﬁcally stage ib through iia non-small cell lung cancer post-surgical therapy they do better than unresectable patients bu...  \n",
       "42                                                                                                                                                                                                   yes and just so that i am clear and almost -- i mean 100% of our use is in the unresectable population post-crt and in the u.s. that represents about 80% of stage iii in terms of the unresectable population  \n",
       "43                 so we will take the marietta's question on the webcast at primavenue and she is asking a question about farxiga and in china and saying \"i did not realize you could get provincial reimbursement without being on the nrdl.\" and also \"is there a chance to get on the nrdl through negotiations that are outside the oﬃcial window for reviews and additions?\" mark do you want to cover this?  \n",
       "44  yes so thanks marietta it is a great question so yes you can we have done this in the past with other products in fact i should say getting on the nrdl does not guarantee you that you get listed on the province level this is why pascal -- one of the reasons pascal keeps highlighting the importance about the quality of our people and the scale of our business is because we have dedicated market...  \n",
       "45                                                                                                                                     not only you can get provincial reimbursement you can sometimes get city reimbursement so there are many many diﬀerent sources of access in china and the last question richard parkes of deutsche bank and we will ﬁnish with richard's question go ahead richard richard j  \n",
       "46  great so again it is on imﬁnzi and the stage iii in resectable lung cancer setting so if you look at the ims weekly sales it looks like you are annualizing now well north of 400 million i am just wondering if you could give us any kind of sense of where you are in terms of penetration of that unresectable setting in the u.s. and maybe whether that strong launch would make you reevaluate your ﬂ...  \n",
       "47                                                                                                                                                                         thanks very much richard i appreciate the question that will help us in our discussions with dave actually and the forecast you are absolutely right the last weekly data points are pretty good and dave do you want to cover that one?  \n",
       "48  yes absolutely so i think the ﬁrst place just to comment on in terms of where we see the penetration and i want to ground it just in the crt behavior so again about 80% of stage iii patients are unresectable of those half gets crt and that is not something that has really changed too dramatically in terms of the number of crt patients post that are unable to get unresected so one of our big ed...  \n",
       "49  thanks dave and as you can imagine of course we are also launching in japan and the rest of the world europe et cetera later this year and into early next year so there is a lot more to come as it relates to imﬁnzi but give me a chance before i conclude give me a chance to thank dave and the oncology team in particular in the u.s with the fantastic imﬁnzi launch and also the tagrisso team and ...  "
      ]
     },
     "execution_count": 36,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df = get_speaker_content(data)\n",
    "df"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 55,
   "id": "51c2f281",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>speaker</th>\n",
       "      <th>position</th>\n",
       "      <th>content</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>Friedrich Joussen</td>\n",
       "      <td>management</td>\n",
       "      <td>good morning and very sorry for actually my delay i am running a little bit late but i will be having enough time and hopefully you will allow me the time as well so turning directly into my presentation i would like before i start showing you results on q1 and preface for one change in reporting and explain a little bit why we are doing it and on page number four you see destination services ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>Horst Baier</td>\n",
       "      <td>management</td>\n",
       "      <td>thank you very much good morning ladies and gentlemen i would like to go quickly through the p&amp;l fritz alluded to the positive development as far as underlying ebita is concerned adjustments are roughly double the size as in the ﬁrst quarter last year however that is a little bit phasing we have included here some restructuring expenses for france and for germany ultimately we stick to our gui...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>Friedrich Joussen</td>\n",
       "      <td>management</td>\n",
       "      <td>horst thank you so turning the page i think and doing some closing and summary remarks i mean when you look at our business i think the next page shows quite nicely how we look at it holiday experiences now 60% this includes our 59% almost 60% this includes now also destination services so it is actually hotels cruises and destination services we talk about a double diversiﬁcation we are activ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>James Ainley</td>\n",
       "      <td>analyst</td>\n",
       "      <td>good morning everybody so i have got three questions please firstly i mean just to hear about how hotel rates are evolving in the summer especially in spain as the demand -- at least demand [ph] improves? secondly if you could give us some -- maybe some more changing patterns around maybe duration or destination mix perhaps you may get more squeezed? and then thirdly if you can comment on germ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>Friedrich Joussen</td>\n",
       "      <td>management</td>\n",
       "      <td>okay james yes our hotel rates -- hotel demand is coming back in turkey and surprisingly rates are still up in spain so it seems to be that it is so elastic we see now more and more good source market mix in spain so i would say generally i would assume that the spanish rates and spanish margin particularly in our hotels seem to be very stable uk demand we were -- in december you saw a little ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5</th>\n",
       "      <td>James Ainley</td>\n",
       "      <td>analyst</td>\n",
       "      <td>very good that is helpful thank you operator and our next question comes from mr tim ramskill who is calling from credit suisse</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6</th>\n",
       "      <td>Tim Ramskill</td>\n",
       "      <td>analyst</td>\n",
       "      <td>thanks good morning i have got three questions as well please and maybe horst if you could just spend a little bit more time running us through the thought process around the airline ﬂeet and the potential for sort of owning more aircraft on the balance sheet just maybe some sense as to the cost overall cost beneﬁt and perhaps accretion you could expect to earnings from a shift in that directi...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>7</th>\n",
       "      <td>Friedrich Joussen</td>\n",
       "      <td>management</td>\n",
       "      <td>horst why do not you take the ownership?</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>8</th>\n",
       "      <td>Horst Baier</td>\n",
       "      <td>management</td>\n",
       "      <td>as far as the re-ﬂeeting is concerned we have improved as a company as far as our rating is concerned we are bb ﬂat however in discussions with banks and then with investors there comes the message to us we perceive you are already strong we rather perceive you as a bb+ something two weeks ago i was in japan which we are doing every year to have a road show in tokyo for our ﬁnancing houses as ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9</th>\n",
       "      <td>Friedrich Joussen</td>\n",
       "      <td>management</td>\n",
       "      <td>cruise growth plans yeah i mean it is an open secret that if you could buy more ships then we could put in service more ships we would do so i mean we -- last year and also last quarter we increased capacity dramatically and still can increase yields i mean that is a very beautiful environment the capital returns by the way of cruising today is 20% and if you think about that you still have an...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>10</th>\n",
       "      <td>Tim Ramskill</td>\n",
       "      <td>analyst</td>\n",
       "      <td>excellent can i just follow up with one very quick one on the cruise side of things in terms of the pricing outlook longer term? would you see an environment where you have less capacity growth as beneﬁcial for pricing or is it the case that new ships where you tend to get a premium price are part of the reason why you have enjoyed an increase in yield? how do those two things play out please?</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>11</th>\n",
       "      <td>Friedrich Joussen</td>\n",
       "      <td>management</td>\n",
       "      <td>both are true both are true newer ships create a premium at the same time when you extend your ﬂeet you have another eﬀect and that is actually you also extend your routing and you usually extend your routing into routes which are not as attractive than the routes you had before because with a respective capacity you do the most proﬁtable routes ﬁrst and then you go at lower proﬁtable routes b...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>12</th>\n",
       "      <td>Tim Ramskill</td>\n",
       "      <td>analyst</td>\n",
       "      <td>okay thank you very much operator and our next question comes from mr patrick coﬀey who is calling from barclays</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>13</th>\n",
       "      <td>Friedrich Joussen</td>\n",
       "      <td>management</td>\n",
       "      <td>hi patrick</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>14</th>\n",
       "      <td>Patrick Coﬀey</td>\n",
       "      <td>analyst</td>\n",
       "      <td>hi just two questions from me firstly on the uk and talking about margin normalization can you just clarify how much extra investment is required in uk marketing this year in total? clearly you previously ﬂagged that you are going to see normalization of uk margins but looking back to my old tui travel model you saw margins at sort of 5% to 7% between 2012 to 2014 but at the time this included...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>15</th>\n",
       "      <td>Friedrich Joussen</td>\n",
       "      <td>management</td>\n",
       "      <td>okay answer to the ﬁrst one 5 and -- 5% and answer to the second one restatement no</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>16</th>\n",
       "      <td>Patrick Coﬀey</td>\n",
       "      <td>analyst</td>\n",
       "      <td>perfect thanks very much operator and our next question comes from tobias sittig who is calling from main first bank</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>17</th>\n",
       "      <td>Tobias Sittig</td>\n",
       "      <td>analyst</td>\n",
       "      <td>yes good morning congrats to the results and three questions from me please firstly the restructuring in france could you elaborate a little bit on what you are doing how much that could reduce costs and basically your level of conﬁdence at france will ﬁnally breakeven or deliver a decent margin this year or next year? second one your relative cost position both for tui ﬂy and corsair were the...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>18</th>\n",
       "      <td>Friedrich Joussen</td>\n",
       "      <td>management</td>\n",
       "      <td>france the restructuring is going well i mean you know the integration of transat and tui france is going well now that said you know we had some inﬂuences of hurricanes in caribbean and so on and so on but the sustainable processes of france is intact second point was and by the way we are targeting as we said for this year breakeven so let us see where it takes us the season is long and but ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>19</th>\n",
       "      <td>Friedrich Joussen</td>\n",
       "      <td>management</td>\n",
       "      <td>the rebranding rebranding in the uk we do not separate our other cost i mean we -- or do we separate our other cost?</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>20</th>\n",
       "      <td>Horst Baier</td>\n",
       "      <td>management</td>\n",
       "      <td>no</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>21</th>\n",
       "      <td>Friedrich Joussen</td>\n",
       "      <td>management</td>\n",
       "      <td>no we do not i just was looking to my ﬁnancial colleague</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>22</th>\n",
       "      <td>Horst Baier</td>\n",
       "      <td>management</td>\n",
       "      <td>it is all inclusive</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>23</th>\n",
       "      <td>Friedrich Joussen</td>\n",
       "      <td>management</td>\n",
       "      <td>it is all inclusive but i can reassure you that we in all the rebrandings in all the countries we earned back the rebranding costs within a year and i can reassure you what i know right now from the uk we will earn back the rebranding of the uk within a year i mean we are up now on unaided awareness of 44% our online traﬃc is up versus year-on-year that is the main point right? so the main poi...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>24</th>\n",
       "      <td>Tobias Sittig</td>\n",
       "      <td>analyst</td>\n",
       "      <td>okay thank you very much operator our next question comes from angus tweedie who is calling from bank of america</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>25</th>\n",
       "      <td>Angus Tweedie</td>\n",
       "      <td>analyst</td>\n",
       "      <td>good morning guys two questions from me firstly on hotel occupancy can you just talk about the trends there? because you are down at the sort of three major brands but up overall i mean is there signs of turkey coming back? i mean could you talk about that? and then secondly on destination services i think i got it on the call you were talking about 15% growth this year in terms of proﬁts coul...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>26</th>\n",
       "      <td>Friedrich Joussen</td>\n",
       "      <td>management</td>\n",
       "      <td>occupancy yes it is true it is mainly driven by actually north africa and turkey coming back</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>27</th>\n",
       "      <td>Horst Baier</td>\n",
       "      <td>management</td>\n",
       "      <td>it is a little bit tunisia which in the -- egypt is in there it is not yet turkey because turkey only starts in april but it is all running pretty positively</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>28</th>\n",
       "      <td>Friedrich Joussen</td>\n",
       "      <td>management</td>\n",
       "      <td>and on destinations services i think what we show is -- we show revenues on the external revenues of course external revenue also generate margin so you can actually not divide that margin by revenues i think when you look at the gearing of the business you are talking 10% or so right? i will look to my colleague here what is it? i cannot read 8 it says it is more around a little bit above 8 t...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>29</th>\n",
       "      <td>Angus Tweedie</td>\n",
       "      <td>analyst</td>\n",
       "      <td>lovely thank you operator next up is mark fortescue who is calling from panmure mark fortescue hello good morning just two from me please one on hotels and resorts one on sales you have got seven new openings in there is that mostly just a timing issue as to when those came into the business in the quarter? just maybe a bit of context around what is coming in and what is leaving given what loo...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>30</th>\n",
       "      <td>Friedrich Joussen</td>\n",
       "      <td>management</td>\n",
       "      <td>and the second question? mark fortescue is on the sales and marketing just coming back to the point around the uk so you talked about margins and the re-brand just to sort of square those two points the summer bookings are down 1% year-on-year is that broadly where you thought you would be given the eﬀorts around the tui re-brand just to touch on that please?</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>31</th>\n",
       "      <td>Friedrich Joussen</td>\n",
       "      <td>management</td>\n",
       "      <td>yeah horst maybe take the second question because i am not 100% sure i understood</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>32</th>\n",
       "      <td>Horst Baier</td>\n",
       "      <td>management</td>\n",
       "      <td>maybe i will start with the hotels where you yeah ﬂexed out the disposal gain and then said this is only 3 million up or 4 million up compared to the ﬁscal year one -- ﬁrst quarter '17 we are in the very low season we have october through december not too much activity and november and december except christmas so you cannot expect a big uplift even though we have added seven hotels in that qu...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>33</th>\n",
       "      <td>Friedrich Joussen</td>\n",
       "      <td>management</td>\n",
       "      <td>and also more capacity drive usually higher losses in winter i mean also these hotels you have a certain seasonality therefore i think you know look at the -- we will have a strong growth for the whole year that is very clear i mean when you look at the bookings for the full year we have the visibility will be quite nice the bookings for summer we have higher margins but we also should have hi...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>34</th>\n",
       "      <td>Horst Baier</td>\n",
       "      <td>management</td>\n",
       "      <td>i think we have not got the question exactly which you raised in respect of sales and marketing? mark fortescue just given the campaign around tui re-brand in the uk i might have thought the summer bookings would be a bit stronger but you are saying they are down 1% compared to where they were last year</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>35</th>\n",
       "      <td>Friedrich Joussen</td>\n",
       "      <td>management</td>\n",
       "      <td>i think when you look at the selling prices are up 3 [ph] i think my view on this is we are playing for the time being the price margin equation that does not say anything but our capacity is up therefore it will be more customers in summer and we will be taking market share because we also have one competitor less i mean that is also clear monarch actually exited by end of season we will be ﬁ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>36</th>\n",
       "      <td>Richard Clarke</td>\n",
       "      <td>analyst</td>\n",
       "      <td>good morning three questions from me if i may all i assume are hotels first one is just on the riu disposals can you maybe just tell us what you sold why you sold it? and if there is any sort of signaling there that this is part of a wider strategy of asset rotation? and then you have not included the 85 million proceeds in your capex bridge on slide 19 any reason why or on what that money mig...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>37</th>\n",
       "      <td>Friedrich Joussen</td>\n",
       "      <td>management</td>\n",
       "      <td>i think the hotels we are talking about are the riu romantica bachata and merengue all of them are actually should have been refurbished they have not been very proﬁtable therefore we said you know these are not the hotels we want to own long-term and on the turkey and on the other hotels it will be turkey which actually will turnaround the whole thing or not i mean that is also clear turkey i...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>38</th>\n",
       "      <td>Horst Baier</td>\n",
       "      <td>management</td>\n",
       "      <td>this chart 19 which you referred to is illustrating our transformational process so what we have done we sold these three so called non-core assets and then when you go down to the right hand side you see all the diﬀerent elements where we spent the money as far as the disposal proceeds from the three riu hotels are concerned these are part of our overall capex guidance so it is sitting within...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>39</th>\n",
       "      <td>Richard Clarke</td>\n",
       "      <td>analyst</td>\n",
       "      <td>okay and then maybe just on the -- whether these disposals are -- are these a signal that you are looking to do more kind of asset recycling going forward or were these three one- oﬀ hotels that you wanted to dispose oﬀ?</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>40</th>\n",
       "      <td>Horst Baier</td>\n",
       "      <td>management</td>\n",
       "      <td>we are reviewing our portfolio of hotels on a regular basis and we regard it as very operational exercise when you have such a portfolio of hotels that you look into the ones who may result in a very high disposal price and compared to that what you can get as an operational result from this hotel so it is again kind of a very rational approach as far as the portfolio of hotels is concerned</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>41</th>\n",
       "      <td>Richard Clarke</td>\n",
       "      <td>analyst</td>\n",
       "      <td>okay very clear thank you operator and our last question today comes from jeﬀery howard who is calling from stifel</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>42</th>\n",
       "      <td>Jeﬀery Howard</td>\n",
       "      <td>analyst</td>\n",
       "      <td>yes good morning just one question left the line all other segments the loss there has moved from 11 to 23 i wondered if you could say what is happening there please?</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>43</th>\n",
       "      <td>Friedrich Joussen</td>\n",
       "      <td>management</td>\n",
       "      <td>that is actually corsair dechecks [ph] 8 million</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>44</th>\n",
       "      <td>Jeﬀery Howard</td>\n",
       "      <td>analyst</td>\n",
       "      <td>i am sorry the 8 million from?</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>45</th>\n",
       "      <td>Friedrich Joussen</td>\n",
       "      <td>management</td>\n",
       "      <td>corsair dechecks so we --</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>46</th>\n",
       "      <td>Jeﬀery Howard</td>\n",
       "      <td>analyst</td>\n",
       "      <td>right okay corsair yes</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>47</th>\n",
       "      <td>Friedrich Joussen</td>\n",
       "      <td>management</td>\n",
       "      <td>need to go into dechecks this is more or less explain the eﬀect</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>48</th>\n",
       "      <td>Jeﬀery Howard</td>\n",
       "      <td>analyst</td>\n",
       "      <td>sure okay that is great thank you</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>49</th>\n",
       "      <td>Friedrich Joussen</td>\n",
       "      <td>management</td>\n",
       "      <td>okay thank you very much all the best from hanover see you latest on our ship in may thank you very much have a great day</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "              speaker    position  \\\n",
       "0   Friedrich Joussen  management   \n",
       "1         Horst Baier  management   \n",
       "2   Friedrich Joussen  management   \n",
       "3        James Ainley     analyst   \n",
       "4   Friedrich Joussen  management   \n",
       "5        James Ainley     analyst   \n",
       "6        Tim Ramskill     analyst   \n",
       "7   Friedrich Joussen  management   \n",
       "8         Horst Baier  management   \n",
       "9   Friedrich Joussen  management   \n",
       "10       Tim Ramskill     analyst   \n",
       "11  Friedrich Joussen  management   \n",
       "12       Tim Ramskill     analyst   \n",
       "13  Friedrich Joussen  management   \n",
       "14      Patrick Coﬀey     analyst   \n",
       "15  Friedrich Joussen  management   \n",
       "16      Patrick Coﬀey     analyst   \n",
       "17      Tobias Sittig     analyst   \n",
       "18  Friedrich Joussen  management   \n",
       "19  Friedrich Joussen  management   \n",
       "20        Horst Baier  management   \n",
       "21  Friedrich Joussen  management   \n",
       "22        Horst Baier  management   \n",
       "23  Friedrich Joussen  management   \n",
       "24      Tobias Sittig     analyst   \n",
       "25      Angus Tweedie     analyst   \n",
       "26  Friedrich Joussen  management   \n",
       "27        Horst Baier  management   \n",
       "28  Friedrich Joussen  management   \n",
       "29      Angus Tweedie     analyst   \n",
       "30  Friedrich Joussen  management   \n",
       "31  Friedrich Joussen  management   \n",
       "32        Horst Baier  management   \n",
       "33  Friedrich Joussen  management   \n",
       "34        Horst Baier  management   \n",
       "35  Friedrich Joussen  management   \n",
       "36     Richard Clarke     analyst   \n",
       "37  Friedrich Joussen  management   \n",
       "38        Horst Baier  management   \n",
       "39     Richard Clarke     analyst   \n",
       "40        Horst Baier  management   \n",
       "41     Richard Clarke     analyst   \n",
       "42      Jeﬀery Howard     analyst   \n",
       "43  Friedrich Joussen  management   \n",
       "44      Jeﬀery Howard     analyst   \n",
       "45  Friedrich Joussen  management   \n",
       "46      Jeﬀery Howard     analyst   \n",
       "47  Friedrich Joussen  management   \n",
       "48      Jeﬀery Howard     analyst   \n",
       "49  Friedrich Joussen  management   \n",
       "\n",
       "                                                                                                                                                                                                                                                                                                                                                                                                            content  \n",
       "0   good morning and very sorry for actually my delay i am running a little bit late but i will be having enough time and hopefully you will allow me the time as well so turning directly into my presentation i would like before i start showing you results on q1 and preface for one change in reporting and explain a little bit why we are doing it and on page number four you see destination services ...  \n",
       "1   thank you very much good morning ladies and gentlemen i would like to go quickly through the p&l fritz alluded to the positive development as far as underlying ebita is concerned adjustments are roughly double the size as in the ﬁrst quarter last year however that is a little bit phasing we have included here some restructuring expenses for france and for germany ultimately we stick to our gui...  \n",
       "2   horst thank you so turning the page i think and doing some closing and summary remarks i mean when you look at our business i think the next page shows quite nicely how we look at it holiday experiences now 60% this includes our 59% almost 60% this includes now also destination services so it is actually hotels cruises and destination services we talk about a double diversiﬁcation we are activ...  \n",
       "3   good morning everybody so i have got three questions please firstly i mean just to hear about how hotel rates are evolving in the summer especially in spain as the demand -- at least demand [ph] improves? secondly if you could give us some -- maybe some more changing patterns around maybe duration or destination mix perhaps you may get more squeezed? and then thirdly if you can comment on germ...  \n",
       "4   okay james yes our hotel rates -- hotel demand is coming back in turkey and surprisingly rates are still up in spain so it seems to be that it is so elastic we see now more and more good source market mix in spain so i would say generally i would assume that the spanish rates and spanish margin particularly in our hotels seem to be very stable uk demand we were -- in december you saw a little ...  \n",
       "5                                                                                                                                                                                                                                                                                   very good that is helpful thank you operator and our next question comes from mr tim ramskill who is calling from credit suisse  \n",
       "6   thanks good morning i have got three questions as well please and maybe horst if you could just spend a little bit more time running us through the thought process around the airline ﬂeet and the potential for sort of owning more aircraft on the balance sheet just maybe some sense as to the cost overall cost beneﬁt and perhaps accretion you could expect to earnings from a shift in that directi...  \n",
       "7                                                                                                                                                                                                                                                                                                                                                                          horst why do not you take the ownership?  \n",
       "8   as far as the re-ﬂeeting is concerned we have improved as a company as far as our rating is concerned we are bb ﬂat however in discussions with banks and then with investors there comes the message to us we perceive you are already strong we rather perceive you as a bb+ something two weeks ago i was in japan which we are doing every year to have a road show in tokyo for our ﬁnancing houses as ...  \n",
       "9   cruise growth plans yeah i mean it is an open secret that if you could buy more ships then we could put in service more ships we would do so i mean we -- last year and also last quarter we increased capacity dramatically and still can increase yields i mean that is a very beautiful environment the capital returns by the way of cruising today is 20% and if you think about that you still have an...  \n",
       "10     excellent can i just follow up with one very quick one on the cruise side of things in terms of the pricing outlook longer term? would you see an environment where you have less capacity growth as beneﬁcial for pricing or is it the case that new ships where you tend to get a premium price are part of the reason why you have enjoyed an increase in yield? how do those two things play out please?  \n",
       "11  both are true both are true newer ships create a premium at the same time when you extend your ﬂeet you have another eﬀect and that is actually you also extend your routing and you usually extend your routing into routes which are not as attractive than the routes you had before because with a respective capacity you do the most proﬁtable routes ﬁrst and then you go at lower proﬁtable routes b...  \n",
       "12                                                                                                                                                                                                                                                                                                 okay thank you very much operator and our next question comes from mr patrick coﬀey who is calling from barclays  \n",
       "13                                                                                                                                                                                                                                                                                                                                                                                                       hi patrick  \n",
       "14  hi just two questions from me firstly on the uk and talking about margin normalization can you just clarify how much extra investment is required in uk marketing this year in total? clearly you previously ﬂagged that you are going to see normalization of uk margins but looking back to my old tui travel model you saw margins at sort of 5% to 7% between 2012 to 2014 but at the time this included...  \n",
       "15                                                                                                                                                                                                                                                                                                                              okay answer to the ﬁrst one 5 and -- 5% and answer to the second one restatement no  \n",
       "16                                                                                                                                                                                                                                                                                             perfect thanks very much operator and our next question comes from tobias sittig who is calling from main first bank  \n",
       "17  yes good morning congrats to the results and three questions from me please firstly the restructuring in france could you elaborate a little bit on what you are doing how much that could reduce costs and basically your level of conﬁdence at france will ﬁnally breakeven or deliver a decent margin this year or next year? second one your relative cost position both for tui ﬂy and corsair were the...  \n",
       "18  france the restructuring is going well i mean you know the integration of transat and tui france is going well now that said you know we had some inﬂuences of hurricanes in caribbean and so on and so on but the sustainable processes of france is intact second point was and by the way we are targeting as we said for this year breakeven so let us see where it takes us the season is long and but ...  \n",
       "19                                                                                                                                                                                                                                                                                             the rebranding rebranding in the uk we do not separate our other cost i mean we -- or do we separate our other cost?  \n",
       "20                                                                                                                                                                                                                                                                                                                                                                                                               no  \n",
       "21                                                                                                                                                                                                                                                                                                                                                         no we do not i just was looking to my ﬁnancial colleague  \n",
       "22                                                                                                                                                                                                                                                                                                                                                                                              it is all inclusive  \n",
       "23  it is all inclusive but i can reassure you that we in all the rebrandings in all the countries we earned back the rebranding costs within a year and i can reassure you what i know right now from the uk we will earn back the rebranding of the uk within a year i mean we are up now on unaided awareness of 44% our online traﬃc is up versus year-on-year that is the main point right? so the main poi...  \n",
       "24                                                                                                                                                                                                                                                                                                 okay thank you very much operator our next question comes from angus tweedie who is calling from bank of america  \n",
       "25  good morning guys two questions from me firstly on hotel occupancy can you just talk about the trends there? because you are down at the sort of three major brands but up overall i mean is there signs of turkey coming back? i mean could you talk about that? and then secondly on destination services i think i got it on the call you were talking about 15% growth this year in terms of proﬁts coul...  \n",
       "26                                                                                                                                                                                                                                                                                                                     occupancy yes it is true it is mainly driven by actually north africa and turkey coming back  \n",
       "27                                                                                                                                                                                                                                                    it is a little bit tunisia which in the -- egypt is in there it is not yet turkey because turkey only starts in april but it is all running pretty positively  \n",
       "28  and on destinations services i think what we show is -- we show revenues on the external revenues of course external revenue also generate margin so you can actually not divide that margin by revenues i think when you look at the gearing of the business you are talking 10% or so right? i will look to my colleague here what is it? i cannot read 8 it says it is more around a little bit above 8 t...  \n",
       "29  lovely thank you operator next up is mark fortescue who is calling from panmure mark fortescue hello good morning just two from me please one on hotels and resorts one on sales you have got seven new openings in there is that mostly just a timing issue as to when those came into the business in the quarter? just maybe a bit of context around what is coming in and what is leaving given what loo...  \n",
       "30                                        and the second question? mark fortescue is on the sales and marketing just coming back to the point around the uk so you talked about margins and the re-brand just to sort of square those two points the summer bookings are down 1% year-on-year is that broadly where you thought you would be given the eﬀorts around the tui re-brand just to touch on that please?  \n",
       "31                                                                                                                                                                                                                                                                                                                                yeah horst maybe take the second question because i am not 100% sure i understood  \n",
       "32  maybe i will start with the hotels where you yeah ﬂexed out the disposal gain and then said this is only 3 million up or 4 million up compared to the ﬁscal year one -- ﬁrst quarter '17 we are in the very low season we have october through december not too much activity and november and december except christmas so you cannot expect a big uplift even though we have added seven hotels in that qu...  \n",
       "33  and also more capacity drive usually higher losses in winter i mean also these hotels you have a certain seasonality therefore i think you know look at the -- we will have a strong growth for the whole year that is very clear i mean when you look at the bookings for the full year we have the visibility will be quite nice the bookings for summer we have higher margins but we also should have hi...  \n",
       "34                                                                                                 i think we have not got the question exactly which you raised in respect of sales and marketing? mark fortescue just given the campaign around tui re-brand in the uk i might have thought the summer bookings would be a bit stronger but you are saying they are down 1% compared to where they were last year  \n",
       "35  i think when you look at the selling prices are up 3 [ph] i think my view on this is we are playing for the time being the price margin equation that does not say anything but our capacity is up therefore it will be more customers in summer and we will be taking market share because we also have one competitor less i mean that is also clear monarch actually exited by end of season we will be ﬁ...  \n",
       "36  good morning three questions from me if i may all i assume are hotels first one is just on the riu disposals can you maybe just tell us what you sold why you sold it? and if there is any sort of signaling there that this is part of a wider strategy of asset rotation? and then you have not included the 85 million proceeds in your capex bridge on slide 19 any reason why or on what that money mig...  \n",
       "37  i think the hotels we are talking about are the riu romantica bachata and merengue all of them are actually should have been refurbished they have not been very proﬁtable therefore we said you know these are not the hotels we want to own long-term and on the turkey and on the other hotels it will be turkey which actually will turnaround the whole thing or not i mean that is also clear turkey i...  \n",
       "38  this chart 19 which you referred to is illustrating our transformational process so what we have done we sold these three so called non-core assets and then when you go down to the right hand side you see all the diﬀerent elements where we spent the money as far as the disposal proceeds from the three riu hotels are concerned these are part of our overall capex guidance so it is sitting within...  \n",
       "39                                                                                                                                                                                     okay and then maybe just on the -- whether these disposals are -- are these a signal that you are looking to do more kind of asset recycling going forward or were these three one- oﬀ hotels that you wanted to dispose oﬀ?  \n",
       "40        we are reviewing our portfolio of hotels on a regular basis and we regard it as very operational exercise when you have such a portfolio of hotels that you look into the ones who may result in a very high disposal price and compared to that what you can get as an operational result from this hotel so it is again kind of a very rational approach as far as the portfolio of hotels is concerned  \n",
       "41                                                                                                                                                                                                                                                                                               okay very clear thank you operator and our last question today comes from jeﬀery howard who is calling from stifel  \n",
       "42                                                                                                                                                                                                                                           yes good morning just one question left the line all other segments the loss there has moved from 11 to 23 i wondered if you could say what is happening there please?  \n",
       "43                                                                                                                                                                                                                                                                                                                                                                 that is actually corsair dechecks [ph] 8 million  \n",
       "44                                                                                                                                                                                                                                                                                                                                                                                   i am sorry the 8 million from?  \n",
       "45                                                                                                                                                                                                                                                                                                                                                                                        corsair dechecks so we --  \n",
       "46                                                                                                                                                                                                                                                                                                                                                                                           right okay corsair yes  \n",
       "47                                                                                                                                                                                                                                                                                                                                                  need to go into dechecks this is more or less explain the eﬀect  \n",
       "48                                                                                                                                                                                                                                                                                                                                                                                sure okay that is great thank you  \n",
       "49                                                                                                                                                                                                                                                                                        okay thank you very much all the best from hanover see you latest on our ship in may thank you very much have a great day  "
      ]
     },
     "execution_count": 55,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df1 = get_speaker_content(data1)\n",
    "df2 = get_speaker_content(data2)\n",
    "df3 = get_speaker_content(data3)\n",
    "df4 = get_speaker_content(data4)\n",
    "df5 = get_speaker_content(data5)\n",
    "df6 = get_speaker_content(data6)\n",
    "df7 = get_speaker_content(data7)\n",
    "df8 = get_speaker_content(data8)\n",
    "df9 = get_speaker_content(data9)\n",
    "df10 = get_speaker_content(data10)\n",
    "df11 = get_speaker_content(data11)\n",
    "df12 = get_speaker_content(data12)\n",
    "df13 = get_speaker_content(data13)\n",
    "df14 = get_speaker_content(data14)\n",
    "df15 = get_speaker_content(data15)\n",
    "df16 = get_speaker_content(data16)\n",
    "df17 = get_speaker_content(data17)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 56,
   "id": "07cedaa8",
   "metadata": {
    "scrolled": false,
    "slideshow": {
     "slide_type": "slide"
    }
   },
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>speaker</th>\n",
       "      <th>position</th>\n",
       "      <th>content</th>\n",
       "      <th>neg</th>\n",
       "      <th>neu</th>\n",
       "      <th>pos</th>\n",
       "      <th>compound</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>Pascal Soriot</td>\n",
       "      <td>management</td>\n",
       "      <td>hello everyone it is pascal soriot here ceo of astrazeneca welcome to our first quarter results conference call and webcast for investors and analysts we are here in london on a very beautiful day for the annual general meeting this afternoon we have people on the phone and on the webcast the presentation is available to you on astrazeneca.com as always for you to download please turn to slide...</td>\n",
       "      <td>0.043</td>\n",
       "      <td>0.823</td>\n",
       "      <td>0.135</td>\n",
       "      <td>0.9995</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>David Fredrickson</td>\n",
       "      <td>management</td>\n",
       "      <td>great thank you so much pascal and i am really pleased here to be here to update all of you on the performance of our new generation of medicines i will start ﬁrst with oncology and then i will hand it over to mark mallon for a summary of cvrm respiratory and emerging markets if we could turn please to page 12 we are really pleased to announce that total oncology grew by 33% quarter-over-quart...</td>\n",
       "      <td>0.030</td>\n",
       "      <td>0.833</td>\n",
       "      <td>0.137</td>\n",
       "      <td>0.9989</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>Mark Mallon</td>\n",
       "      <td>management</td>\n",
       "      <td>thanks dave now moving to new cvrm which as pascal mentioned is deﬁned as our medicines in cardiovascular renal and metabolic diseases sales were up by 8% despite the intense competition with first quarter sales at 900 million farxiga and brilinta continued to remain strong with double-digit growth across all regions brilinta sales of 293 million with 24% growth driven by the u.s at 32% and em...</td>\n",
       "      <td>0.017</td>\n",
       "      <td>0.825</td>\n",
       "      <td>0.158</td>\n",
       "      <td>0.9981</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>Marc Dunoyer</td>\n",
       "      <td>management</td>\n",
       "      <td>thank you mark and hello everyone i am going to spend the next few minutes taking you through our ﬁnancial performance in the first quarter of the year as well as our unchanged guidance please turn to slide 22 as usual i will begin with the reported p&amp;l before turning to the core numbers as pascal mentioned earlier product sales declined by 2% impacted by the reduced sales of crestor in europe...</td>\n",
       "      <td>0.031</td>\n",
       "      <td>0.840</td>\n",
       "      <td>0.129</td>\n",
       "      <td>0.9977</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>Sean Bohen</td>\n",
       "      <td>management</td>\n",
       "      <td>thank you marc i would now like to run through the late-stage pipeline events since the last results announcement and the highlights of recent data presentations at medical meetings and as usual i will ﬁnish with a look at our upcoming news ﬂow please turn to slide 28 we delivered more good progress in the quarter in oncology lynparza received eu approval for a broad second-line ovarian cancer...</td>\n",
       "      <td>0.151</td>\n",
       "      <td>0.756</td>\n",
       "      <td>0.094</td>\n",
       "      <td>-0.9986</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5</th>\n",
       "      <td>Pascal Soriot</td>\n",
       "      <td>management</td>\n",
       "      <td>thank you sean please turn to slide 33 now let me summarize before we end we are really pleased with the ongoing launches and the performance of our newer medicines during the first quarter as they underpin the guidance of growth in product sales in 2018 our ﬁnancials are on track with our performance being weighted towards the second half of the year and with product sales leading the way tot...</td>\n",
       "      <td>0.008</td>\n",
       "      <td>0.838</td>\n",
       "      <td>0.154</td>\n",
       "      <td>0.9868</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6</th>\n",
       "      <td>Pascal Soriot</td>\n",
       "      <td>management</td>\n",
       "      <td>so we have a question here from simon baker at exane simon go ahead simon p</td>\n",
       "      <td>0.000</td>\n",
       "      <td>1.000</td>\n",
       "      <td>0.000</td>\n",
       "      <td>0.0000</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>7</th>\n",
       "      <td>Baker</td>\n",
       "      <td>analyst</td>\n",
       "      <td>one for sean please if i may we can see from the press release this morning the expanding and evolving parp io combination trials that you are conducting but i was just wondering how much further there is to expand that i am thinking areas like colorectal where there is been some interesting work published this year on the potential applicability of parp in that indication and also therefore p...</td>\n",
       "      <td>0.000</td>\n",
       "      <td>0.889</td>\n",
       "      <td>0.111</td>\n",
       "      <td>0.8860</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>8</th>\n",
       "      <td>Sean Bohen</td>\n",
       "      <td>management</td>\n",
       "      <td>okay so let me -- sort of 2 questions there one is the expansion of i am going to call lynparza io so lynparza imﬁnzi or imﬁnzi plus treme so when we shared our ovarian cancer data we also shared that we have -- we are initiating a trial called duo-o which is looking at that combination speciﬁcally in ovarian cancer then we are looking at other data sets to see where we might expand beyond tha...</td>\n",
       "      <td>0.042</td>\n",
       "      <td>0.893</td>\n",
       "      <td>0.065</td>\n",
       "      <td>0.3429</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9</th>\n",
       "      <td>Pascal Soriot</td>\n",
       "      <td>management</td>\n",
       "      <td>thank you sean there is a question on the webcast that we will read aloud from vincent meunier at morgan stanley so he is trying to understand the potential of tagrisso initiative that were before you and the question is are there countries where the prevalence of the egfr mutations is higher than other countries? what about japan? and also in china what is the breakdown of volumes sales that ...</td>\n",
       "      <td>0.000</td>\n",
       "      <td>0.963</td>\n",
       "      <td>0.037</td>\n",
       "      <td>0.4660</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>10</th>\n",
       "      <td>David Fredrickson</td>\n",
       "      <td>management</td>\n",
       "      <td>so thank you for the question so yes there are countries where the prevalence is higher and in asian countries it tends to be the highest around the globe prevalence rates in countries we see it around 30% even as much as 35% japan china korea this would all be the case for those countries as you look through that on the second question in terms of the breakdown of volumes and sales in china t...</td>\n",
       "      <td>0.017</td>\n",
       "      <td>0.925</td>\n",
       "      <td>0.058</td>\n",
       "      <td>0.6594</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>11</th>\n",
       "      <td>Pascal Soriot</td>\n",
       "      <td>management</td>\n",
       "      <td>thank you dave then there is a question from tim anderson at bernstein tim go ahead timothy</td>\n",
       "      <td>0.000</td>\n",
       "      <td>0.857</td>\n",
       "      <td>0.143</td>\n",
       "      <td>0.3612</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>12</th>\n",
       "      <td>Minton Anderson</td>\n",
       "      <td>analyst</td>\n",
       "      <td>emerging markets and china are a big part of your business and in china your proportion of total sales coming from that region is much higher than peers i usually thought of emerging markets exposure as a good thing but you could argue it is the other way around because proﬁt levels are less markets like china you may get volatility tied to price cuts so with astra investors generally look for...</td>\n",
       "      <td>0.036</td>\n",
       "      <td>0.916</td>\n",
       "      <td>0.048</td>\n",
       "      <td>-0.2564</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>13</th>\n",
       "      <td>Pascal Soriot</td>\n",
       "      <td>management</td>\n",
       "      <td>let me just cover the second question tim then mark mallon you might want to cover the china question the second is very simple and straightforward tim we were not approached did not talk to michael cohen so we are totally out of this discussion china mark?</td>\n",
       "      <td>0.000</td>\n",
       "      <td>0.973</td>\n",
       "      <td>0.027</td>\n",
       "      <td>0.0772</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>14</th>\n",
       "      <td>Mark Mallon</td>\n",
       "      <td>management</td>\n",
       "      <td>so we deﬁnitely see china as a positive and to have such a strong position in there and we see continued growth and future potential of course every country around the globe is wrestling with health care costs and as we have seen in the last week in the u.s. there is risks around pricing actions and i do not think china represents particularly more or less risk than any other countries in fact...</td>\n",
       "      <td>0.027</td>\n",
       "      <td>0.865</td>\n",
       "      <td>0.108</td>\n",
       "      <td>0.9899</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>15</th>\n",
       "      <td>Matthew Weston</td>\n",
       "      <td>analyst</td>\n",
       "      <td>pascal my question's on the cost base really higher sg&amp;a has been one of the key discussion points this morning with investors mark mentioned the low base eﬀects but also the guidance range of low; to mid-single-digit growth is a large window so can you just give us some of the drivers of that range? is it competitors potentially reacting in respiratory that you may need to react to? it does n...</td>\n",
       "      <td>0.076</td>\n",
       "      <td>0.826</td>\n",
       "      <td>0.098</td>\n",
       "      <td>0.6922</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>16</th>\n",
       "      <td>Pascal Soriot</td>\n",
       "      <td>management</td>\n",
       "      <td>yes i mean let me try and mark mallon and marc dunoyer you could also help me but just in terms of the new launches i mean we have talked about quite a number of new launches tagrisso et cetera et cetera for sure now in the second half i think you have got to think of roxa and lokelma but they are like more in the prelaunch mode if you will including in the u.s. lokelma after we get approval w...</td>\n",
       "      <td>0.018</td>\n",
       "      <td>0.858</td>\n",
       "      <td>0.124</td>\n",
       "      <td>0.9370</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>17</th>\n",
       "      <td>Marc Dunoyer</td>\n",
       "      <td>management</td>\n",
       "      <td>no i think we are -- just one word we are obviously launching 8 -- in total 8 new medicine line extensions or new formulation and obviously we are -- this is very -- an important timing for the ﬁnal trajectory so we are closely monitoring the performance of these brands as they are being launched and this is why we try to allocate as much resources as we can dedicate to ensure the ﬁnal success...</td>\n",
       "      <td>0.010</td>\n",
       "      <td>0.883</td>\n",
       "      <td>0.108</td>\n",
       "      <td>0.9304</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>18</th>\n",
       "      <td>Mark Mallon</td>\n",
       "      <td>management</td>\n",
       "      <td>i will just add one (point) again is china and china to your point we have great scope and scale but we still have so much more to penetrate and so we have to continuously -- we are continuously expanding into new hospitals and customers and even cities and also we are doing multiple new launches in china so it is not just the established portfolio we have got many launches occurring at the sa...</td>\n",
       "      <td>0.000</td>\n",
       "      <td>0.970</td>\n",
       "      <td>0.030</td>\n",
       "      <td>0.3716</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>19</th>\n",
       "      <td>Pascal Soriot</td>\n",
       "      <td>management</td>\n",
       "      <td>so as you can hear we are -- yes go ahead matt</td>\n",
       "      <td>0.000</td>\n",
       "      <td>0.803</td>\n",
       "      <td>0.197</td>\n",
       "      <td>0.4019</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>20</th>\n",
       "      <td>Matthew Weston</td>\n",
       "      <td>analyst</td>\n",
       "      <td>if i could just ask one quick follow-up so i have no question regarding the increased spending in sg&amp;a because clearly you are in full launch mode i understand that everything that everybody seems to have referred to in your answer is events that are known to you or very highly likely to happen with the exception of really declare and roxa my question was really about what about the 5percentag...</td>\n",
       "      <td>0.034</td>\n",
       "      <td>0.926</td>\n",
       "      <td>0.040</td>\n",
       "      <td>0.1930</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>21</th>\n",
       "      <td>Marc Dunoyer</td>\n",
       "      <td>management</td>\n",
       "      <td>matt ﬁrst of all we provide guidance on product sales and eps so these are the 2 variables we obviously closely look at there are obviously several lines in the p&amp;l between product sales and eps but you need to remember we have provided guidance on these 2 and we will be doing our best to meet or exceed this guidance for the year</td>\n",
       "      <td>0.000</td>\n",
       "      <td>0.913</td>\n",
       "      <td>0.087</td>\n",
       "      <td>0.7783</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>22</th>\n",
       "      <td>Pascal Soriot</td>\n",
       "      <td>management</td>\n",
       "      <td>so we committed to the guidance and in fact the variation matt is really based on what opportunities we see i mean we see a new opportunity somewhere that could drive additional sales and proﬁt and we ﬂex at that point but essentially as marc said we will stick to the guidance so we can move maybe -- maybe the last point i was going to make earlier is that you can see we are in a -- and as you...</td>\n",
       "      <td>0.064</td>\n",
       "      <td>0.806</td>\n",
       "      <td>0.131</td>\n",
       "      <td>0.9337</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>23</th>\n",
       "      <td>Marc Dunoyer</td>\n",
       "      <td>management</td>\n",
       "      <td>so the 5 point reduction is obviously a reduction from quarter one 2017 quarter one 2018 and roughly the 4 factors that have been proposed are more or less equivalent to explain the diﬀerence so the buildout of the biologic manufacturing the lower absorption because we are early in the launch this is about 1/4 of it mix eﬀect on products such as crestor this is another 1/4 of this variance the...</td>\n",
       "      <td>0.036</td>\n",
       "      <td>0.895</td>\n",
       "      <td>0.069</td>\n",
       "      <td>0.8095</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>24</th>\n",
       "      <td>Pascal Soriot</td>\n",
       "      <td>management</td>\n",
       "      <td>thank you marc as far as the capacity build we are kind of almost done with this we are completing our ﬁlling plant in sweden but in terms of manufacturing product substance we are done and then we will start using that capacity over time so we now have a question from andrew baum at citi andrew go ahead andrew</td>\n",
       "      <td>0.000</td>\n",
       "      <td>0.971</td>\n",
       "      <td>0.029</td>\n",
       "      <td>0.1901</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>25</th>\n",
       "      <td>Simon Baum</td>\n",
       "      <td>analyst</td>\n",
       "      <td>so i suspect astra has received the request for information from the hss following the drug pricing announced could you give us a sense of how much follow-through to expect in relation to this announcement particularly the conversations about removing the protective class? and i am thinking of categories such as parp and maybe just then a quick one for sean could you just outline your plans fo...</td>\n",
       "      <td>0.042</td>\n",
       "      <td>0.931</td>\n",
       "      <td>0.027</td>\n",
       "      <td>0.3109</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>26</th>\n",
       "      <td>Pascal Soriot</td>\n",
       "      <td>management</td>\n",
       "      <td>2 great questions i must say the line was breaking up the second question is clear for sure and the ﬁrst one hopefully mark you got that one okay?</td>\n",
       "      <td>0.000</td>\n",
       "      <td>0.618</td>\n",
       "      <td>0.382</td>\n",
       "      <td>0.9118</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>27</th>\n",
       "      <td>Mark Mallon</td>\n",
       "      <td>management</td>\n",
       "      <td>yes what i heard andrew and if i am oﬀ track please correct me but you asked about did we get a request to provide information as part of the drug pricing plans that the administration are working on and how much do we expect that to come through the system i think as you know and we all know i mean there were a lot of i think over 50 potential actions highlighted in the administration's plan ...</td>\n",
       "      <td>0.009</td>\n",
       "      <td>0.884</td>\n",
       "      <td>0.107</td>\n",
       "      <td>0.9726</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>28</th>\n",
       "      <td>Pascal Soriot</td>\n",
       "      <td>management</td>\n",
       "      <td>yes yes so i mean we have been very successful with some of the outcome-based pricing contracts we have implemented and if we could expand on those as part of a broader policy that the administration would want to put in place i think it would really be very welcomed by us and i am sure by many other companies sean do you want to cover the akt question?</td>\n",
       "      <td>0.000</td>\n",
       "      <td>0.744</td>\n",
       "      <td>0.256</td>\n",
       "      <td>0.9489</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>29</th>\n",
       "      <td>Sean Bohen</td>\n",
       "      <td>management</td>\n",
       "      <td>sure sure thank you for the question andrew so the question relates to the phase ii data that (you've seen the abstract and) we will present it in more detail at the asco meeting capivasertib our akt inhibitor in triple negative breast cancer metastatic breast cancer we think the data's encouraging we think it is pretty strong indication of activity of the akt pathway in triple negative breast...</td>\n",
       "      <td>0.134</td>\n",
       "      <td>0.727</td>\n",
       "      <td>0.139</td>\n",
       "      <td>-0.6013</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>30</th>\n",
       "      <td>Pascal Soriot</td>\n",
       "      <td>management</td>\n",
       "      <td>thank you sean as you can see more to come on this one but certainly very exciting early data with this new agent coming out of cambridge research team so really really good new development we will extend the (tc) by about 10 minutes so that we give everybody a chance to ask a question and the next one on the list here is sachin jain at bank of america sachin go ahead on lynparza similar to th...</td>\n",
       "      <td>0.000</td>\n",
       "      <td>0.863</td>\n",
       "      <td>0.137</td>\n",
       "      <td>0.9618</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>31</th>\n",
       "      <td>Sean Bohen</td>\n",
       "      <td>management</td>\n",
       "      <td>okay so i think -- sachin let me clarify your -- in this case you are referring speciﬁcally the study 8 data in prostate cancer when you say in combination for..</td>\n",
       "      <td>0.132</td>\n",
       "      <td>0.811</td>\n",
       "      <td>0.057</td>\n",
       "      <td>-0.5423</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>32</th>\n",
       "      <td>Sachin Jain</td>\n",
       "      <td>analyst</td>\n",
       "      <td>correct</td>\n",
       "      <td>0.000</td>\n",
       "      <td>1.000</td>\n",
       "      <td>0.000</td>\n",
       "      <td>0.0000</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>33</th>\n",
       "      <td>Sean Bohen</td>\n",
       "      <td>management</td>\n",
       "      <td>okay okay great well i think the -- i mean i think the answer is not dissimilar to the answer i gave for andrew's question with regard to capivasertib again we do -- we ﬁnd that data encouraging from study 8 again the question is really whether there is a regulatory pathway to bring that forward and that is a discussion with regulators in order to decide whether or not we are going to do that ...</td>\n",
       "      <td>0.029</td>\n",
       "      <td>0.882</td>\n",
       "      <td>0.090</td>\n",
       "      <td>0.6249</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>34</th>\n",
       "      <td>Pascal Soriot</td>\n",
       "      <td>management</td>\n",
       "      <td>excellent so there is a question on the webcast by sam fazeli at bloomberg and the question is can you explain the reasoning behind starting pacific 2? so sort of the pacific program sean do you want to cover that?</td>\n",
       "      <td>0.000</td>\n",
       "      <td>0.873</td>\n",
       "      <td>0.127</td>\n",
       "      <td>0.6553</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>35</th>\n",
       "      <td>Sean Bohen</td>\n",
       "      <td>management</td>\n",
       "      <td>yes sure yes the rationale behind pacific 2 really has to do with the fact that while concurrent administration of chemotherapy and radiation therapy are the well-established standard of care in the united states and europe there are many parts of the world where concurrent is not the standard of care and a lot of that has to do with the challenges of coordinating that radiation therapy and ch...</td>\n",
       "      <td>0.008</td>\n",
       "      <td>0.873</td>\n",
       "      <td>0.119</td>\n",
       "      <td>0.9423</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>36</th>\n",
       "      <td>Pascal Soriot</td>\n",
       "      <td>management</td>\n",
       "      <td>thank you sean i think we have -- maybe we will take another 2 so we have one question</td>\n",
       "      <td>0.000</td>\n",
       "      <td>0.865</td>\n",
       "      <td>0.135</td>\n",
       "      <td>0.3612</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>37</th>\n",
       "      <td>Alex Arfaei</td>\n",
       "      <td>analyst</td>\n",
       "      <td>great well just looking at your operating margin here i fully appreciate the headwinds you are facing with the patent expirations and the investments the maximum pressure points on launches et cetera but as you step back and look at your business how realistic is it for investors to expect that once things normalize you should have an operating margin that is more in line with your european an...</td>\n",
       "      <td>0.014</td>\n",
       "      <td>0.901</td>\n",
       "      <td>0.085</td>\n",
       "      <td>0.7968</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>38</th>\n",
       "      <td>Pascal Soriot</td>\n",
       "      <td>management</td>\n",
       "      <td>okay so the second question will be -- dave you could take and in the ﬁrst question is about margins when you look at our peers you really have to be careful who you look at because some companies have such a very focused business around say specialty care and sometimes it is even beyond that specialty care u.s with a little bit of european presence so the margins of course reﬂect a little bit...</td>\n",
       "      <td>0.023</td>\n",
       "      <td>0.860</td>\n",
       "      <td>0.116</td>\n",
       "      <td>0.9614</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>39</th>\n",
       "      <td>David Fredrickson</td>\n",
       "      <td>management</td>\n",
       "      <td>yes so on the ﬁrst question of the uptake that we have been seeing with imﬁnzi in stage iii unresectable as i mentioned earlier the lion's share in fact the overwhelming majority of our sales in the first quarter came from that population as you saw earlier in one of the slides from pascal you can see the demand increasing with imﬁnzi within this population we had an estimated 3,500 monthly in...</td>\n",
       "      <td>0.013</td>\n",
       "      <td>0.916</td>\n",
       "      <td>0.071</td>\n",
       "      <td>0.7891</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>40</th>\n",
       "      <td>Pascal Soriot</td>\n",
       "      <td>management</td>\n",
       "      <td>sorry did you want to..</td>\n",
       "      <td>0.232</td>\n",
       "      <td>0.536</td>\n",
       "      <td>0.232</td>\n",
       "      <td>0.0000</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>41</th>\n",
       "      <td>Sean Bohen</td>\n",
       "      <td>management</td>\n",
       "      <td>yes i believe if i heard you right alex there was a question as well around resectable disease and obviously that is not the indication so that is not something we track i just want to point out that we do have an adjuvant study ongoing which studies that question very speciﬁcally stage ib through iia non-small cell lung cancer post-surgical therapy they do better than unresectable patients bu...</td>\n",
       "      <td>0.025</td>\n",
       "      <td>0.864</td>\n",
       "      <td>0.111</td>\n",
       "      <td>0.7269</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>42</th>\n",
       "      <td>David Fredrickson</td>\n",
       "      <td>management</td>\n",
       "      <td>yes and just so that i am clear and almost -- i mean 100% of our use is in the unresectable population post-crt and in the u.s. that represents about 80% of stage iii in terms of the unresectable population</td>\n",
       "      <td>0.000</td>\n",
       "      <td>0.866</td>\n",
       "      <td>0.134</td>\n",
       "      <td>0.6771</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>43</th>\n",
       "      <td>Pascal Soriot</td>\n",
       "      <td>management</td>\n",
       "      <td>so we will take the marietta's question on the webcast at primavenue and she is asking a question about farxiga and in china and saying \"i did not realize you could get provincial reimbursement without being on the nrdl.\" and also \"is there a chance to get on the nrdl through negotiations that are outside the oﬃcial window for reviews and additions?\" mark do you want to cover this?</td>\n",
       "      <td>0.000</td>\n",
       "      <td>0.947</td>\n",
       "      <td>0.053</td>\n",
       "      <td>0.3939</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>44</th>\n",
       "      <td>Mark Mallon</td>\n",
       "      <td>management</td>\n",
       "      <td>yes so thanks marietta it is a great question so yes you can we have done this in the past with other products in fact i should say getting on the nrdl does not guarantee you that you get listed on the province level this is why pascal -- one of the reasons pascal keeps highlighting the importance about the quality of our people and the scale of our business is because we have dedicated market...</td>\n",
       "      <td>0.010</td>\n",
       "      <td>0.822</td>\n",
       "      <td>0.168</td>\n",
       "      <td>0.9915</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>45</th>\n",
       "      <td>Pascal Soriot</td>\n",
       "      <td>management</td>\n",
       "      <td>not only you can get provincial reimbursement you can sometimes get city reimbursement so there are many many diﬀerent sources of access in china and the last question richard parkes of deutsche bank and we will ﬁnish with richard's question go ahead richard richard j</td>\n",
       "      <td>0.000</td>\n",
       "      <td>1.000</td>\n",
       "      <td>0.000</td>\n",
       "      <td>0.0000</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>46</th>\n",
       "      <td>Parkes</td>\n",
       "      <td>analyst</td>\n",
       "      <td>great so again it is on imﬁnzi and the stage iii in resectable lung cancer setting so if you look at the ims weekly sales it looks like you are annualizing now well north of 400 million i am just wondering if you could give us any kind of sense of where you are in terms of penetration of that unresectable setting in the u.s. and maybe whether that strong launch would make you reevaluate your ﬂ...</td>\n",
       "      <td>0.032</td>\n",
       "      <td>0.842</td>\n",
       "      <td>0.126</td>\n",
       "      <td>0.9022</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>47</th>\n",
       "      <td>Pascal Soriot</td>\n",
       "      <td>management</td>\n",
       "      <td>thanks very much richard i appreciate the question that will help us in our discussions with dave actually and the forecast you are absolutely right the last weekly data points are pretty good and dave do you want to cover that one?</td>\n",
       "      <td>0.000</td>\n",
       "      <td>0.687</td>\n",
       "      <td>0.313</td>\n",
       "      <td>0.9321</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>48</th>\n",
       "      <td>David Fredrickson</td>\n",
       "      <td>management</td>\n",
       "      <td>yes absolutely so i think the ﬁrst place just to comment on in terms of where we see the penetration and i want to ground it just in the crt behavior so again about 80% of stage iii patients are unresectable of those half gets crt and that is not something that has really changed too dramatically in terms of the number of crt patients post that are unable to get unresected so one of our big ed...</td>\n",
       "      <td>0.006</td>\n",
       "      <td>0.860</td>\n",
       "      <td>0.134</td>\n",
       "      <td>0.9837</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>49</th>\n",
       "      <td>Pascal Soriot</td>\n",
       "      <td>management</td>\n",
       "      <td>thanks dave and as you can imagine of course we are also launching in japan and the rest of the world europe et cetera later this year and into early next year so there is a lot more to come as it relates to imﬁnzi but give me a chance before i conclude give me a chance to thank dave and the oncology team in particular in the u.s with the fantastic imﬁnzi launch and also the tagrisso team and ...</td>\n",
       "      <td>0.007</td>\n",
       "      <td>0.750</td>\n",
       "      <td>0.243</td>\n",
       "      <td>0.9985</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "              speaker    position  \\\n",
       "0       Pascal Soriot  management   \n",
       "1   David Fredrickson  management   \n",
       "2         Mark Mallon  management   \n",
       "3        Marc Dunoyer  management   \n",
       "4          Sean Bohen  management   \n",
       "5       Pascal Soriot  management   \n",
       "6       Pascal Soriot  management   \n",
       "7               Baker     analyst   \n",
       "8          Sean Bohen  management   \n",
       "9       Pascal Soriot  management   \n",
       "10  David Fredrickson  management   \n",
       "11      Pascal Soriot  management   \n",
       "12    Minton Anderson     analyst   \n",
       "13      Pascal Soriot  management   \n",
       "14        Mark Mallon  management   \n",
       "15     Matthew Weston     analyst   \n",
       "16      Pascal Soriot  management   \n",
       "17       Marc Dunoyer  management   \n",
       "18        Mark Mallon  management   \n",
       "19      Pascal Soriot  management   \n",
       "20     Matthew Weston     analyst   \n",
       "21       Marc Dunoyer  management   \n",
       "22      Pascal Soriot  management   \n",
       "23       Marc Dunoyer  management   \n",
       "24      Pascal Soriot  management   \n",
       "25         Simon Baum     analyst   \n",
       "26      Pascal Soriot  management   \n",
       "27        Mark Mallon  management   \n",
       "28      Pascal Soriot  management   \n",
       "29         Sean Bohen  management   \n",
       "30      Pascal Soriot  management   \n",
       "31         Sean Bohen  management   \n",
       "32        Sachin Jain     analyst   \n",
       "33         Sean Bohen  management   \n",
       "34      Pascal Soriot  management   \n",
       "35         Sean Bohen  management   \n",
       "36      Pascal Soriot  management   \n",
       "37        Alex Arfaei     analyst   \n",
       "38      Pascal Soriot  management   \n",
       "39  David Fredrickson  management   \n",
       "40      Pascal Soriot  management   \n",
       "41         Sean Bohen  management   \n",
       "42  David Fredrickson  management   \n",
       "43      Pascal Soriot  management   \n",
       "44        Mark Mallon  management   \n",
       "45      Pascal Soriot  management   \n",
       "46             Parkes     analyst   \n",
       "47      Pascal Soriot  management   \n",
       "48  David Fredrickson  management   \n",
       "49      Pascal Soriot  management   \n",
       "\n",
       "                                                                                                                                                                                                                                                                                                                                                                                                            content  \\\n",
       "0   hello everyone it is pascal soriot here ceo of astrazeneca welcome to our first quarter results conference call and webcast for investors and analysts we are here in london on a very beautiful day for the annual general meeting this afternoon we have people on the phone and on the webcast the presentation is available to you on astrazeneca.com as always for you to download please turn to slide...   \n",
       "1   great thank you so much pascal and i am really pleased here to be here to update all of you on the performance of our new generation of medicines i will start ﬁrst with oncology and then i will hand it over to mark mallon for a summary of cvrm respiratory and emerging markets if we could turn please to page 12 we are really pleased to announce that total oncology grew by 33% quarter-over-quart...   \n",
       "2   thanks dave now moving to new cvrm which as pascal mentioned is deﬁned as our medicines in cardiovascular renal and metabolic diseases sales were up by 8% despite the intense competition with first quarter sales at 900 million farxiga and brilinta continued to remain strong with double-digit growth across all regions brilinta sales of 293 million with 24% growth driven by the u.s at 32% and em...   \n",
       "3   thank you mark and hello everyone i am going to spend the next few minutes taking you through our ﬁnancial performance in the first quarter of the year as well as our unchanged guidance please turn to slide 22 as usual i will begin with the reported p&l before turning to the core numbers as pascal mentioned earlier product sales declined by 2% impacted by the reduced sales of crestor in europe...   \n",
       "4   thank you marc i would now like to run through the late-stage pipeline events since the last results announcement and the highlights of recent data presentations at medical meetings and as usual i will ﬁnish with a look at our upcoming news ﬂow please turn to slide 28 we delivered more good progress in the quarter in oncology lynparza received eu approval for a broad second-line ovarian cancer...   \n",
       "5   thank you sean please turn to slide 33 now let me summarize before we end we are really pleased with the ongoing launches and the performance of our newer medicines during the first quarter as they underpin the guidance of growth in product sales in 2018 our ﬁnancials are on track with our performance being weighted towards the second half of the year and with product sales leading the way tot...   \n",
       "6                                                                                                                                                                                                                                                                                                                                       so we have a question here from simon baker at exane simon go ahead simon p   \n",
       "7   one for sean please if i may we can see from the press release this morning the expanding and evolving parp io combination trials that you are conducting but i was just wondering how much further there is to expand that i am thinking areas like colorectal where there is been some interesting work published this year on the potential applicability of parp in that indication and also therefore p...   \n",
       "8   okay so let me -- sort of 2 questions there one is the expansion of i am going to call lynparza io so lynparza imﬁnzi or imﬁnzi plus treme so when we shared our ovarian cancer data we also shared that we have -- we are initiating a trial called duo-o which is looking at that combination speciﬁcally in ovarian cancer then we are looking at other data sets to see where we might expand beyond tha...   \n",
       "9   thank you sean there is a question on the webcast that we will read aloud from vincent meunier at morgan stanley so he is trying to understand the potential of tagrisso initiative that were before you and the question is are there countries where the prevalence of the egfr mutations is higher than other countries? what about japan? and also in china what is the breakdown of volumes sales that ...   \n",
       "10  so thank you for the question so yes there are countries where the prevalence is higher and in asian countries it tends to be the highest around the globe prevalence rates in countries we see it around 30% even as much as 35% japan china korea this would all be the case for those countries as you look through that on the second question in terms of the breakdown of volumes and sales in china t...   \n",
       "11                                                                                                                                                                                                                                                                                                                      thank you dave then there is a question from tim anderson at bernstein tim go ahead timothy   \n",
       "12  emerging markets and china are a big part of your business and in china your proportion of total sales coming from that region is much higher than peers i usually thought of emerging markets exposure as a good thing but you could argue it is the other way around because proﬁt levels are less markets like china you may get volatility tied to price cuts so with astra investors generally look for...   \n",
       "13                                                                                                                                                let me just cover the second question tim then mark mallon you might want to cover the china question the second is very simple and straightforward tim we were not approached did not talk to michael cohen so we are totally out of this discussion china mark?   \n",
       "14  so we deﬁnitely see china as a positive and to have such a strong position in there and we see continued growth and future potential of course every country around the globe is wrestling with health care costs and as we have seen in the last week in the u.s. there is risks around pricing actions and i do not think china represents particularly more or less risk than any other countries in fact...   \n",
       "15  pascal my question's on the cost base really higher sg&a has been one of the key discussion points this morning with investors mark mentioned the low base eﬀects but also the guidance range of low; to mid-single-digit growth is a large window so can you just give us some of the drivers of that range? is it competitors potentially reacting in respiratory that you may need to react to? it does n...   \n",
       "16  yes i mean let me try and mark mallon and marc dunoyer you could also help me but just in terms of the new launches i mean we have talked about quite a number of new launches tagrisso et cetera et cetera for sure now in the second half i think you have got to think of roxa and lokelma but they are like more in the prelaunch mode if you will including in the u.s. lokelma after we get approval w...   \n",
       "17  no i think we are -- just one word we are obviously launching 8 -- in total 8 new medicine line extensions or new formulation and obviously we are -- this is very -- an important timing for the ﬁnal trajectory so we are closely monitoring the performance of these brands as they are being launched and this is why we try to allocate as much resources as we can dedicate to ensure the ﬁnal success...   \n",
       "18  i will just add one (point) again is china and china to your point we have great scope and scale but we still have so much more to penetrate and so we have to continuously -- we are continuously expanding into new hospitals and customers and even cities and also we are doing multiple new launches in china so it is not just the established portfolio we have got many launches occurring at the sa...   \n",
       "19                                                                                                                                                                                                                                                                                                                                                                   so as you can hear we are -- yes go ahead matt   \n",
       "20  if i could just ask one quick follow-up so i have no question regarding the increased spending in sg&a because clearly you are in full launch mode i understand that everything that everybody seems to have referred to in your answer is events that are known to you or very highly likely to happen with the exception of really declare and roxa my question was really about what about the 5percentag...   \n",
       "21                                                                      matt ﬁrst of all we provide guidance on product sales and eps so these are the 2 variables we obviously closely look at there are obviously several lines in the p&l between product sales and eps but you need to remember we have provided guidance on these 2 and we will be doing our best to meet or exceed this guidance for the year   \n",
       "22  so we committed to the guidance and in fact the variation matt is really based on what opportunities we see i mean we see a new opportunity somewhere that could drive additional sales and proﬁt and we ﬂex at that point but essentially as marc said we will stick to the guidance so we can move maybe -- maybe the last point i was going to make earlier is that you can see we are in a -- and as you...   \n",
       "23  so the 5 point reduction is obviously a reduction from quarter one 2017 quarter one 2018 and roughly the 4 factors that have been proposed are more or less equivalent to explain the diﬀerence so the buildout of the biologic manufacturing the lower absorption because we are early in the launch this is about 1/4 of it mix eﬀect on products such as crestor this is another 1/4 of this variance the...   \n",
       "24                                                                                         thank you marc as far as the capacity build we are kind of almost done with this we are completing our ﬁlling plant in sweden but in terms of manufacturing product substance we are done and then we will start using that capacity over time so we now have a question from andrew baum at citi andrew go ahead andrew   \n",
       "25  so i suspect astra has received the request for information from the hss following the drug pricing announced could you give us a sense of how much follow-through to expect in relation to this announcement particularly the conversations about removing the protective class? and i am thinking of categories such as parp and maybe just then a quick one for sean could you just outline your plans fo...   \n",
       "26                                                                                                                                                                                                                                                               2 great questions i must say the line was breaking up the second question is clear for sure and the ﬁrst one hopefully mark you got that one okay?   \n",
       "27  yes what i heard andrew and if i am oﬀ track please correct me but you asked about did we get a request to provide information as part of the drug pricing plans that the administration are working on and how much do we expect that to come through the system i think as you know and we all know i mean there were a lot of i think over 50 potential actions highlighted in the administration's plan ...   \n",
       "28                                              yes yes so i mean we have been very successful with some of the outcome-based pricing contracts we have implemented and if we could expand on those as part of a broader policy that the administration would want to put in place i think it would really be very welcomed by us and i am sure by many other companies sean do you want to cover the akt question?   \n",
       "29  sure sure thank you for the question andrew so the question relates to the phase ii data that (you've seen the abstract and) we will present it in more detail at the asco meeting capivasertib our akt inhibitor in triple negative breast cancer metastatic breast cancer we think the data's encouraging we think it is pretty strong indication of activity of the akt pathway in triple negative breast...   \n",
       "30  thank you sean as you can see more to come on this one but certainly very exciting early data with this new agent coming out of cambridge research team so really really good new development we will extend the (tc) by about 10 minutes so that we give everybody a chance to ask a question and the next one on the list here is sachin jain at bank of america sachin go ahead on lynparza similar to th...   \n",
       "31                                                                                                                                                                                                                                                okay so i think -- sachin let me clarify your -- in this case you are referring speciﬁcally the study 8 data in prostate cancer when you say in combination for..   \n",
       "32                                                                                                                                                                                                                                                                                                                                                                                                          correct   \n",
       "33  okay okay great well i think the -- i mean i think the answer is not dissimilar to the answer i gave for andrew's question with regard to capivasertib again we do -- we ﬁnd that data encouraging from study 8 again the question is really whether there is a regulatory pathway to bring that forward and that is a discussion with regulators in order to decide whether or not we are going to do that ...   \n",
       "34                                                                                                                                                                                           excellent so there is a question on the webcast by sam fazeli at bloomberg and the question is can you explain the reasoning behind starting pacific 2? so sort of the pacific program sean do you want to cover that?   \n",
       "35  yes sure yes the rationale behind pacific 2 really has to do with the fact that while concurrent administration of chemotherapy and radiation therapy are the well-established standard of care in the united states and europe there are many parts of the world where concurrent is not the standard of care and a lot of that has to do with the challenges of coordinating that radiation therapy and ch...   \n",
       "36                                                                                                                                                                                                                                                                                                                           thank you sean i think we have -- maybe we will take another 2 so we have one question   \n",
       "37  great well just looking at your operating margin here i fully appreciate the headwinds you are facing with the patent expirations and the investments the maximum pressure points on launches et cetera but as you step back and look at your business how realistic is it for investors to expect that once things normalize you should have an operating margin that is more in line with your european an...   \n",
       "38  okay so the second question will be -- dave you could take and in the ﬁrst question is about margins when you look at our peers you really have to be careful who you look at because some companies have such a very focused business around say specialty care and sometimes it is even beyond that specialty care u.s with a little bit of european presence so the margins of course reﬂect a little bit...   \n",
       "39  yes so on the ﬁrst question of the uptake that we have been seeing with imﬁnzi in stage iii unresectable as i mentioned earlier the lion's share in fact the overwhelming majority of our sales in the first quarter came from that population as you saw earlier in one of the slides from pascal you can see the demand increasing with imﬁnzi within this population we had an estimated 3,500 monthly in...   \n",
       "40                                                                                                                                                                                                                                                                                                                                                                                          sorry did you want to..   \n",
       "41  yes i believe if i heard you right alex there was a question as well around resectable disease and obviously that is not the indication so that is not something we track i just want to point out that we do have an adjuvant study ongoing which studies that question very speciﬁcally stage ib through iia non-small cell lung cancer post-surgical therapy they do better than unresectable patients bu...   \n",
       "42                                                                                                                                                                                                   yes and just so that i am clear and almost -- i mean 100% of our use is in the unresectable population post-crt and in the u.s. that represents about 80% of stage iii in terms of the unresectable population   \n",
       "43                 so we will take the marietta's question on the webcast at primavenue and she is asking a question about farxiga and in china and saying \"i did not realize you could get provincial reimbursement without being on the nrdl.\" and also \"is there a chance to get on the nrdl through negotiations that are outside the oﬃcial window for reviews and additions?\" mark do you want to cover this?   \n",
       "44  yes so thanks marietta it is a great question so yes you can we have done this in the past with other products in fact i should say getting on the nrdl does not guarantee you that you get listed on the province level this is why pascal -- one of the reasons pascal keeps highlighting the importance about the quality of our people and the scale of our business is because we have dedicated market...   \n",
       "45                                                                                                                                     not only you can get provincial reimbursement you can sometimes get city reimbursement so there are many many diﬀerent sources of access in china and the last question richard parkes of deutsche bank and we will ﬁnish with richard's question go ahead richard richard j   \n",
       "46  great so again it is on imﬁnzi and the stage iii in resectable lung cancer setting so if you look at the ims weekly sales it looks like you are annualizing now well north of 400 million i am just wondering if you could give us any kind of sense of where you are in terms of penetration of that unresectable setting in the u.s. and maybe whether that strong launch would make you reevaluate your ﬂ...   \n",
       "47                                                                                                                                                                         thanks very much richard i appreciate the question that will help us in our discussions with dave actually and the forecast you are absolutely right the last weekly data points are pretty good and dave do you want to cover that one?   \n",
       "48  yes absolutely so i think the ﬁrst place just to comment on in terms of where we see the penetration and i want to ground it just in the crt behavior so again about 80% of stage iii patients are unresectable of those half gets crt and that is not something that has really changed too dramatically in terms of the number of crt patients post that are unable to get unresected so one of our big ed...   \n",
       "49  thanks dave and as you can imagine of course we are also launching in japan and the rest of the world europe et cetera later this year and into early next year so there is a lot more to come as it relates to imﬁnzi but give me a chance before i conclude give me a chance to thank dave and the oncology team in particular in the u.s with the fantastic imﬁnzi launch and also the tagrisso team and ...   \n",
       "\n",
       "      neg    neu    pos  compound  \n",
       "0   0.043  0.823  0.135    0.9995  \n",
       "1   0.030  0.833  0.137    0.9989  \n",
       "2   0.017  0.825  0.158    0.9981  \n",
       "3   0.031  0.840  0.129    0.9977  \n",
       "4   0.151  0.756  0.094   -0.9986  \n",
       "5   0.008  0.838  0.154    0.9868  \n",
       "6   0.000  1.000  0.000    0.0000  \n",
       "7   0.000  0.889  0.111    0.8860  \n",
       "8   0.042  0.893  0.065    0.3429  \n",
       "9   0.000  0.963  0.037    0.4660  \n",
       "10  0.017  0.925  0.058    0.6594  \n",
       "11  0.000  0.857  0.143    0.3612  \n",
       "12  0.036  0.916  0.048   -0.2564  \n",
       "13  0.000  0.973  0.027    0.0772  \n",
       "14  0.027  0.865  0.108    0.9899  \n",
       "15  0.076  0.826  0.098    0.6922  \n",
       "16  0.018  0.858  0.124    0.9370  \n",
       "17  0.010  0.883  0.108    0.9304  \n",
       "18  0.000  0.970  0.030    0.3716  \n",
       "19  0.000  0.803  0.197    0.4019  \n",
       "20  0.034  0.926  0.040    0.1930  \n",
       "21  0.000  0.913  0.087    0.7783  \n",
       "22  0.064  0.806  0.131    0.9337  \n",
       "23  0.036  0.895  0.069    0.8095  \n",
       "24  0.000  0.971  0.029    0.1901  \n",
       "25  0.042  0.931  0.027    0.3109  \n",
       "26  0.000  0.618  0.382    0.9118  \n",
       "27  0.009  0.884  0.107    0.9726  \n",
       "28  0.000  0.744  0.256    0.9489  \n",
       "29  0.134  0.727  0.139   -0.6013  \n",
       "30  0.000  0.863  0.137    0.9618  \n",
       "31  0.132  0.811  0.057   -0.5423  \n",
       "32  0.000  1.000  0.000    0.0000  \n",
       "33  0.029  0.882  0.090    0.6249  \n",
       "34  0.000  0.873  0.127    0.6553  \n",
       "35  0.008  0.873  0.119    0.9423  \n",
       "36  0.000  0.865  0.135    0.3612  \n",
       "37  0.014  0.901  0.085    0.7968  \n",
       "38  0.023  0.860  0.116    0.9614  \n",
       "39  0.013  0.916  0.071    0.7891  \n",
       "40  0.232  0.536  0.232    0.0000  \n",
       "41  0.025  0.864  0.111    0.7269  \n",
       "42  0.000  0.866  0.134    0.6771  \n",
       "43  0.000  0.947  0.053    0.3939  \n",
       "44  0.010  0.822  0.168    0.9915  \n",
       "45  0.000  1.000  0.000    0.0000  \n",
       "46  0.032  0.842  0.126    0.9022  \n",
       "47  0.000  0.687  0.313    0.9321  \n",
       "48  0.006  0.860  0.134    0.9837  \n",
       "49  0.007  0.750  0.243    0.9985  "
      ]
     },
     "execution_count": 56,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "def vader_sentiment_score(data):\n",
    "    import nltk\n",
    "    from nltk.sentiment.vader import SentimentIntensityAnalyzer\n",
    "    analyzer = SentimentIntensityAnalyzer()\n",
    "    \n",
    "    df = get_speaker_content(data)\n",
    "    df['neg'] = df['content'].apply(lambda x:analyzer.polarity_scores(x)['neg'])\n",
    "    df['neu'] = df['content'].apply(lambda x:analyzer.polarity_scores(x)['neu'])\n",
    "    df['pos'] = df['content'].apply(lambda x:analyzer.polarity_scores(x)['pos'])\n",
    "    df['compound'] = df['content'].apply(lambda x:analyzer.polarity_scores(x)['compound'])\n",
    "    \n",
    "    return df\n",
    "\n",
    "\n",
    "vader_sentiment_score(data)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 63,
   "id": "e65114e0",
   "metadata": {},
   "outputs": [],
   "source": [
    "score = vader_sentiment_score(data)\n",
    "score1 = vader_sentiment_score(data1)\n",
    "score2 = vader_sentiment_score(data2)\n",
    "score3 = vader_sentiment_score(data3)\n",
    "score4 = vader_sentiment_score(data4)\n",
    "score5 = vader_sentiment_score(data5)\n",
    "score6 = vader_sentiment_score(data6)\n",
    "score7 = vader_sentiment_score(data7)\n",
    "score8 = vader_sentiment_score(data8)\n",
    "score9 = vader_sentiment_score(data9)\n",
    "score10 = vader_sentiment_score(data10)\n",
    "score11 = vader_sentiment_score(data11)\n",
    "score12 = vader_sentiment_score(data12)\n",
    "score13 = vader_sentiment_score(data13)\n",
    "score14 = vader_sentiment_score(data14)\n",
    "score15 = vader_sentiment_score(data15)\n",
    "score16 = vader_sentiment_score(data16)\n",
    "score17 = vader_sentiment_score(data17)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 66,
   "id": "aa8afab7",
   "metadata": {},
   "outputs": [],
   "source": [
    "a_score = score['compound'].mean()\n",
    "a_score1 = score1['compound'].mean()\n",
    "a_score2 = score2['compound'].mean()\n",
    "a_score3 = score3['compound'].mean()\n",
    "a_score4 = score4['compound'].mean()\n",
    "a_score5 = score5['compound'].mean()\n",
    "a_score6 = score6['compound'].mean()\n",
    "a_score7 = score7['compound'].mean()\n",
    "a_score8 = score8['compound'].mean()\n",
    "a_score9 = score9['compound'].mean()\n",
    "a_score10 = score10['compound'].mean()\n",
    "a_score11 = score11['compound'].mean()\n",
    "a_score12 = score12['compound'].mean()\n",
    "a_score13 = score13['compound'].mean()\n",
    "a_score14 = score14['compound'].mean()\n",
    "a_score15 = score15['compound'].mean()\n",
    "a_score16 = score16['compound'].mean()\n",
    "a_score17 = score17['compound'].mean()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 72,
   "id": "6878d492",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>AZN</th>\n",
       "      <th>AHT</th>\n",
       "      <th>BARC</th>\n",
       "      <th>BP</th>\n",
       "      <th>BTA</th>\n",
       "      <th>SHEL</th>\n",
       "      <th>GSK</th>\n",
       "      <th>HSBC</th>\n",
       "      <th>IAG</th>\n",
       "      <th>IMB</th>\n",
       "      <th>LLOY</th>\n",
       "      <th>NWG</th>\n",
       "      <th>RRS</th>\n",
       "      <th>SKY</th>\n",
       "      <th>SHP</th>\n",
       "      <th>SN</th>\n",
       "      <th>TUI</th>\n",
       "      <th>EDV</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>0.568912</td>\n",
       "      <td>0.863036</td>\n",
       "      <td>0.637718</td>\n",
       "      <td>0.452556</td>\n",
       "      <td>0.584858</td>\n",
       "      <td>0.787675</td>\n",
       "      <td>0.642855</td>\n",
       "      <td>0.714915</td>\n",
       "      <td>0.638052</td>\n",
       "      <td>0.476495</td>\n",
       "      <td>0.632377</td>\n",
       "      <td>0.45598</td>\n",
       "      <td>0.3279</td>\n",
       "      <td>0.8447</td>\n",
       "      <td>0.627206</td>\n",
       "      <td>0.564843</td>\n",
       "      <td>0.54784</td>\n",
       "      <td>0.746963</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "        AZN       AHT      BARC        BP       BTA      SHEL       GSK  \\\n",
       "0  0.568912  0.863036  0.637718  0.452556  0.584858  0.787675  0.642855   \n",
       "\n",
       "       HSBC       IAG       IMB      LLOY      NWG     RRS     SKY       SHP  \\\n",
       "0  0.714915  0.638052  0.476495  0.632377  0.45598  0.3279  0.8447  0.627206   \n",
       "\n",
       "         SN      TUI       EDV  \n",
       "0  0.564843  0.54784  0.746963  "
      ]
     },
     "execution_count": 72,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "avg_score = pd.DataFrame(np.array([[a_score, a_score1, a_score2, a_score3, a_score4, a_score5, a_score6, a_score7, a_score8, a_score9, a_score10, a_score11, a_score12, a_score13, a_score14, a_score15, a_score16, a_score17]]),\n",
    "                   columns=['AZN', 'AHT', 'BARC', 'BP', 'BTA', 'SHEL', 'GSK', 'HSBC', 'IAG', 'IMB', 'LLOY', 'NWG', 'RRS', 'SKY', 'SHP', 'SN', 'TUI', 'EDV'])\n",
    "avg_score"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 78,
   "id": "fd21ba9b",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>Ticker Name</th>\n",
       "      <th>Q1 Revenue</th>\n",
       "      <th>Q2 Revenue</th>\n",
       "      <th>Q3 Revenue</th>\n",
       "      <th>Q4 Revenue</th>\n",
       "      <th>19 Q1 Revenue</th>\n",
       "      <th>Q1-t-Q2 change</th>\n",
       "      <th>Q2-t-Q3 change</th>\n",
       "      <th>Q3-t-Q4 change</th>\n",
       "      <th>Q4-t-Q5 change</th>\n",
       "      <th>...</th>\n",
       "      <th>19 Q1 NI</th>\n",
       "      <th>Q1-t-Q2 change.1</th>\n",
       "      <th>Q2-t-Q3 change.1</th>\n",
       "      <th>Q3-t-Q4 change.1</th>\n",
       "      <th>Q4-t-Q5 change.1</th>\n",
       "      <th>Q1 EPS</th>\n",
       "      <th>Q2 EPS</th>\n",
       "      <th>Q3 EPS</th>\n",
       "      <th>Q4 EPS</th>\n",
       "      <th>19 Q1 EPS</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>AZN</td>\n",
       "      <td>5178.00</td>\n",
       "      <td>5155.00</td>\n",
       "      <td>5340.00</td>\n",
       "      <td>6417.00</td>\n",
       "      <td>5491.00</td>\n",
       "      <td>-0.00444</td>\n",
       "      <td>0.03589</td>\n",
       "      <td>0.20169</td>\n",
       "      <td>-0.14430</td>\n",
       "      <td>...</td>\n",
       "      <td>839.00</td>\n",
       "      <td>0.96085</td>\n",
       "      <td>-0.54338</td>\n",
       "      <td>3.51908</td>\n",
       "      <td>-0.26209</td>\n",
       "      <td>0.22</td>\n",
       "      <td>0.43</td>\n",
       "      <td>0.20</td>\n",
       "      <td>0.90</td>\n",
       "      <td>0.66</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>AHT</td>\n",
       "      <td>1135.95</td>\n",
       "      <td>1340.11</td>\n",
       "      <td>1235.52</td>\n",
       "      <td>1247.59</td>\n",
       "      <td>1393.85</td>\n",
       "      <td>0.17973</td>\n",
       "      <td>-0.07805</td>\n",
       "      <td>0.00977</td>\n",
       "      <td>0.11723</td>\n",
       "      <td>...</td>\n",
       "      <td>279.33</td>\n",
       "      <td>0.29126</td>\n",
       "      <td>-0.18808</td>\n",
       "      <td>-0.20032</td>\n",
       "      <td>0.72086</td>\n",
       "      <td>0.39</td>\n",
       "      <td>0.50</td>\n",
       "      <td>0.41</td>\n",
       "      <td>0.33</td>\n",
       "      <td>0.57</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>BARC</td>\n",
       "      <td>5358.00</td>\n",
       "      <td>5576.00</td>\n",
       "      <td>5129.00</td>\n",
       "      <td>5073.00</td>\n",
       "      <td>5252.00</td>\n",
       "      <td>0.04069</td>\n",
       "      <td>-0.08016</td>\n",
       "      <td>-0.01092</td>\n",
       "      <td>0.03528</td>\n",
       "      <td>...</td>\n",
       "      <td>1087.40</td>\n",
       "      <td>0.36960</td>\n",
       "      <td>0.00531</td>\n",
       "      <td>-0.86962</td>\n",
       "      <td>6.34730</td>\n",
       "      <td>0.05</td>\n",
       "      <td>0.07</td>\n",
       "      <td>0.07</td>\n",
       "      <td>0.01</td>\n",
       "      <td>0.06</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>BP</td>\n",
       "      <td>68172.00</td>\n",
       "      <td>75439.00</td>\n",
       "      <td>79468.00</td>\n",
       "      <td>75677.00</td>\n",
       "      <td>66321.00</td>\n",
       "      <td>0.10660</td>\n",
       "      <td>0.05341</td>\n",
       "      <td>-0.04770</td>\n",
       "      <td>-0.12363</td>\n",
       "      <td>...</td>\n",
       "      <td>3113.90</td>\n",
       "      <td>0.22092</td>\n",
       "      <td>0.14029</td>\n",
       "      <td>-0.55319</td>\n",
       "      <td>0.75847</td>\n",
       "      <td>0.14</td>\n",
       "      <td>0.17</td>\n",
       "      <td>0.20</td>\n",
       "      <td>0.09</td>\n",
       "      <td>0.15</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>BTA</td>\n",
       "      <td>5837.00</td>\n",
       "      <td>5951.00</td>\n",
       "      <td>5970.00</td>\n",
       "      <td>5967.00</td>\n",
       "      <td>5715.00</td>\n",
       "      <td>0.01953</td>\n",
       "      <td>0.00319</td>\n",
       "      <td>-0.00050</td>\n",
       "      <td>-0.04223</td>\n",
       "      <td>...</td>\n",
       "      <td>549.00</td>\n",
       "      <td>0.00407</td>\n",
       "      <td>0.01970</td>\n",
       "      <td>0.38288</td>\n",
       "      <td>-0.33144</td>\n",
       "      <td>0.06</td>\n",
       "      <td>0.06</td>\n",
       "      <td>0.06</td>\n",
       "      <td>0.08</td>\n",
       "      <td>0.06</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5</th>\n",
       "      <td>SHEL</td>\n",
       "      <td>64141.80</td>\n",
       "      <td>71172.50</td>\n",
       "      <td>76880.40</td>\n",
       "      <td>79495.90</td>\n",
       "      <td>64327.10</td>\n",
       "      <td>0.10961</td>\n",
       "      <td>0.08020</td>\n",
       "      <td>0.03402</td>\n",
       "      <td>-0.19081</td>\n",
       "      <td>...</td>\n",
       "      <td>4616.20</td>\n",
       "      <td>0.01790</td>\n",
       "      <td>0.12048</td>\n",
       "      <td>-0.32202</td>\n",
       "      <td>0.50512</td>\n",
       "      <td>0.47</td>\n",
       "      <td>0.48</td>\n",
       "      <td>0.54</td>\n",
       "      <td>0.37</td>\n",
       "      <td>0.56</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6</th>\n",
       "      <td>GSK</td>\n",
       "      <td>7222.00</td>\n",
       "      <td>7310.00</td>\n",
       "      <td>8092.00</td>\n",
       "      <td>8197.00</td>\n",
       "      <td>7661.00</td>\n",
       "      <td>0.01218</td>\n",
       "      <td>0.10698</td>\n",
       "      <td>0.01298</td>\n",
       "      <td>-0.06539</td>\n",
       "      <td>...</td>\n",
       "      <td>1339.00</td>\n",
       "      <td>0.03761</td>\n",
       "      <td>0.37224</td>\n",
       "      <td>-0.09278</td>\n",
       "      <td>-0.04901</td>\n",
       "      <td>0.22</td>\n",
       "      <td>0.23</td>\n",
       "      <td>0.31</td>\n",
       "      <td>0.28</td>\n",
       "      <td>0.27</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>7</th>\n",
       "      <td>HSBA</td>\n",
       "      <td>13710.00</td>\n",
       "      <td>13577.00</td>\n",
       "      <td>13798.00</td>\n",
       "      <td>12695.00</td>\n",
       "      <td>14428.00</td>\n",
       "      <td>-0.00970</td>\n",
       "      <td>0.01628</td>\n",
       "      <td>-0.07994</td>\n",
       "      <td>0.13651</td>\n",
       "      <td>...</td>\n",
       "      <td>4262.80</td>\n",
       "      <td>0.00215</td>\n",
       "      <td>-0.00575</td>\n",
       "      <td>-0.54571</td>\n",
       "      <td>1.29776</td>\n",
       "      <td>0.20</td>\n",
       "      <td>0.20</td>\n",
       "      <td>0.20</td>\n",
       "      <td>0.07</td>\n",
       "      <td>0.22</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>8</th>\n",
       "      <td>IAG</td>\n",
       "      <td>5022.00</td>\n",
       "      <td>6184.00</td>\n",
       "      <td>7140.00</td>\n",
       "      <td>6014.00</td>\n",
       "      <td>5318.00</td>\n",
       "      <td>0.23138</td>\n",
       "      <td>0.15459</td>\n",
       "      <td>-0.15770</td>\n",
       "      <td>-0.11573</td>\n",
       "      <td>...</td>\n",
       "      <td>70.00</td>\n",
       "      <td>3.18323</td>\n",
       "      <td>0.75046</td>\n",
       "      <td>-0.56546</td>\n",
       "      <td>-0.85807</td>\n",
       "      <td>0.05</td>\n",
       "      <td>0.21</td>\n",
       "      <td>0.38</td>\n",
       "      <td>0.15</td>\n",
       "      <td>0.02</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9</th>\n",
       "      <td>LLOY</td>\n",
       "      <td>4492.00</td>\n",
       "      <td>4886.00</td>\n",
       "      <td>4686.00</td>\n",
       "      <td>4570.00</td>\n",
       "      <td>4489.00</td>\n",
       "      <td>0.08771</td>\n",
       "      <td>-0.04093</td>\n",
       "      <td>-0.02475</td>\n",
       "      <td>-0.01772</td>\n",
       "      <td>...</td>\n",
       "      <td>1536.20</td>\n",
       "      <td>-0.03365</td>\n",
       "      <td>0.23052</td>\n",
       "      <td>-0.27842</td>\n",
       "      <td>0.27910</td>\n",
       "      <td>0.02</td>\n",
       "      <td>0.02</td>\n",
       "      <td>0.02</td>\n",
       "      <td>0.02</td>\n",
       "      <td>0.02</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>10</th>\n",
       "      <td>NWG</td>\n",
       "      <td>3530.00</td>\n",
       "      <td>3662.00</td>\n",
       "      <td>3882.00</td>\n",
       "      <td>3260.00</td>\n",
       "      <td>3324.00</td>\n",
       "      <td>0.03739</td>\n",
       "      <td>0.06008</td>\n",
       "      <td>-0.16023</td>\n",
       "      <td>0.01963</td>\n",
       "      <td>...</td>\n",
       "      <td>903.83</td>\n",
       "      <td>-0.11454</td>\n",
       "      <td>0.12602</td>\n",
       "      <td>-0.30150</td>\n",
       "      <td>0.28097</td>\n",
       "      <td>0.08</td>\n",
       "      <td>0.07</td>\n",
       "      <td>0.08</td>\n",
       "      <td>0.06</td>\n",
       "      <td>0.07</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>11</th>\n",
       "      <td>RRS</td>\n",
       "      <td>273.28</td>\n",
       "      <td>283.66</td>\n",
       "      <td>243.57</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>0.03798</td>\n",
       "      <td>-0.14133</td>\n",
       "      <td>-1.00000</td>\n",
       "      <td>NaN</td>\n",
       "      <td>...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>-0.09680</td>\n",
       "      <td>0.18184</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>0.60</td>\n",
       "      <td>0.54</td>\n",
       "      <td>0.64</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>12</th>\n",
       "      <td>SHP</td>\n",
       "      <td>3765.70</td>\n",
       "      <td>3919.50</td>\n",
       "      <td>3871.70</td>\n",
       "      <td>3922.80</td>\n",
       "      <td>3799.50</td>\n",
       "      <td>0.04084</td>\n",
       "      <td>-0.01220</td>\n",
       "      <td>0.01320</td>\n",
       "      <td>-0.03143</td>\n",
       "      <td>...</td>\n",
       "      <td>1140.00</td>\n",
       "      <td>0.03296</td>\n",
       "      <td>-0.17057</td>\n",
       "      <td>0.70943</td>\n",
       "      <td>0.00185</td>\n",
       "      <td>0.85</td>\n",
       "      <td>0.87</td>\n",
       "      <td>0.72</td>\n",
       "      <td>1.24</td>\n",
       "      <td>1.27</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>13</th>\n",
       "      <td>SKY</td>\n",
       "      <td>3296.00</td>\n",
       "      <td>3441.00</td>\n",
       "      <td>3407.00</td>\n",
       "      <td>3441.00</td>\n",
       "      <td>1369.00</td>\n",
       "      <td>0.04399</td>\n",
       "      <td>-0.00988</td>\n",
       "      <td>0.00998</td>\n",
       "      <td>-0.60215</td>\n",
       "      <td>...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>14</th>\n",
       "      <td>SN</td>\n",
       "      <td>1196.00</td>\n",
       "      <td>1245.00</td>\n",
       "      <td>1169.00</td>\n",
       "      <td>1294.00</td>\n",
       "      <td>1202.00</td>\n",
       "      <td>0.04097</td>\n",
       "      <td>-0.06104</td>\n",
       "      <td>0.10693</td>\n",
       "      <td>-0.07110</td>\n",
       "      <td>...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>15</th>\n",
       "      <td>TUI</td>\n",
       "      <td>3548.90</td>\n",
       "      <td>3145.30</td>\n",
       "      <td>4576.70</td>\n",
       "      <td>7326.10</td>\n",
       "      <td>3574.80</td>\n",
       "      <td>-0.11373</td>\n",
       "      <td>0.45509</td>\n",
       "      <td>0.60074</td>\n",
       "      <td>-0.51205</td>\n",
       "      <td>...</td>\n",
       "      <td>-156.66</td>\n",
       "      <td>0.71499</td>\n",
       "      <td>-1.66924</td>\n",
       "      <td>7.23764</td>\n",
       "      <td>-1.17674</td>\n",
       "      <td>-0.09</td>\n",
       "      <td>-0.14</td>\n",
       "      <td>0.10</td>\n",
       "      <td>0.80</td>\n",
       "      <td>-0.14</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>16</th>\n",
       "      <td>EDV</td>\n",
       "      <td>198.90</td>\n",
       "      <td>189.50</td>\n",
       "      <td>155.80</td>\n",
       "      <td>207.80</td>\n",
       "      <td>151.30</td>\n",
       "      <td>-0.04726</td>\n",
       "      <td>-0.17784</td>\n",
       "      <td>0.33376</td>\n",
       "      <td>-0.27190</td>\n",
       "      <td>...</td>\n",
       "      <td>-15.50</td>\n",
       "      <td>-0.96465</td>\n",
       "      <td>0.00000</td>\n",
       "      <td>-27.14286</td>\n",
       "      <td>-0.15301</td>\n",
       "      <td>0.18</td>\n",
       "      <td>0.01</td>\n",
       "      <td>-0.03</td>\n",
       "      <td>-0.17</td>\n",
       "      <td>-0.14</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>17 rows × 24 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "   Ticker Name  Q1 Revenue  Q2 Revenue  Q3 Revenue  Q4 Revenue  19 Q1 Revenue  \\\n",
       "0          AZN     5178.00     5155.00     5340.00     6417.00        5491.00   \n",
       "1          AHT     1135.95     1340.11     1235.52     1247.59        1393.85   \n",
       "2         BARC     5358.00     5576.00     5129.00     5073.00        5252.00   \n",
       "3           BP    68172.00    75439.00    79468.00    75677.00       66321.00   \n",
       "4          BTA     5837.00     5951.00     5970.00     5967.00        5715.00   \n",
       "5         SHEL    64141.80    71172.50    76880.40    79495.90       64327.10   \n",
       "6          GSK     7222.00     7310.00     8092.00     8197.00        7661.00   \n",
       "7         HSBA    13710.00    13577.00    13798.00    12695.00       14428.00   \n",
       "8          IAG     5022.00     6184.00     7140.00     6014.00        5318.00   \n",
       "9         LLOY     4492.00     4886.00     4686.00     4570.00        4489.00   \n",
       "10         NWG     3530.00     3662.00     3882.00     3260.00        3324.00   \n",
       "11         RRS      273.28      283.66      243.57         NaN            NaN   \n",
       "12         SHP     3765.70     3919.50     3871.70     3922.80        3799.50   \n",
       "13         SKY     3296.00     3441.00     3407.00     3441.00        1369.00   \n",
       "14          SN     1196.00     1245.00     1169.00     1294.00        1202.00   \n",
       "15         TUI     3548.90     3145.30     4576.70     7326.10        3574.80   \n",
       "16         EDV      198.90      189.50      155.80      207.80         151.30   \n",
       "\n",
       "    Q1-t-Q2 change  Q2-t-Q3 change  Q3-t-Q4 change  Q4-t-Q5 change  ...  \\\n",
       "0         -0.00444         0.03589         0.20169        -0.14430  ...   \n",
       "1          0.17973        -0.07805         0.00977         0.11723  ...   \n",
       "2          0.04069        -0.08016        -0.01092         0.03528  ...   \n",
       "3          0.10660         0.05341        -0.04770        -0.12363  ...   \n",
       "4          0.01953         0.00319        -0.00050        -0.04223  ...   \n",
       "5          0.10961         0.08020         0.03402        -0.19081  ...   \n",
       "6          0.01218         0.10698         0.01298        -0.06539  ...   \n",
       "7         -0.00970         0.01628        -0.07994         0.13651  ...   \n",
       "8          0.23138         0.15459        -0.15770        -0.11573  ...   \n",
       "9          0.08771        -0.04093        -0.02475        -0.01772  ...   \n",
       "10         0.03739         0.06008        -0.16023         0.01963  ...   \n",
       "11         0.03798        -0.14133        -1.00000             NaN  ...   \n",
       "12         0.04084        -0.01220         0.01320        -0.03143  ...   \n",
       "13         0.04399        -0.00988         0.00998        -0.60215  ...   \n",
       "14         0.04097        -0.06104         0.10693        -0.07110  ...   \n",
       "15        -0.11373         0.45509         0.60074        -0.51205  ...   \n",
       "16        -0.04726        -0.17784         0.33376        -0.27190  ...   \n",
       "\n",
       "    19 Q1 NI  Q1-t-Q2 change.1  Q2-t-Q3 change.1  Q3-t-Q4 change.1  \\\n",
       "0     839.00           0.96085          -0.54338           3.51908   \n",
       "1     279.33           0.29126          -0.18808          -0.20032   \n",
       "2    1087.40           0.36960           0.00531          -0.86962   \n",
       "3    3113.90           0.22092           0.14029          -0.55319   \n",
       "4     549.00           0.00407           0.01970           0.38288   \n",
       "5    4616.20           0.01790           0.12048          -0.32202   \n",
       "6    1339.00           0.03761           0.37224          -0.09278   \n",
       "7    4262.80           0.00215          -0.00575          -0.54571   \n",
       "8      70.00           3.18323           0.75046          -0.56546   \n",
       "9    1536.20          -0.03365           0.23052          -0.27842   \n",
       "10    903.83          -0.11454           0.12602          -0.30150   \n",
       "11       NaN          -0.09680           0.18184               NaN   \n",
       "12   1140.00           0.03296          -0.17057           0.70943   \n",
       "13       NaN               NaN               NaN               NaN   \n",
       "14       NaN               NaN               NaN               NaN   \n",
       "15   -156.66           0.71499          -1.66924           7.23764   \n",
       "16    -15.50          -0.96465           0.00000         -27.14286   \n",
       "\n",
       "    Q4-t-Q5 change.1  Q1 EPS  Q2 EPS  Q3 EPS  Q4 EPS  19 Q1 EPS  \n",
       "0           -0.26209    0.22    0.43    0.20    0.90       0.66  \n",
       "1            0.72086    0.39    0.50    0.41    0.33       0.57  \n",
       "2            6.34730    0.05    0.07    0.07    0.01       0.06  \n",
       "3            0.75847    0.14    0.17    0.20    0.09       0.15  \n",
       "4           -0.33144    0.06    0.06    0.06    0.08       0.06  \n",
       "5            0.50512    0.47    0.48    0.54    0.37       0.56  \n",
       "6           -0.04901    0.22    0.23    0.31    0.28       0.27  \n",
       "7            1.29776    0.20    0.20    0.20    0.07       0.22  \n",
       "8           -0.85807    0.05    0.21    0.38    0.15       0.02  \n",
       "9            0.27910    0.02    0.02    0.02    0.02       0.02  \n",
       "10           0.28097    0.08    0.07    0.08    0.06       0.07  \n",
       "11               NaN    0.60    0.54    0.64     NaN        NaN  \n",
       "12           0.00185    0.85    0.87    0.72    1.24       1.27  \n",
       "13               NaN     NaN     NaN     NaN     NaN        NaN  \n",
       "14               NaN     NaN     NaN     NaN     NaN        NaN  \n",
       "15          -1.17674   -0.09   -0.14    0.10    0.80      -0.14  \n",
       "16          -0.15301    0.18    0.01   -0.03   -0.17      -0.14  \n",
       "\n",
       "[17 rows x 24 columns]"
      ]
     },
     "execution_count": 78,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "fund = pd.read_excel('/Users/luzemok/Desktop/Fundamentals_comp.xls')\n",
    "fund"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 82,
   "id": "5cef7843",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "0      5178.00\n",
       "1      1135.95\n",
       "2      5358.00\n",
       "3     68172.00\n",
       "4      5837.00\n",
       "5     64141.80\n",
       "6      7222.00\n",
       "7     13710.00\n",
       "8      5022.00\n",
       "9      4492.00\n",
       "10     3530.00\n",
       "11      273.28\n",
       "12     3765.70\n",
       "13     3296.00\n",
       "14     1196.00\n",
       "15     3548.90\n",
       "16      198.90\n",
       "Name: Q1 Revenue, dtype: float64"
      ]
     },
     "execution_count": 82,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "fund['Q1 Revenue']"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 80,
   "id": "3e4e7bb5",
   "metadata": {},
   "outputs": [
    {
     "ename": "ValueError",
     "evalue": "all the input array dimensions for the concatenation axis must match exactly, but along dimension 0, the array at index 0 has size 18 and the array at index 1 has size 17",
     "output_type": "error",
     "traceback": [
      "\u001b[0;31m---------------------------------------------------------------------------\u001b[0m",
      "\u001b[0;31mValueError\u001b[0m                                Traceback (most recent call last)",
      "\u001b[0;32m<ipython-input-80-56ae552d427e>\u001b[0m in \u001b[0;36m<module>\u001b[0;34m\u001b[0m\n\u001b[1;32m      2\u001b[0m \u001b[0;32mfrom\u001b[0m \u001b[0mscipy\u001b[0m \u001b[0;32mimport\u001b[0m \u001b[0mstats\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m      3\u001b[0m \u001b[0mscores\u001b[0m \u001b[0;34m=\u001b[0m \u001b[0;34m[\u001b[0m\u001b[0ma_score\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0ma_score1\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0ma_score2\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0ma_score3\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0ma_score4\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0ma_score5\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0ma_score6\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0ma_score7\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0ma_score8\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0ma_score9\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0ma_score10\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0ma_score11\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0ma_score12\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0ma_score13\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0ma_score14\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0ma_score15\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0ma_score16\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0ma_score17\u001b[0m\u001b[0;34m]\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0;32m----> 4\u001b[0;31m \u001b[0mstats\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mspearmanr\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mscores\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mfund\u001b[0m\u001b[0;34m[\u001b[0m\u001b[0;34m'Q1 Revenue'\u001b[0m\u001b[0;34m]\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0m",
      "\u001b[0;32m~/opt/anaconda3/lib/python3.8/site-packages/scipy/stats/stats.py\u001b[0m in \u001b[0;36mspearmanr\u001b[0;34m(a, b, axis, nan_policy)\u001b[0m\n\u001b[1;32m   3831\u001b[0m         \u001b[0mb\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0m_\u001b[0m \u001b[0;34m=\u001b[0m \u001b[0m_chk_asarray\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mb\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0maxis\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m   3832\u001b[0m         \u001b[0;32mif\u001b[0m \u001b[0maxisout\u001b[0m \u001b[0;34m==\u001b[0m \u001b[0;36m0\u001b[0m\u001b[0;34m:\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0;32m-> 3833\u001b[0;31m             \u001b[0ma\u001b[0m \u001b[0;34m=\u001b[0m \u001b[0mnp\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mcolumn_stack\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0ma\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mb\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0m\u001b[1;32m   3834\u001b[0m         \u001b[0;32melse\u001b[0m\u001b[0;34m:\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m   3835\u001b[0m             \u001b[0ma\u001b[0m \u001b[0;34m=\u001b[0m \u001b[0mnp\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mrow_stack\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0ma\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mb\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n",
      "\u001b[0;32m<__array_function__ internals>\u001b[0m in \u001b[0;36mcolumn_stack\u001b[0;34m(*args, **kwargs)\u001b[0m\n",
      "\u001b[0;32m~/opt/anaconda3/lib/python3.8/site-packages/numpy/lib/shape_base.py\u001b[0m in \u001b[0;36mcolumn_stack\u001b[0;34m(tup)\u001b[0m\n\u001b[1;32m    654\u001b[0m             \u001b[0marr\u001b[0m \u001b[0;34m=\u001b[0m \u001b[0marray\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0marr\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mcopy\u001b[0m\u001b[0;34m=\u001b[0m\u001b[0;32mFalse\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0msubok\u001b[0m\u001b[0;34m=\u001b[0m\u001b[0;32mTrue\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mndmin\u001b[0m\u001b[0;34m=\u001b[0m\u001b[0;36m2\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mT\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m    655\u001b[0m         \u001b[0marrays\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mappend\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0marr\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0;32m--> 656\u001b[0;31m     \u001b[0;32mreturn\u001b[0m \u001b[0m_nx\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mconcatenate\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0marrays\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0;36m1\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0m\u001b[1;32m    657\u001b[0m \u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m    658\u001b[0m \u001b[0;34m\u001b[0m\u001b[0m\n",
      "\u001b[0;32m<__array_function__ internals>\u001b[0m in \u001b[0;36mconcatenate\u001b[0;34m(*args, **kwargs)\u001b[0m\n",
      "\u001b[0;31mValueError\u001b[0m: all the input array dimensions for the concatenation axis must match exactly, but along dimension 0, the array at index 0 has size 18 and the array at index 1 has size 17"
     ]
    }
   ],
   "source": [
    "# run spearman correlation with net revenue, then with net income, then EPS\n",
    "from scipy import stats\n",
    "scores = [a_score, a_score1, a_score2, a_score3, a_score4, a_score5, a_score6, a_score7, a_score8, a_score9, a_score10, a_score11, a_score12, a_score13, a_score14, a_score15, a_score16, a_score17]\n",
    "stats.spearmanr(scores, fund['Q1 Revenue'])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 62,
   "id": "1ffe6933",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Management: {'Pascal Soriot', 'David Fredrickson', 'Mark Mallon', 'Marc Dunoyer', 'Sean Bohen'}\n",
      "Average 'Compound Score': 0.569\n"
     ]
    },
    {
     "data": {
      "image/png": "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",
      "text/plain": [
       "<Figure size 1728x1440 with 4 Axes>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "import matplotlib.pyplot as plt\n",
    "from matplotlib.pylab import mpl\n",
    "import seaborn as sns\n",
    "\n",
    "def vader_sentiment_graph(data):\n",
    "    df = vader_sentiment_score(data)\n",
    "    \n",
    "    plt.style.context('ggplot')\n",
    "    mpl.rcParams['font.family'] = 'serif'\n",
    "    fig, ax = plt.subplots(2,2, figsize=(24,20))\n",
    "\n",
    "    speaker = df.groupby(['speaker'])[['pos', 'neu', 'neg', 'compound']].mean()\n",
    "    speaker.plot(kind='barh', stacked=True, ax=ax[0][0])\n",
    "    print('Management: {}'.format(set(df[df['position']=='management']['speaker'])))\n",
    "\n",
    "    position = df.groupby(['position'])[['pos', 'neu', 'neg', 'compound']].mean()\n",
    "    position.plot(kind='barh', stacked=True, ax=ax[0][1])\n",
    "    sns.barplot(y=\"speaker\", x=\"pos\", hue=\"position\", data=df, ax=ax[1][0])\n",
    "    sns.barplot(y=\"speaker\", x=\"neg\", hue=\"position\", data=df, ax=ax[1][1])\n",
    "    print(\"Average 'Compound Score': {0:.3f}\".format(df['compound'].mean()))\n",
    "\n",
    "    \n",
    "\n",
    "vader_sentiment_graph(data)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 73,
   "id": "0fb02aa5",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Management: {'Geoﬀrey Drabble', 'Suzanne Wood'}\n",
      "Average 'Compound Score': 0.863\n"
     ]
    },
    {
     "data": {
      "image/png": "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",
      "text/plain": [
       "<Figure size 1728x1440 with 4 Axes>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "vader_sentiment_graph(data1)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 74,
   "id": "0f0f630d",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Management: {'Mark Bristow', 'Patrick Shuttleworth', 'Lewis Coleman'}\n",
      "Average 'Compound Score': 0.328\n"
     ]
    },
    {
     "data": {
      "image/png": "iVBORw0KGgoAAAANSUhEUgAABm8AAAS9CAYAAAChyc0UAAAAOXRFWHRTb2Z0d2FyZQBNYXRwbG90bGliIHZlcnNpb24zLjMuNCwgaHR0cHM6Ly9tYXRwbG90bGliLm9yZy8QVMy6AAAACXBIWXMAAAsTAAALEwEAmpwYAADITklEQVR4nOzdeZQV9YE2/qfbBtlBFIRWFoGg4o6gxpUoOi6RIDFoFMTErBqJMeObTOaXMZtZHF+TGLcJ7jLGIVFR45LEoKIxxjBGMQiiIDTYAo3sNKv07w9feySItiPNLejP5xzP6Vu3btXT365T9359qLpldXV1dQEAAAAAAKAQyksdAAAAAAAAgP+hvAEAAAAAACgQ5Q0AAAAAAECBKG8AAAAAAAAKRHkDAAAAAABQIMobAAAAAACAAqkodQC2DdXV1aWOQJLKykp/CxrEsUJDOVZoKMcKDVWKY6WysnKr7o9tj/NX4/M+0fiMceMzxo3PGG8dxrnxGePG15TGeHPzGVfeAAAAAAAAFIjyBgAAAAAAoECUNwAAAAAAAAWivAEAAAAAACgQ5Q0AAAAAAECBKG8AAAAAAAAKRHkDAAAAAABQIBWlDgAAANurNz8/ZItub4cx923R7QEAAGyO+UxpufIGAAAAAACgQJQ3AAAAAAAABeK2aQAAsJ343e9+l1/84hc5++yzs2rVqsyYMSNf+cpXsnDhwvzud7/Lbrvtlqqqqpx33nnZZZdd8vOf/zwdOnTImjVrsssuu2TYsGGl/hUAAIAm6p3zmR122CHPP/98k57PKG8AAGA78U//9E+5+eabc/TRR2e33XbLhAkT8h//8R+ZMmVKxowZkw4dOmTChAm57rrrctFFF+Wpp57K1VdfnU6dOuXvf/97qeMDAABN2DvnMwMHDszYsWOb9HxGeQMAANuZrl27Jkl22223vPrqq6mtrU2HDh3ql82YMSNt27bNV77ylVxxxRVZs2ZNRo4cWcLEAAAAbzGfeYvvvAEAgO3M66+/niSZO3duevTokdatW2fx4sVJktdeey19+vTJihUr0qFDh/zkJz/JV7/61Vx77bWljAwAAJDEfOZtrrwBAIBGssOY+0qy3//+7//OQw89lFdeeSUXXnhhFi1alDFjxqSysjJz5szJl7/85bz55pv5zW9+k8mTJ2fp0qX55Cc/WZKsAABAMZVyPvPkk0/mb3/7W5OezyhvYBsy55QBpY7woQ0bdHmpIzQR00odgG3EcW9cVeoIbMbo0aNLHYFt2JAhQzZ6vNtuu2W//fbbZL3vfve7WysSAABAgwwZMiSVlZWprq5O0nTnM26bBgAA24k//OEPWblyZcaPH1/qKAAAAB+I+czGXHkDAADbieOPPz7HH398qWMAAAB8YOYzG3PlDQAAAAAAQIEobwAAAAAAAApEeQMAAAAAAFAgvvMGAAAaySf+c9oW3d69Z++1RbcHAACwOeYzpeXKGwAAAAAAgAJR3gAAAAAAABSI26YBAMB24qGHHsqYMWPyqU99KtXV1amqqsoPf/jDLFiwIL/61a/Sq1evVFVVZcSIEWnRokWuvPLK9OnTJ+eee27GjBmTKVOm5Gc/+1mpfw0AAKAJeud8ZunSpZk6dWqTns+48gYAALYTJ510Urp3757evXvn61//evbYY49MmjQpV1xxRYYMGZIzzzwzJ5xwQq677rp07NgxRx55ZP1rTz311BImBwAAmrp3zme+973vNfn5jCtvAABgO9OtW7ckSYcOHbJq1arMnDkzkyZNyuTJk7NmzZq0bNmyxAkBAADenfnMW5Q3AACwnSkrK9voce/evXPUUUeld+/eWbt2bZ588skkScuWLbNy5cokyfz587d6TgAAgH9kPvMW5Q0AADSSe8/ea6vub9KkSZk/f34efPDBnHjiiZk8eXJmzpyZL3zhC7n77rvTtWvXLFiwIMcff3yS5OCDD86DDz6YX/3qV2nWrFnmz5+fv/zlLzn00EO3am4AAKB4Sjmf6dSpU5Ofz5TV1dXVNeYOXnnllYwdOzbr16/P/vvvn2XLlqW8vDznnntuysvf/St3nnnmmfTs2TOdO3fe7HYvu+yyfOUrX0n79u3f9fknnngiN910U26++eb3zPfMM89k0qRJ2WWXXbJkyZKsXbs2X/nKV/Lss8/mxhtvzKWXXvqeOf7RAw88kFNOOeVdHzc005Y0a9asrFy5Mvvss09WrVqVW265JRs2bMgFF1zwgbZTXV3dSAn5IN78/JBSR/jQhg26vNQRgHc47o3flzoCmzF69OhSR9hIZWWlzwM0SCmOlcrKyq26P7Y9zl+Nz/tE4zPGjc8YNz5jvHUY58ZnjBtfUxrjzc1n3r092YL69OmTfv36pW/fvhk+fHg+97nPZfbs2Xnuuec2+5q//vWvqampec/tfutb39pscZMkRx11VFq1avW++f7jP/4j5557boYPH54vfOELqah462Kk/v37p1OnTu/7+n/04IMPbvZxQzNtSbNmzcqUKVOSvHUZ2dFHH71V9w8AAAAAAHwwW/22aW+++WaWL1+edu3a5frrr0/Hjh2zevXq7LTTTjn11FPzyiuvZNasWXnsscfy8ssvp1+/fhkzZkx69eqV1q1bZ+LEibn44otz880359xzz80+++yTadOm5bHHHktlZWVeeeWVDBkyJH369Knf51NPPZX7778/xx13XAYPHrxRng4dOuTuu+/OySefnI4dO+ZLX/rSRs//+c9/zvz58/Paa6/lG9/4RtauXZtf/vKX6dmzZ4YPH5477rgj06dPz3e+85089dRTWblyZcaNG5fddtstZWVlGz0+4ogjNtr273//+1RXV6dt27apra3NiBEj8thjj+XWW2/Nl7/85Rx66KG58MIL873vfS8rV67Mddddl+HDh6dbt24ZN25cunbtmtdffz2DBg3KXnvtlZ/+9KdZsGBB9ttvv0ybNi0HH3xwXnrppdTW1mbcuHE54YQTkiTLli3LHXfckZdffjlHHHHEJmMCAAAAAACUzlYrb6ZPn55x48ZlxYoVGTZsWPr06ZPFixdn4MCBSZJLLrkkgwcPTp8+fdKzZ88MGjQo++yzT5Jk4MCBWbt2bUaMGJFjjjkmu+22W3r27Jkkqaury89+9rP8+Mc/TocOHVJVVZU1a9bU73fRokV56aWX8m//9m9p2bLlJrn+5V/+Jffcc0/+5V/+Je3bt8+pp56ao446qv75PfbYI5/4xCdy4403ZvLkyTnssMNyyCGHZMGCBUmSwYMHZ/r06UmSww8/PP/5n/+Z4cOH17/+Hx+/be7cuXnooYdy5ZVXpqysLNdcc00mTZqUj33sY/nDH/6QHj16ZPr06WnRokX+/Oc/58QTT8yee+6ZAw44ID/72c9y2GGH5bDDDsuSJUvyzW9+M9ddd13OPvvsfPvb387w4cOzbt26LF68OO3bt8+CBQvqM7z22mupra3NWWedlWXLluW73/1ug8obt6IohjmlDgDAVlPE994iZqKYHCsAAAAfzlYrb96+bdo7LV68OHfccUdatWqVVatWZfny5e9asCTJbrvtliTp0aPHRsuXL1+eVatWpUOHDkmS7t27b/T8nXfemblz56ZZs2bvut1ddtkln//85/O5z30uU6ZMyRVXXJEePXrUb6dLly5JkrZt22b16tUf7Jd+D3PmzElZWVnuvffeJMkOO+yQVatWJXmrBPrzn/+cNWvW5Etf+lJuueWW7L777tl3332TJFVVVRky5K3vPunQoUNqa2uzfPny+rwVFRWpqKhIy5Yt64uld9p1112TJO3atWvw79RU7i8IAEVRtPfepnS/YT4c33kDAADw4TX6d95szqxZs3LfffflrLPOytChQ+vLlyQpLy9PXV1d5s2bV18ulJWVvet22rZtm1atWmXp0qVJktmzZ+ell16qf/7LX/5yDjzwwNx+++3v+vrvfe979dvfd999s/POO2f9+vXvmb1Fixb1RcvChQs3eu7t7K+++uq7Pn5b9+7d07x58wwdOjRDhw7NCSecUH810Uc/+tE89dRTWb9+fXr37p1Vq1ZlwoQJ2X///ZO8VWDNnz8/SbJkyZK0bt06bdu2fddxKi9/60+8YsWK+qybG0sAAAAAAKD0Gv3KmxkzZmTq1KlZv359nn766Rx22GFJ3vrXcbvttluuv/76VFZWZtGiRXn00UdzxhlnZL/99suECROyYcOGnHbaaZk6dWqqqqrSrVu39O7dO9OmTUtVVVUmTpyY3r1756tf/WruuOOOdO3aNYsWLcqZZ56ZP//5z6mtrc2ECROy77775sc//nHKy8vz6U9/Os2bN6/P16ZNm9xwww1p165dFi9enI9+9KPp1atXJk+enJqamjz66KMZNGhQfYb+/ftn//33z4QJEzJ+/Pg0a9YsNTU1+dvf/paDDjooBx10UG6//fZs2LAhe+yxx0aP586dm9ra2vz+97/PCSeckMGDB+fWW29Ny5Yts3z58px99tlJkp133jktWrRIv379krxV5tTU1KSi4q0/18iRI3PnnXfm9ddfz7x58/LVr341ZWVlmTBhQmpqajJhwoQce+yxSZI+ffrkiSeeyG233Zbjjz8+EydOTFVVVWbMmJE5c+aktrZ2o78LAABbzv3/tWSLbu/UMzps0e0BAABsjvlMaZXV1dXVlToExec2KcXw5ueHlDrChzZs0OWljgC8w3Fv/L7UEdiM0aNHlzrCRtw27X+nKU523DaNInL+anzeJxqfMW58xrjxGeOtwzg3vqYyxqWczzSVMU42P58p2W3TAAAAAAAA2FSj3zYNAADYOh566KGMGTMmn/rUp1JdXZ2qqqr88Ic/zIIFC/KrX/0qvXr1SlVVVUaMGJHKyspMnz49t9xyS/bcc8+sXbs2f/zjH3PhhRfmiCOOKPWvAgAANDHvnM8sXbo0U6dObdLzGVfeAADAduKkk05K9+7d07t373z961/PHnvskUmTJuWKK67IkCFDcuaZZ+aEE07IddddlyS58sorM2LEiIwaNSr9+/dPly5dtpuJDgAAsG1553zme9/7XpOfz7jyBgAAtjPdunVLknTo0CGrVq3KzJkzM2nSpEyePDlr1qxJy5YtkySzZs3K7rvvniTp2rVryfICAAC8zXzmLcobAADYzpSVlW30uHfv3jnqqKPSu3fvrF27Nk8++WSSpEePHpk7d2769euX119/vRRRAQAANmI+8xblDQAANJJTz+iwVfc3adKkzJ8/Pw8++GBOPPHETJ48OTNnzswXvvCF3H333enatWsWLFiQ448/Pkly8cUX56abbspee+2VZs2abTJJAgAAmq5Szmc6derU5OczyhsAANhODBgwIL/61a/qH1955ZX1P++///6brF9eXp7vf//7ad68eZ5//vnt8l+rAQAA24Z3zmcqKyub/HxGeQMAAE3Uq6++mvHjx6dbt26ZO3duRo0aVepIAAAADbK9z2eUNwAA0ESdcMIJOeGEE0odAwAA4APb3ucz5aUOAAAAAAAAwP9Q3gAAAAAAABSI26bBNqTbA5NSXV1d6hgfyr2lDtBEVFZWbvPHCltHZeWxjhUAAACAglHeAABAI7nqqqu26PZGjx69RbcHAACwOeYzpeW2aQAAQGFcf/31ueiii0odAwAA4APbkvMZ5Q0AAFAYQ4cOLXUEAACA/5UtOZ9x2zQAANiO3HrrrVm/fn0qKioyc+bMXHjhhbn55puz++6757XXXss//dM/Zb/99st3v/vdzJs3LwMGDMiUKVNyxBFHZOnSpXn55ZfzkY98JJ/97Gfzpz/9Kb/4xS9y3HHHpXnz5nnppZdy7rnnpm/fvpk9e3bGjRuX3XffPVVVVTnzzDPTtm3b/OAHP8juu++ec889N2PGjMmUKVPys5/9LA899FDGjBmTT33qU6murk5VVVV++MMfpnXr1pk+fXpuueWW7LXXXqmoMEUBAICm6u35zE477ZTnn39+q89nrrzyyvTp06cQ8xlX3gAAwHbimWeeydSpU3Peeedl1KhROeSQQ3LdddflkEMOyac//el89rOfzfe+973U1dXli1/8YhYvXpzPfOYz+d73vpcxY8bk05/+dC677LL87ne/S5IcccQR6dKlS/r3759Ro0ZlxIgRufLKK5Mkl19+eYYMGZJPf/rTOfXUU/Pv//7v6dixYwYPHlyf59RTT63/+aSTTkr37t3Tu3fvfP3rX88ee+yRSZMmJUmuvPLKjBgxIuecc0723HPPrThiAABAUbxzPvOVr3ylJPOZI488sj5PqeczyhsAANhOzJw5M5WVlfWPTznllMyYMSNdu3ZNknTs2DErV67M0qVLkyRdunRJeXl52rRpkw4dOqRly5YpLy9PWVnZRtt9+/W77bZbZs2aVb+vdy6fMWNGgzJ269YtSdKhQ4esWrUqSTJr1qzsvvvuG+0LAABoWsxnNqa8AQCA7UTv3r1TXV1d//jBBx/caNmiRYvSpk2btG/f/gNt9/XXX0+SzJ07Nz169NhkX6+99lp69+6dJGndunVWrlyZJJk/f/4m2/rHiVSS9OjRI3Pnzt1oXwAAQNNShPlMy5YtCzOfcUNpAABoJKNHj96q+xs4cGBefPHFjBkzJs2bN0+7du3y5S9/OTfeeGPmzp2b1157Ld/+9rdTVlaWBx54IPPnz8/f/va3zJ8/PytXrswTTzyRJFm5cmUeeOCBnHLKKUmSadOmZfLkyZk2bVouvvjiJMkll1ySO++8M5MmTcqcOXNyySWXJEkOP/zwjB07Nr/61a/SrFmzzJ8/P3/5y1+yww47ZP78+XnwwQdz4oknZvLkyZk5c2YOO+ywXHzxxbnpppuy5557Zv369Zk/f37+/Oc/56Mf/ehWHT8AAOB/lHI+s/POO6esrGyrz2cOPvjgPPjgg4WYz5TV1dXVfagt0CS8s/GkdCorK/0taBDHCg3lWKGhHCtN10UXXZRvfvOb6dKlS4PWL8Wx8s5bK8C7cf5qfN4nGp8xbnzGuPEZ463DODc+Y9z4ttQYf9D5TClsbj7jtmkAAMC7+vOf/5z58+dn/PjxpY4CAADwgWzr8xm3TQMAAN7VRz/6UbcuAwAAtknb+nzGlTcAAAAAAAAForwBAAAAAAAoEOUNAAAAAABAgShvAAAAAAAACkR5AwAAAAAAUCAVpQ4AAAAAjenNzw8pdYQGGzbo8lJH+F+aVuoATYAxbnzGuPEZ4w/jcxVdGrTeq/OvauQksP0YPXp0qSNslitvAAAAAAAACkR5AwAAAAAAUCDKGwAAAAAAgAJR3gAAAAAAABSI8gYAAAAAAKBAlDcAAAAAAAAForwBAAAAAAAoEOUNAAAAAABAgShvAAAAAAAACkR5AwAAAAAAUCDKGwAAAAAAgAJR3gAAAAAAABSI8gYAAAAAAKBAlDcAAAAAAAAForwBAAAAAAAokIpSBwAabs4pAxp1+8MGXd6o22drmlbqABTI5yq6bPa5V+dftRWTUGqjR48udQQAAACgAVx5AwAAAAAAUCDKGwAAAAAAgAJR3gAAAAAAABSI8gYAAAAAAKBAlDcAAAAAAAAForwBAAAAAAAoEOUNAAAAAABAgShvAAAAAAAACkR5AwAAAAAAUCDKGwAAAAAAgAJR3gAAAAAAABSI8gYAAAAAAKBAlDcAAAAAAAAF0iTLmxdffDHf+c53cv7552f9+vUbPTd27Nh88YtfzB//+McPtM1nn302F1xwQRYsWLDZdZYuXZprrrkmX/ziFzNu3Ljcfvvt+f73v5/58+dv9jUTJkzIQw89tNnnV65cmccee+wDZQUAAAAAAIqrSZY3/fr1S79+/dK+ffuNSpply5ZlxowZ2WmnnXLcccd9oG32798/nTp1es912rdvn0GDBmWnnXbK8OHDM3LkyOy11155+OGHN/uaY489NieeeOJmn1feAAAAAADA9qWi1AFK6fTTT88NN9yQY489Ns2aNcvDDz+cE044Iffee2/9Otdff306duyY1atXZ6eddsqpp56a6dOnZ8yYMenVq1dat26diRMn5uc//3n9a1588cXceOONOfroo/OJT3ziPTMsW7YsHTt2TJL89Kc/zYIFC7Lffvtl2rRp2X///euvyrngggvyl7/8JS+88EI6deqUGTNm5OKLL84jjzySmpqajBs3LgceeGC6deuW22+/PZ07d87ChQtzwAEHZL/99stPf/rTrFmzJl/+8pdTU1OT++67L9/61rfy2GOP5dFHH83FF1+c9u3bN8IoAwAAAAAAH0STLm+6deuWvn375pFHHslHP/rRlJeXp127dhutc/DBB2fgwIFJkksuuSSDBw9O3759M3DgwKxduzYjRozIMccckx133DFJUltbm7/85S/59re/nQ4dOrzrfpcsWZLx48dn8eLFefXVVzNs2LAkydlnn51vf/vbGT58eNatW5fFixdn8eLF9VfWPP744znkkEMyaNCgvPTSS0mSwYMHZ/r06Rk+fHiS5I477kiXLl0yZMiQrFu3LhdeeGGuuOKKjBw5MmPGjMmuu+6aP/7xj6murs7y5cvTpk2bnH766e9b3FRWVv6vxpgta06pAwCwTfuw7+c+D9BQjhUAAIAPp0mXN0nyqU99KpdddlkWLlyYT3ziE5kzZ+P/Pb548eLccccdadWqVVatWpXly5enZcuWSZLddtstSdKjR4/69e+77768+uqr+dSnPrXZfXbo0CFDhw5NkkyfPj0//OEP8+///u9Jki5duqSioiIVFRVp2bJlFi9eXP+6UaNG5Z577snDDz+cgw46KH379t1k27Nnz86xxx6bJGnWrFlat26defPmpU+fPqmtrU1NTU2S5JBDDslf/vKXVFdXZ8SIEe87TtXV1e+7DgBQbB/m/byystLnARqkFMeKsggAANjeNMnvvHmn3XffPXvvvXcqKio2uepm1qxZue+++3LWWWdl6NChm1xJU1ZWtsn2zjzzzAwZMiTXXnttg/bfoUOHLFq06D23+bY5c+bkS1/6Un7wgx/khRdeyKuvvpry8vLU1dXV5+3Ro0f9rdbWrVuXlStXpmvXrkmSj370o/nlL3+Z/fbbL0cccUQef/zxVFRUpLy8yR8GAAAAAABQGE3yypsZM2Zk6tSpWb16dc4666yMHj06yVvfPzNx4sQsXrw4TzzxRA499NDstttuuf7661NZWZlFixbl0UcfzVFHHZWpU6emqqoq3bp1S+/evTN58uTU1NRkwoQJOfzww3PnnXfm2muvzac//enstNNOm2z/rrvuSpLMnTs3X/jCF5IkEyZMqN/Gsccem1WrVmXixImpqqrKSy+9lOnTp+fll1/OjjvumG7duqV79+4pKytL8+bNc+utt2b33XfPaaedlltvvTV33XVXFi5cmPPOOy+tW7dOkhx++OF56KGHss8++6S8vDxLly5N//79S/AXAAAAAAAANqes7u3LNuA9uE1KMbz5+SGNuv1hgy5v1O0DpfG5ii6bfe7V+bdtxSSU2tv/YOV/w23TaCi3TaOI5pwyoNQRGsxncgA2573mdu9kngcN92HmyVvK5uYz7pcFAAAAAABQIMobAAAAAACAAlHeAAAAAAAAFIjyBgAAAAAAoECUNwAAAAAAAAWivAEAAAAAACgQ5Q0AAAAAAECBKG8AAAAAAAAKRHkDAAAAAABQIMobAAAAAACAAlHeAAAAAAAAFEhFqQMADdftgUmprq5utO3f22hbZmurrKxs1GOF7Udl5Y8dKwAAAAAF48obAAAAAACAAlHeAAAAAAAAFIjyBgAAAAAAoECUNwAAAAAAAAWivAEAAAAAACgQ5Q0AAAAAAECBKG8AAAAAAAAKRHkDAAAAAABQIMobAAAAAACAAlHeAAAAAAAAFIjyBgAAAAAAoECUNwAAAAAAAAWivAEAAAAAACgQ5Q0AAADblClTpmTWrFmljgEAAI1GeQMAAMA2RXkDAMD2rqLUAQAAAPjfefTRR3PHHXfk1FNPzezZs7N8+fIMGjQozz//fObNm5dvfOMbefLJJzNnzpy0b98+CxcuzOc///msWrUqP//5z1NeXp4ePXrk5ZdfzhFHHJHBgwdn9erV+elPf5q999471dXVOfLII7P//vsnSW666aa8+eab6dixY5577rl06dIln/nMZzJ79uw8+uij2X333VNdXZ2zzjorK1euzLXXXpvOnTundevWmTFjRk455ZRMnz49M2bMyGmnnZb+/fvnzTffzC233JL27duntrY2PXv2zNFHH5377rsvv/71rzNy5Mi8/PLLWbZsWb7xjW9k3rx5efHFFzNr1qwsWLAgQ4cOTfPmzUv8lwAAgC1LeQMAALCN+tjHPpbHH388e+yxR4YMGZLLL788q1evzpe//OXcfPPNmTx5cjp27JjBgwenvLw8N910U55//vn0798/Q4cOzR133JGzzjory5Yty3e/+90MHjw4ZWVlOeWUU7L//vtnxYoVueyyy7L//vvn2Wefzbx58/Ktb30rSfLcc89l0KBBadmyZX72s5/lRz/6UTp27JjHHnssd999d84999wcd9xxeeGFF/LZz342zzzzTH7729/me9/7Xl599dX813/9V/r3758JEyZk/fr1Of3001NXV5evfe1rOeCAAzJkyJD87ne/y7777psTTjghP/rRjzJr1qz06tUr/fr1S+fOnTNo0KDS/gEAANimVVZWljrCZilvAAAAtnG77rprkqR169Yb/bx69ersvPPOGTt2bNq1a5fXXnstvXr1qn9d165dkyTt2rXL6tWrkyR1dXV58cUXM3369FRUVGTZsmVJkjlz5qRLly6b7HP58uVZsWJFJk6cmCRZsWJFysvLN1nv3bIlyezZs7N48eKMHz8+SdKtW7csWbIk7du33yTjqlWrtsh4AQBAklRXV5c6wmYLJOUNAADAduzKK6/Mv//7v2eXXXZJbW3tRs+VlZVtsv6ECROyaNGinH/++Vm/fn3+8Ic/JEl23333/P3vf69fb/78+UmStm3bpl27dhk8eHDatGmT5cuXZ/r06Q3O17NnzzRr1ixDhw5NkjzzzDPp1KnTe2YsLy9PXV1dFi1alIqKirRr167B+wMAgG2B8gYAAGAbNXny5NTU1OSxxx7LgAEDUlVVlYkTJ2annXbK1KlTU1VVlcMPPzw33HBD9tprr7z88suprq7OgQcemIkTJ6aqqiozZszInDlzUltbm6effjoHHHBAnn766dx+++1p06ZN/fJDDz00f/vb33L99denS5cuadasWcrKylJWVpaLLroo//mf/5mdd945CxcuzMc//vEsWbIkkyZNysqVK1NdXV2/v5kzZ2bSpEmpqanJ5MmTc+yxx2bs2LEZN25c1q9fn+bNm+eQQw7Jn//859TW1mbChAnp2bNn/e+25557pl+/fvntb3+byZMnZ+TIkaX+MwAAwBZXVldXV1fqEBRfES4f461L6PwtaAjHCg3lWKGhHCs0VCmOlSLfp3p789JLL2XPPfdMknzve9/L+eefn1122aXEqd7fnFMGlDpCgw0bdHmpIwBQUJ+r6PL+KyV5df5tjZwEth+jR48udQS3TQMAAODDGTduXPbbb7+sWrUqAwYM2CaKGwAA2BYpbwAAAGiQb3/726WOAAAATUJ5qQMAAAAAAADwP5Q3AAAAAAAABaK8AQAAAAAAKBDlDQAAAAAAQIEobwAAAAAAAApEeQMAAAAAAFAgyhsAAAAAAIACUd4AAAAAAAAUiPIGAAAAAACgQJQ3AAAAAAAABVJR6gBAw805ZUCpI7yvYYMuL3UEkiTTSh2AAvtcRZf6n1+df1UJkwDbi9GjR5c6AgAAwHbFlTcAAAAAAAAForwBAAAAAAAoEOUNAAAAAABAgShvAAAAAAAACkR5AwAAAAAAUCDKGwAAAAAAgAJR3gAAAAAAABSI8gYAAAAAAKBAlDcAAAAAAAAForwBAAAAAAAoEOUNAAAAAABAgShvAAAAAAAACqSi1AEawyuvvJKxY8dm/fr1Oeecc9K3b98tst3LLrssX/nKV9K+ffsGrf/EE09k1qxZadGiRZYtW5aVK1dm+PDh6dKly7uu/+yzz+bGG2/MpZdems6dO2+RzAAAAAAAwLZluyxv+vTpk379+mX16tVbrLhJkm9961spKytr0LqPPfZYZs6cmc9+9rP1y8aOHZuqqqrNljf9+/fPfffdt0WyAgAAAAAA26btsrx5L4sWLcodd9yRbt26Zd68eTn++OPTvn37/OxnP0vbtm1z/vnn569//WteeeWVfP7zn8+vf/3rzJw5M6eeempuvvnmnHvuudlnn31y4403pl27dlm7dm06duyYk046aaP93H///bnooos2WjZ8+PBs2LAhSfLII4+kuro6rVu3zrJlyzJq1KiUl298F7tnnnkmzz33XDp37pyFCxfmnHPOyaxZszJmzJjsvffeefPNNzNr1qwMGTIkU6ZMyYwZM/LZz342vXv3zvTp0/Pggw9mjz32yKxZs3L22Wdnl112ydixY/OnP/0pJ554YmbMmJEWLVrk/PPPb9QxBwAAAAAAGq7JlTe33XZbBgwYkCOPPDILFizIFVdckcsvvzzDhg3Ln/70p7Rp0yavvvpq/va3v2XDhg1p27ZtRo0alS5duqRnz55JkhUrVmTSpEm57LLL0rFjx7z00kub7GfevHnp0KHDRsuaN2+eJJk7d24efvjhXHHFFUmSMWPGZMKECRk8eHD9uitWrMgNN9yQq6++Os2bN8+4cePyyCOP5OSTT87AgQOzYcOGnHnmmXnggQfyzDPP5MILL8wzzzyTxx9/PL17906LFi1y1llnpXPnzvnLX/6Shx56KCNHjsyIESPy0EMP5fjjj88nPvGJXHzxxVm+fHnatm37nuNWWVn5IUadLWVOqQMAALyLf/ys6LMjAADAh9Pkypuqqqq0b98+CxcuTF1dXdq3b58NGzZkv/32y4033pg33ngjO++8c3r37p2///3vmTdv3ia3OWvTpk0+85nP5Prrr8/atWszbNiwTfaz8847Z8mSJe9aisyZMyedOnWqf9ylS5fMmjVro3XmzZuXsrKyPPjgg0neKnNatGix0WuSpHXr1tl1113rf161alWSt4qihx9+OG3bts2CBQuyfv36+te2b98+rVq1SpK0a9cuq1atet/yprq6+j2fBwCg6XrnZ8XKysqt/tlRWQQAAGxvmkx5U1VVlaVLl6ZHjx7Zb7/9MmDAgNTV1aVjx44pLy9PeXl59t1331x//fU577zzsuuuu+b+++/PAQccsMm2Vq5cmXbt2uVb3/pW5syZk5///Of1V9G87dRTT80f//jHnHvuufXL/uM//iNHHXVUunfvngULFtQvf/3119OrV6+NXt+lS5c0a9Ysp556anbYYYfMmzcvixcvbvDve/vtt+eQQw7JMccck+effz5PPvlk/XMN/d4eAAAAAABg69suy5sZM2Zk6tSpWb9+fe66664kyYIFC7L33ntn5MiRGTduXKqqqrJkyZLss88+9a87/PDD86tf/SpdunRJx44dc9111+WLX/xikmTatGmpqqrKxIkT07Vr1zzwwAOZOnVqli9fnpNPPnmTDMcff3wmTpyYsWPHpnnz5lm2bFl69+6dfv36JUlOOumk3HLLLWnVqlUqKipy7LHH5tlnn01NTU3+8Ic/5Oyzz86oUaNy8803p0OHDnnjjTdyxhlnpLq6OlOnTk1VVVX69u2bSZMmZeXKlamurs7EiRNTVVWVV155JUcddVQefvjhLFiwIG+88UaqqqoyY8aMzJo1K7W1tXn66afTpk2b1NTU5NFHH80ZZ5yxFf4yAAAAAADA+ymrq6urK3UIis9t04rhzc8PKXWE9zVs0OWljgC8j89V/M/tQF+df1sJkwDbi9GjR9f/7LZpFNGcUwaUOkKD+TwNwOa8cy73XszzoOHeOZcplc3NZ8q3cg4AAAAAAADeg/IGAAAAAACgQJQ3AAAAAAAABaK8AQAAAAAAKBDlDQAAAAAAQIEobwAAAAAAAApEeQMAAAAAAFAgyhsAAAAAAIACUd4AAAAAAAAUiPIGAAAAAACgQJQ3AAAAAAAABaK8AQAAAAAAKJCKUgcAGq7bA5NSXV1d6hjv6d5SByBJUllZWfhjhWKorPyxY4UGcV4BAACArceVNwAAAAAAAAWivAEAAAAAACgQ5Q0AAAAAAECBKG8AAAAAAAAKRHkDAAAAAABQIMobAAAAAACAAlHeAAAAAAAAFIjyBgAAAAAAoECUNwAAAAAAAAWivAEAAAAAACgQ5Q0AAAAAAECBKG8AAAAAAAAKRHkDAAAAAABQIMobAAAAAACAAlHeAAAAAAAAFEhFqQMAAABAY9phzH2ljtBg95Y6wP9SZWVlqqurSx1ju2aMG58xbnzGeOuorPyxcW5kjuXGZ4xdeQMAAAAAAFAoyhsAAAAAAIACUd4AAAAAAAAUiPIGAAAAAACgQJQ3AAAAAAAABaK8AQAAAAAAKBDlDQAAAAAAQIEobwAAAAAAAApEeQMAAAAAAFAgyhsAAAAAAIACUd4AAAAAAAAUiPIGAAAAAACgQJQ3AAAAAAAABaK8AQAAAAAAKBDlDQAAAAAAQIEobwAAAAAAAAqkotQBgIabc8qAd10+bNDlWzkJxTet1AHYRhz3xlWljrBVjB49utQRAAAAABrMlTcAAAAAAAAForwBAAAAAAAoEOUNAAAAAABAgShvAAAAAAAACkR5AwAAAAAAUCDKGwAAAAAAgAJR3gAAAAAAABSI8gYAAAAAAKBAlDcAAAAAAAAForwBAAAAAAAoEOUNAAAAAABAgShvAAAAAAAACkR5AwAAAAAAUCBNurz5+9//nssvvzxf+9rXMmnSpM2u99hjj2XlypX1jy+77LIsXbq0wft59tlnc8EFF2TBggUfKu/atWtz1113Zdy4cfn1r3+dMWPG5Be/+EVWrFjxgbc1bdq0fOMb38iUKVM+VCYAAAAAAGDLqih1gFLad999s3Dhwvz3f/93BgwYsNn1HnvssfTr1y+tW7dOknzrW99KWVlZg/fTv3//3HfffR867w033JCDDz44hx56aP2yW265JStWrEibNm0+0Lb22muvdO/e/UNnAgAAAAAAtqwmXd78o3//939P7969s2jRouy555456qij8vzzz6empiYPPvhgKisrs/vuu+fmm2/Oueeem44dO+baa69Np06dstNOO2X69Ok57bTT0r9//6xbty7XXXddOnTokJ122imrVq2q388zzzyT5557Lp07d87ChQtzzjnnZNasWRkzZkx69eqV1q1bZ+LEifn5z39eXxgtX748zz77bM4///yNMp977rn1P//1r3/N5MmTs/POO2f+/Pk555xz0rJly3fdX/PmzT/Q2FRWVv7vB5YtZk6pAwBso7yPbRnGkYZyrAAAAHw4ypt3GDRoUAYOHJgNGzbka1/7Wo466qgccMAB6dSpU04++eR07tw5SdKzZ88kSdeuXXPcccflueeey8iRI/PKK6/kN7/5Tfr3758//vGPadmyZc4555xs2LAhDz74YJJkxYoVueGGG3L11VenefPmGTduXB555JGcfPLJGThwYNauXZsRI0bkmGOOyY477lifbf78+Wnfvn3947q6utx7772ZO3duDj300Oy999658cYbc/XVV6eioiLjx4/PPffckyFDhmx2fx9EdXX1hxxdACgd72MfXmVlpXGkQUpxrCiLAACA7Y3y5v958803M3fu3Lz66qtp3rx5li1b1uDXvj1ZbNeuXVavXp0kmTt3brp27ZokKS8vry9+5s2bl7Kyso3KnBYtWtRva7fddkuS9OjRY6N97LrrrlmyZEn947KysgwdOjTXXHNN3njjjcybNy9t2rRJRcVbf9IuXbrk0Ucffd/9AQAAAAAAxaK8+X+effbZTJ48OZdeemmS5KGHHqp/rry8PElSVVWV3XffvUHb23333VNVVZUk2bBhQxYsWJDkrVKlWbNmOfXUU7PDDjtk3rx5Wbx4cf3rNvddOm3bts3BBx+cp556Kocffnj98jfffLN+uytWrMj69etTUVGRefPmpWfPnu+7PwAAAAAAoFiUN3mrMOnbt28eeOCB3HTTTenYsWPWrFmTCRMm5Nhjj82BBx6Y8ePHZ+3atRk8eHCqqqoyceLEdO7cOZMmTcrKlSszb968TJw4MTU1NXnhhRdy7LHH5rrrrstNN92UNm3apEWLFvn973+fESNGZNSoUbn55pvToUOHvPHGGznjjDNSXV2dqVOnpqqqKt26dUvv3r03yfm5z30u9913X+68886Ul5dn6dKlad68eQ466KC0adMm5513Xm666absvPPOqampyahRo9KyZct33d+0adPqf4/evXu7GgcAAAAAAAqirK6urq7UIUph8uTJ2X///fPAAw9k/vz5+exnP1vqSIXmHvfF8Obnh7zr8mGDLt/KSYDtxXFv/L7UEbaK0aNHlzrCNs933tBQvvOGInL+anzeJxqfMW58xrjxGeOtwzg3PmPc+JrSGG9uPtNkr7z53e9+l7///e+ZO3duzj777FLHAQAAAAAASNKEy5tLLrmk1BEAAAAAAAA2UV7qAAAAAAAAAPwP5Q0AAAAAAECBKG8AAAAAAAAKpMHlzYsvvphZs2Y1YhQAAADetnLlylJHAAAASqTB5c0Pf/jDvPbaa42ZBQAAoEnasGFDlixZkoULF9b/96Mf/ajUsQAAgBKpaOiK++yzT4444ohNlk+ZMiX77LPPFg0FAADQVPz+97/P2LFjs2bNmlJHAQAACqLB5U3//v1z9913Z8CAAWnVqlX98l/96lf5wQ9+0CjhAAAAtne//e1v82//9m/p0aNHmjVrVr/8iiuuKGEqAACglBpc3tx0001Jkv/6r/9qtDAAAABNTbdu3dKnT59Nlo8aNaoEaQAAgCJocHnTr1+/XHrppZssv+yyy7ZoIAAAgKakb9++ufHGG3PggQemZcuW9ctvvfXW/OQnPylhMgAAoFQaXN7867/+6wdaDmx53R6YlOrq6k2W31uCLBRbZWXlux4r8I8qK491rACU2Lhx49KhQ4c8++yzGy1funRpiRIBAACl1uDypqKiIk8++WQmTpyYurq6fPWrX80999yTM844I82bN2/MjAAAANutgw46KP/8z/+8yfKrr766BGkAAIAiKG/oir/5zW/yu9/9LgcccEBWrFiRNm3aZPfdd88vf/nLxswHAACwXXu34iZJvvKVr2zlJAAAQFE0+MqbF154Id/97ndTXl6eSZMmJUk+9rGP5Yknnmi0cAAAANu7DRs2ZPz48Xn00UezaNGidOzYMR/72McydOjQlJc3+N/bAQAA25EGlzcbNmzYZOKwYcOGrFmzZouHAgAAaCruuOOOzJ49O2eccUbatWuXZcuW5Yknnsgdd9yRESNGlDoeAABQAg0ub/r27Zvvf//7OeaYY7Jy5co8/fTTefLJJ7PPPvs0Zj4AAIDt2ksvvVR/l4O3HX744bn00ktLmAoAACilBl+Df9ZZZ2WfffbJXXfdlerq6tx5553p3bt3zjzzzMbMBwAAsN1zezQAAOCdGnzlzaJFizJs2LAMGzZso+WPPvpoPvaxj23xYAAAAE3BnnvumR/84Ac5+uijN7pt2t57713qaAAAQIk0+J93XXvttZssq66uzm9+85stGggAAKAp+fSnP5299tord911V6644orcdddd6devX84444xSRwMAAEqkwVfevPLKK3n88cdzzDHHpK6uLvfdd1/uvvvu7LDDDo2ZDwAAYLu2ww475PTTT8/pp5++0fLFixdnp512KlEqAACglBpc3px22mlZtGhR7rrrrkyaNClJ8v3vfz/Tpk1rtHAAAADbu4ULF77r8p/97Gf5wQ9+sJXTAAAARdDg8ubt77oZP3582rRpk3/5l39JeXl5XnjhhUYLBwAAsD36+te/nu9///tp1apVLrjgglLHAQAACuY9y5t3+56bJJk9e3auuuqqNG/ePM8//3xOOeWURgkHAACwPfrmN7+ZVq1aJUn23XfffPvb395kne9///tbOxYAAFAQ71neTJkyJYMGDdpk+fHHH/8/G6ho8MU7AAAAJOnUqVP9zyNGjNjk+Yceeiif+cxntmYkAACgQN6zeTnttNMyePDg99xA165dt2ggAACApuS2227LpZdeutGy7t275/rrr/edNwAA0ES9Z3nzfsVNkjz//PM58sgjt1ggAACApuDFF19MktTW1mbq1Kmpq6urf27t2rWpra0tVTQAAKDEGnzPsyVLlmTs2LF59dVXs2bNmo2W+4JNAACAD+aaa65J8tac6uqrr97ouVatWuWEE04oRSwAAKAAGlze/Md//EcOPfTQVFVV5fzzz8/69evz3HPPbVTkAAAA0DBvlzfXXnttzj///BKnAQAAiqS8oSuuXbs2gwYNSsuWLdOvX7/sv//+Oeecc7JkyZJGjAcAALB921xxc88992zlJAAAQFE0+MqbtWvXJknKy8szc+bM9OrVK/Pmzcvs2bMbLRwAAMD2aOLEiTnyyCNTXl6ea6+99l3Xef7553Paaadt5WQAAEARNLi8OfDAA/Pwww/n5JNPzv/3//1/adWqVVauXGkyAQAA8AG99NJLOfTQQ7PjjjtmypQpGTRo0CbrVFQ0eLoGAABsZxo8G/jkJz9Z//OVV16ZV199NV26dMkee+zRKMEAAAC2V5///Ofrfz7jjDNy9NFHb7LOrrvuujUjAQAABfKB/ynXyy+/nOXLl+eQQw5JbW1tY2QCAABoMg477LAsXLgwu+yyS+rq6vL4449nw4YNOeaYY0odDQAAKJHyhq5YXV2diy66KJdddlluvfXWrF27Npdddln+9re/NWY+AACA7dpNN92UW265JevXr88999yTe+65J0888URuuOGGUkcDAABKpMHlzY033phzzjknt9xySzp27JiWLVvmO9/5Tu69997GzAcAALBdmz9/fv75n/85O+ywQx555JH867/+ay699NLMnj271NEAAIASaXB58+abb6Z///4bLWvRokXKysq2eCgAAICmYsOGDUmSF154IV27dk3nzp2TJC1btixlLAAAoIQa/J03dXV1efHFF9OvX7/6ZTNmzGiUUAAAAE1Ft27d8qMf/ShVVVX54he/mLVr1+aRRx5Js2bNSh0NAAAokQaXN6NGjcoPf/jDtGzZMsuXL8/Xv/71rFixIt/85jcbMx8AAMB27bzzzstzzz2X1q1bp2/fvqmtrU2rVq1yzjnnlDoaAABQIg0ub3r16pWrrroqzz77bN54443svPPOOfjgg13KDwAA8CGUlZXlgAMOyPTp0/OnP/0pO++8c44++uiUlzf4LtcAAMB2psHlTZK0atUqe++9dxYvXpyddtpJcQMAAPAhzZs3Lz/5yU9SU1OT1q1bZ+XKlenUqVO+8Y1vpEuXLqWOBwAAlECDy5uamppcddVVmT59ev2yvn375sILL6z/Qk0AAAA+mJtuuinDhg3LEUcckfLy8mzYsCFPPfVUbrrppnzrW98qdTwAAKAEGnwd/tVXX53+/fvn2muvze23355rrrkmBx54YK655prGzAcAALBdW7t2bY466qj626SVl5fnyCOPzNq1a0ucDAAAKJUGlzdvvvlmTjvttOy8885p3rx5dtlll3zyk5/Mm2++2Zj5AAAAtmtvvvlm5s2bt9Gy+fPnm2sBAEAT1uDbpnXu3DlLly5N+/bt65ctWbIklZWV9Y/vueeenHbaaVs2IVBv4L9PKHUEthnTSh2AbcRfL6l8/5UAaFSf/OQn83/+z//JRz7ykbRt2zbLli3LzJkzc/HFF5c6GgAAUCINLm/Wrl2biy66KP369Uvr1q2zYsWKTJ8+Pfvuu2+uvfbaJMnzzz+vvAEAAPgADjzwwFxxxRV58skns2jRovTo0SNf+tKXfLcoAAA0YQ0ub1599dWcfPLJ9Y87deqUPfbYY6N1mjVrtuWSAQAANAErVqzInXfemaeffjpvvvlmKioqMnfu3HzmM59JmzZtSh0PAAAogQaXN6ecckoOOeSQ7Lzzzqmrq8vEiROzYcOGHHPMMdlhhx2SJDvttFOjBQUAANgeXX311enYsWP+7d/+LW3atMny5cvz+OOP5+qrr843v/nNUscDAABKoMHlTVVVVV588cVcdNFFue+++/L444+nY8eOeeWVV/KFL3whSTJ48OBGCwoAALA9Wrp06SYlzd57751/+Zd/KVEiAACg1MobuuL8+fPzz//8z9lhhx3yyCOP5F//9V9z6aWXZtasWY0YDwAAYPvWsWPHrFmzZqNlq1evTqdOneofP/roo1s7FgAAUEINvvJmw4YNSZIXXnghXbt2rf/yzJYtWzZOMgAAgCagbdu2+T//5//koIMOSps2bbJixYo8//zz2W+//fKb3/wmSfLYY4/lYx/7WImTAgAAW0uDy5tu3brlRz/6UaqqqvLFL34xa9euzSOPPJJmzZo1Zj4AAIDt2rPPPpsDDzwwtbW1qa2tTZJ85CMfyerVq7N69eokybp160oZEQAA2MoaXN6cd955ee6559K6dev07ds3tbW1adWqVc4555zGzAcAALBdO+GEE3L66ae/5zpvX4EDAAA0DQ0ub8rKynLQQQfVP27VqlUGDRrUGJkAAACajPcrbhq6DgAAsP0oL3UAAAAAAAAA/ofyBgAAAAAAoECUNwAAAAAAAAWivAEAAAAAACiQilIH2NpeeeWVjB07NuvXr8/IkSOz55575umnn87tt9+evn375uyzz84uu+yyRfZ12WWX5Stf+Urat2+/0fLFixfn9ttvz6677poNGzZk5syZGTlyZLp3775F9gsAAAAAAGy7mlx506dPn/Tr1y+rV6/OnnvumSQ57LDD8vDDD+fII4/cYsVNknzrW99KWVnZJsvvv//+9OnTJyeffHKS5LHHHkttbe0W2y8AAAAAALDtanLlTUPU1tbmlltuSdeuXfPGG29kwIABOfDAAzN27Nj86U9/yoknnpgZM2akRYsWOf/88zN9+vSMGTMmvXr1SuvWrTNx4sRcfPHFufnmm3Puuedmn3322Wj7HTp0yBNPPJE+ffrkIx/5SAYNGpQkmT17dm6++eZ06NAh3bt3z6uvvpoBAwbkmGOO+cCZkuSvf/1rnn/++XTq1CnTp0/PqFGjsvPOO+eWW25J+/btU1tbm549e+boo4/e2kMMAAAAAABsRpMtb6ZMmZJbbrml/vG8efPqfx4/fny6dOmS0047LWvXrs1FF12UX/ziFxkxYkQeeuihHH/88fnEJz6Riy++OMuXL0/fvn0zcODArF27NiNGjMgxxxyT3XbbLT179nzXfX/84x9Ps2bNcuONN2bRokU5/PDDc+aZZ6ZHjx7p169fNmzYkGHDhmXdunW54IIL0r9//9x///0fKFNZWVluvPHG/OIXv0izZs0yZcqUbNiwIRMmTMj69etz+umnp66uLl/72tdywAEHbHJrt39UWVm5JYadD21aqQMA2yHneBrKsUJDOVYAAAA+nCZb3uyzzz4555xz6h/PmjWr/ufZs2enbdu2GT9+fJKke/fuWbFiRdq3b5/27dunVatWSZJ27dpl1apVadu2bZJkt912S5L06NHjPfddXl6ek046KSeddFLeeOONXH/99fn1r39dn6dz585JkmbNmqVt27aZP3/+B860bNmytGnTJs2aNav/fZPkt7/9bRYvXly/nW7dumXJkiXvW95UV1e/5/MAbLuc42mIyspKxwoNUopjRVkEAABsb5psefNeevTokQ4dOtR/J83EiRPrC5p3+w6bt73Xc+90zTXX5Iwzzsguu+ySnXfeOfvvv39qamrqn1+wYEGSZO3atVm2bFl23XXXD5ypS5cuWbFiRdavX5+KiopMmTIlHTp0SM+ePdOsWbMMHTo0SfLMM8+kU6dODcoNAAAAAAA0viZX3syYMSNTp07N+vXrM3369PTt2zfPPPNMampq8tRTT6VHjx457bTTMnbs2Nx1112pra3NrrvumvLy8vzxj39MbW1tnn766bRp0yY1NTV59NFHc9RRR2Xq1KmpqqpKt27d0rt370ybNi1VVVWZOHFievfunRYtWtRn2HvvvXPLLbeke/fuWbduXWpqanLuuefWP7906dLcfffdeeWVV3LWWWelbdu2HzjTGWeckfPOOy833XRTOnXqlBUrVuTTn/50unbtmrFjx2bcuHFZv359mjdvnkMOOaQEfwkAAAAAAODdlNXV1dWVOgT/Y9y4cencuXMGDRpU6igbcZuUYvjEf/rOG2DL+uslxzrH0yBum0ZDuW0aReT81fi8TzQ+Y9z4jHHjM8Zbh3FufMa48TWlMd7cfKZ8K+fgPVRVVWXq1KmZNGlSFi5cWOo4AAAAAABACTS526YVWffu3XPppZeWOgYAAAAAAFBCrrwBAAAAAAAoEOUNAAAAAABAgShvAAAAAAAACkR5AwAAAAAAUCDKGwAAAAAAgAJR3gAAAAAAABSI8gYAAAAAAKBAlDcAAAAAAAAForwBAAAAAAAokIpSBwAa7q+XHJvq6upSx2AbUFlZ6VgBAAAAgG2UK28AAAAAAAAKRHkDAAAAAABQIMobAAAAAACAAlHeAAAAAAAAFIjyBgAAAAAAoECUNwAAAAAAAAWivAEAAAAAACgQ5Q0AAAAAAECBKG8AAAAAAAAKRHkDAAAAAABQIMobAAAAAACAAlHeAAAAAAAAFIjyBgAAAAAAoECUNwAAAAAAAAWivAEAAAAAACgQ5Q0AAAAAAECBVJQ6AAAAADSmNz8/ZKvsZ9igy7fKfoppWqkDNAHGuPEZ48ZnjLeEz1V0ec/nX51/1VZK0vhGjx5d6ghQMq68AQAAAAAAKBDlDQAAAAAAQIEobwAAAAAAAApEeQMAAAAAAFAgyhsAAAAAAIACUd4AAAAAAAAUiPIGAAAAAACgQJQ3AAAAAAAABaK8AQAAAAAAKBDlDQAAAAAAQIEobwAAAAAAAApEeQMAAAAAAFAgyhsAAAAAAIACUd4AAAAAAAAUiPIGAAAAAACgQCpKHQBouDmnDCh1hAYZNujyUkcg00odgBL6XEWXBq/76vyrGjHJljd69OhSRwAAAABodK68AQAAAAAAKBDlDQAAAAAAQIEobwAAAAAAAApEeQMAAAAAAFAgyhsAAAAAAIACUd4AAAAAAAAUiPIGAAAAAACgQJQ3AAAAAAAABaK8AQAAAAAAKBDlDQAAAAAAQIEobwAAAAAAAApEeQMAAAAAAFAgyhsAAAAAAIACqSh1gFJbvHhx7r///rRq1SobNmxIdXV1OnfunLPOOmuL7WPKlClp3bp1evbs+a77v/3227Prrrtmw4YNmTlzZkaOHJnu3btvsf0DAAAAAADbjiZd3qxbty6XX355vv71r2eXXXZJkqxfvz4///nPt+h+pkyZks6dO79reXP//fenT58+Ofnkk5Mkjz32WGpra7fo/gEAAAAAgG1Hky5v/vu//zudOnWqL26SpKKiIl//+teTJI8++mjuuOOOnHDCCXnjjTcye/bsXHTRRbn11luz5557pqqqKqeeemp69uyZ++67L7/+9a8zcuTIvPzyy1m2bFm+8Y1vZN68eXnxxRcza9asLFiwIEOHDk3z5s3r99ehQ4c88cQT6dOnTz7ykY9k0KBBSZLZs2fn5ptvTocOHdK9e/e8+uqrGTBgQI455pisWrUqt99+ezp37pyFCxfmgAMOyMCBAzN27Nj86U9/ynHHHZdXXnklXbp0yeLFi7NgwYLst99+mTZtWg499NDsv//+uffee9O9e/e89tprGTZsWHbdddetOvYAAAAAAMC7a9LlzYIFC9KhQ4f6xzU1NfnTn/6UadOm5bOf/Ww+9rGP5fHHH0/v3r3zqU99KjNmzEhFRUVOP/309OrVKzNnzszdd9+diy++OEOGDMnvfve77LvvvjnhhBPyox/9KLNmzUqvXr3Sr1+/dO7cub6YeaePf/zjadasWW688cYsWrQohx9+eM4888z06NEj/fr1y4YNGzJs2LCsW7cuF1xwQfr375/7778/Xbp0yZAhQ7Ju3bpceOGF2XvvvTNixIg89NBDOfHEE9OqVatUVVWlVatW+fa3v53hw4dn3bp1Wbx4ca655pqcc8452XPPPTNlypTcdtttueSSS95zrCorK7fw6PO/MafUAQBKzPtRaRl/GsqxAgAA8OE06fJm1113zcsvv1z/uFOnThk6dGguuOCCrF69un757rvvniTp3bt3lixZkqeeeirPPfdcamtrs2zZso222bVr1yRJu3btsmrVqvfNUF5enpNOOiknnXRS3njjjVx//fX59a9/nXPOOSdJ0rlz5yRJs2bN0rZt28yfPz+zZ8/OscceW7+8devWmTdvXvr06ZP27dunTZs2SZKePXtmwYIF6dKlSyoqKlJRUZGWLVumqqoqzz//fKZOnZq1a9emRYsW75uzurr6fdcBgMbm/ah0KisrjT8NUopjRVkEAABsb8pLHaCU+vfvn5qamixYsGCj5Rs2bNjsa8aPH58WLVpk2LBh9QXKO5WVlW2yrLy8PHV1dVm0aNEmZc8111yThQsXJkl23nnn7L///lm/fn39829nW7t2bZYtW5Zdd901PXr0yPz585O89b09K1eurC+N3m3//7isR48eOfTQQzN06NCcdtpp6d+//2Z/XwAAAAAAYOtq0lfeNGvWLN/4xjdy7733pnXr1tmwYUPmzZuXY445Jp07d87kyZNTU1OThx9+OEOHDk27du1y2GGH5Y477si6deuyfv361NTU5IUXXsiKFStSW1ubCRMmpGfPnqmqqsrEiROz5557pl+/fvntb3+byZMnZ+TIkRtl2HvvvXPLLbeke/fuWbduXWpqanLuuefWP7906dLcfffdeeWVV3LWWWelbdu2Oe2003LrrbfmrrvuysKFC3PeeeeldevW+eMf/5ja2tr89re/zcc//vEkyYQJE1JTU5MJEybUl01f+tKX8tvf/rb+O3OOPvrorTbmAAAAAADAeyurq6urK3UI3t24ceM2+105W5vbpBTDm58fUuoIDTJs0OWljgBN2ucqujR43Vfn39aISba80aNHlzpCk+W2aTSU26ZRRHNOGbBV9uNzMABbw/vN+ba1ed57Keoc0Pyo8TWlMd7cfKZJ3zatyKqqqjJ16tRMmjSp/rZqAAAAAADA9q9J3zatyLp3755LL7201DEAAAAAAICtzJU3AAAAAAAABaK8AQAAAAAAKBDlDQAAAAAAQIEobwAAAAAAAApEeQMAAAAAAFAgyhsAAAAAAIACUd4AAAAAAAAUiPIGAAAAAACgQJQ3AAAAAAAABVJR6gBAw3V7YFKqq6tLHeN93VvqAKSysnKbOFYovcrKHztWAAAAAArGlTcAAAAAAAAForwBAAAAAAAoEOUNAAAAAABAgShvAAAAAAAACkR5AwAAAAAAUCDKGwAAAAAAgAJR3gAAAAAAABSI8gYAAAAAAKBAlDcAAAAAAAAForwBAAAAAAAoEOUNAAAAAABAgShvAAAAAAAACkR5AwAAAAAAUCDKGwAAALa6hQsX5oorrsi4ceM+8GufeeaZLFiwoBFSAQBAMShvAAAA2Op22WWXDBgw4H/12r/+9a+pqanZwokAAKA4KkodAAAAgG3L6tWr89Of/jR77713qqurc+SRR+aNN97IHXfckVNOOSULFizIa6+9lm984xtp1apVfv/732fOnDlp3759Fi5cmM9//vPZYYcd6rc3Y8aMXHXVVdlzzz1z/vnn57HHHssjjzySL33pS7n//vvTuXPnLF26NP369csuu+ySWbNm5bHHHsvLL7+coUOHlm4gAACgkShvAAAA+EDKyspyyimnZP/998+KFSty2WWX5Uc/+lEef/zx9OzZM0OHDs0NN9yQyZMn57DDDkvHjh0zePDglJeX56abbsrzzz+f/v3712+vd+/e+cQnPpGZM2cmScrLyzNixIisX78+s2bNysiRI9OiRYvMnj07vXv3Ts+ePTNo0KDss88+pRoCAGArqKysLHWEzSpytu1FUx9j5Q0AAAAfSF1dXV588cVMnz49FRUVWbZsWf1zb0+y27Vrl9WrVydJdtxxx4wdOzbt2rXLa6+9ll69em2yzSOPPDJ33XVXamtrM23atBx99NFJkhNOOCH/9//+31RUVOTTn/70VvjtAICiqK6uLnWEd1VZWVnYbNuLpjTGmyupfOcNAAAAH8iECROyaNGinH766fn4xz/+vutfeeWVOfnkkzN06ND07t37Xddp3rx5jjrqqFx//fXZc889kyQLFizIRz7ykVx66aU56aST8utf/zrJW1fm1NXVZd68efUFEQAAbE+UNwAAAHwgBxxwQObNm5fbb789999/f2pra/PUU0+lpqYmjz76aObPn5+pU6dm0qRJWbZsWY4//vjccMMNGT9+fF5++eVMmjQpCxcuzKRJkzJ16tTMnTs3yVtX2bz88ss5/PDDkyTr16/P3XffnfHjx+fZZ5/N8ccfnyTZb7/9MmHChNx5550pKysr2TgAAEBjKaurq6srdQiKr6lcolZ0TelyQT4cxwoN5VihoRwrNFQpjpWmfi/s7cX69euzbNmyPProo/nkJz+5Rbc955QBW3R7mzNs0OVbZT8ANG2fq+jyns+/Ov+2rZSk8Y0ePbrUEd6V+VHja0pjvLn5jO+8AQAAoKTWrFmTn/zkJ6msrMzw4cNLHQcAAEpOeQMAAEBJ7bjjjvm3f/u3UscAAIDC8J03AAAAAAAABaK8AQAAAAAAKBDlDQAAAAAAQIEobwAAAAAAAApEeQMAAAAAAFAgyhsAAAAAAIACUd4AAAAAAAAUiPIGAAAAAACgQJQ3AAAAAAAABaK8AQAAAAAAKJCKUgeA93LVVVeVOkKhXPDCI++6fNigy7dyEopvWqkDUBCfq+jyns9/8WuVWykJAAAAAA3lyhsAAAAAAIACUd4AAAAAAAAUiPIGAAAAAACgQJQ3AAAAAAAABaK8AQAAAAAAKBDlDQAAAAAAQIEobwAAAAAAAApEeQMAAAAAAFAgyhsAAAAAAIACUd4AAAAAAAAUiPIGAAAAAACgQJQ3AAAAAAAABaK8+Qe1tbUZOXJkZs6cudX3vX79+txyyy0ZMWJExo0blzvuuCPf+9738sorr3yo7f7ud7/LBRdcsIVSAgAAAAAAjUl58w+efPLJDBw4MI888shW33dFRUVOPvnk7Ljjjhk+fHjOOuusHH300Rk/fvyH2u4//dM/bZmAAAAAAABAo6sodYCief311zNq1KhcfPHFOeecc1JVVZUxY8Zkzz33TEVFRV5++eV89rOfTe/evfOXv/wlL7zwQjp16pQZM2bk4osvzqpVq3L77benc+fOWbhwYQ444IAMHDgwY8eOzZ/+9KeceOKJmTFjRlq0aJHzzz//ffMsW7Ys7dq1S5L6bRx33HF55ZVX0qVLlwwZMiTjxo1L165d8/rrr2fQoEHZa6+9smDBgtx8883ZY4890rFjx/rtrV69Oj/96U+z9957p7q6OkceeWT233//RhtPAAAAAADgg1HevMPLL7+cvffeO+3bt88BBxyQJ598MoMHD87AgQOzfv36nHXWWfnzn/+cxx9/PL17987jjz+eQw45JIMGDcpLL72UJLnnnnvqS5V169blwgsvzN57750RI0bkoYceyvHHH59PfOITufjii7N8+fK0bdt2kxxr167N+PHjs3Llyrzwwgv1tzx7exsnnnhiWrVqlaqqqtx222057LDDcthhh2XJkiX55je/meuuuy5jx47NUUcdlcMPPzzz5s3LPffckyQpKyvLKaeckv333z8rVqzIZZdd1qDyprKycguONABF4hxPQzlWaCjHCgAAwIejvHmHp556KjvuuGNmzZqVZs2a5Q9/+EMGDx6cJOnatWuSpF27dlm1alWSZNSoUbnnnnvy8MMP56CDDkrfvn0ze/bsHHvssUmSZs2apXXr1pk3b1769OmT9u3bp1WrVhtt593Km+bNm2fo0KFJkkWLFuWb3/xmrrnmmjRr1izt27dPmzZtkiQ9e/ZMVVVVhgwZkiTp0KFDamtrs3z58syZM6d+G507d67fdl1dXV588cVMnz49FRUVWbZsWYPGprq6+oMMJQDbEOd4GqKystKxQoOU4lhRFgEAANsb5c3/U1tbm9atW+f000+vX3bhhRdm5syZSd66YuUfzZkzJ1/60peyfv36fOc738nAgQPTo0ePzJ8/P0mybt26rFy5sr74ebdtvJ+2bdumtrY269evT7NmzTbZxtv769WrV5YsWZLWrVunbdu22X333fP666+nV69eWbBgQf36EyZMyKJFi3L++edn/fr1+cMf/vCBMwEAAAAAAI1HeZO3SpYxY8akouJ/huO1115LmzZtcvvttydJqqqqcsABB2TixImpqqrKjBkzMn369Lz88svZcccd061bt3Tv3j1du3bNrbfemrvuuisLFy7Meeedl9atW+ePf/xjamtr8/TTT6dNmzapqanJo48+mjPOOKN+n+vXr8/DDz+ctWvX5q677kpZWVlef/31nHPOOWnZsmX9Nn7729/m4x//eJJk5MiRufPOO/P6669n3rx5+epXv5qysrKcffbZufnmmzN79uy0atUqtbW1eeKJJ3LAAQfk6aefzu233542bdrUZzrssMO27qADAAAAAADvqqyurq6u1CEovlLdJuWqq64qyX6L6oIXHnnX5cMGXb6VkwDbis9VdHnP57/4tX5uhUWDuG0aDeW2aRTRnFMGbJX9+FwOwNbwfvO8V+fftpWSNL7Ro0eXOsK7Mj9qfE1pjDc3nynfyjkAAAAAAAB4D8obAAAAAACAAlHeAAAAAAAAFIjyBgAAAAAAoECUNwAAAAAAAAWivAEAAAAAACgQ5Q0AAAAAAECBKG8AAAAAAAAKRHkDAAAAAABQIMobAAAAAACAAlHeAAAAAAAAFIjyBgAAAAAAoEAqSh0A3svo0aNLHaFQKit/nOrq6k2W31uCLBRbZWXlux4rAAAAAEDxufIGAAAAAACgQJQ3AAAAAAAABaK8AQAAAAAAKBDlDQAAAAAAQIEobwAAAAAAAApEeQMAAAAAAFAgyhsAAAAAAIACUd4AAAAAAAAUiPIGAAAAAACgQJQ3AAAAAAAABaK8AQAAAAAAKBDlDQAAAAAAQIEobwAAAAAAAApEeQMAAAAAAFAgyhsAAAAAAIACqSh1AAAAAGhMO4y5b6vs596tspdiqqysTHV1daljbNeMceMzxo3PGG8dlZU/Ns6wHXDlDQAAAAAAQIEobwAAAAAAAApEeQMAAAAAAFAgyhsAAAAAAIACUd4AAAAAAAAUiPIGAAAAAACgQJQ3AAAAAAAABaK8AQAAAAAAKBDlDQAAAAAAQIEobwAAAAAAAApEeQMAAAAAAFAgyhsAAAAAAIACUd4AAAAAAAAUiPIGAAAAAACgQJQ3AAAAAAAABaK8AQAAAAAAKJCKUgcAGm7OKQO2yHaGDbp8i2yHIptW6gAU0Ocqumyy7NX5V5UgyfsbPXp0qSMAAAAAlIwrbwAAAAAAAApEeQMAAAAAAFAgyhsAAAAAAIACUd4AAAAAAAAUiPIGAAAAAACgQJQ3AAAAAAAABaK8AQAAAAAAKBDlDQAAAAAAQIEobwAAAAAAAApEeQMAAAAAAFAgyhsAAAAAAIACUd4AAAAAAAAUiPIGAAAAAACgQJQ3/09tbW1GjhyZmTNnJkmmTZuWb3zjG5kyZcp7vu6//uu/MmnSpA+0r7Vr1+auu+7KuHHj8utf/zpjxozJL37xi6xYsWKzr2lonrdNmDAhDz300HuuM3bs2HznO9/5INEBAAAAAIBGVlHqAEXx5JNPZuDAgXnkkUfyhS98IXvttVe6d+/+vq8bPnx4ysrKPtC+brjhhhx88ME59NBD65fdcsstWbFiRdq0afOur2lonrcde+yxqaure891TjjhhLzyyisN3iYAAAAAAND4lDf/z+uvv55Ro0bl4osvzjnnnJMWLVps9Pydd96Z9evXp6KiIuvWrcvIkSOzcOHC3HTTTenZs2eGDx+en/70p6mpqcmBBx6YGTNmpHfv3hk+fPhG21m+fHmeffbZnH/++RstP/fcc+t/vv7669OxY8esXr06O+20U0499dT65/72t79l+vTpefnll3PCCSfkwAMPzE9/+tMsWLAg++23X6ZNm5b9998/8+fPT5JccMEFqa2tzS233JKuXbvmjTfeyIABA3LggQd+oPGprKz8QOvTOOaUOgDAVuJ9p5j8XWgoxwoAAMCHo7xJ8vLLL2fvvfdO+/btc8ABB+TJJ5/M4MGDN1qnd+/eGThwYJLkJz/5SebMmZNu3brlkEMOyYIFC5IkZ599di699NKcfvrpSZIvf/nLm5Q38+fPT/v27esf19XV5d57783cuXNz6KGHZuDAgTn44IPr93XJJZdk8ODBadmyZZKka9euOe6447JkyZJccskl+eUvf5mzzz473/72tzN8+PCsW7cuixcvzuLFi/PYY48lScaPH58uXbrktNNOy9q1a3PRRRflF7/4xQcao+rq6g+0PgB8GN53iqeystLfhQYpxbGiLAIAALY3ypskTz31VHbcccfMmjUrzZo1yx/+8IdNypv169dn7NixadOmTRYtWpRly5a967Y6d+6c8vK3vkqoomLT4d11112zZMmS+sdlZWUZOnRorrnmmrzxxhtJksWLF+eOO+5Iq1atsmrVqixfvry+vNl1112TJB06dMiaNWvqc3Tp0iUVFRWpqKhIy5Yts3jx4vp9zJ49O23bts348eOTJN27d3/P79cBAAAAAABKp8mXN7W1tWndunX91TJJcuGFF2bmzJn1j1euXJmrr746t956ayoqKjJ79uzNbu/9vv+mbdu2Ofjgg/PUU0/l8MMPr1/+5ptvJklmzZqV++67L1dffXWSZNKkSRu9fv78+dl3332zePHi7LjjjmnXrl1qamrec789evRIhw4dcvLJJydJJk6cmLZt22bNmjXvmRUAAAAAANj6mnR5s27duowZM2ajK2Ree+21tGnTJrfffntmzZqV8vLy9O7dOx/96Edz9dVXp1evXpk7d24mTpyYXXfdNZMmTcrKlSszd+7cPPnkk6mpqckLL7yQVatWpba2NhMmTMixxx670X4/97nP5b777sudd96Z8vLyLF26NM2bN89BBx2UnXbaKbvttluuv/76VFZWZtGiRXn00UdzwAEHpKqqKs2aNcsbb7yRGTNm5Pzzz09ZWVkmTJiQmpqa+n2tWrUqEydOTFVVVV566aWcdtppGTt2bO66667U1tZm1113TXl5eX7/+9+npqYmf/vb33LQQQdt7eEHAAAAAADeRVldXV1dqUNQfO5xXwxvfn7IFtnOsEGXb5HtANuWz1V02WTZq/NvK0GS9zd69OhSR+Af+M4bGsp33lBEzl+Nz/tE4zPGjc8YNz5jvHUY58ZnjBtfUxrjzc1nyrdyDgAAAAAAAN6D8gYAAAAAAKBAlDcAAAAAAAAForwBAAAAAAAoEOUNAAAAAABAgShvAAAAAAAACkR5AwAAAAAAUCDKGwAAAAAAgAJR3gAAAAAAABSI8gYAAAAAAKBAlDcAAAAAAAAFUlHqAEDDdXtgUqqrqz/0du7dAlkotsrKyi1yrLD9q6z8sWMFAAAAoGBceQMAAAAAAFAgyhsAAAAAAIACUd4AAAAAAAAUiPIGAAAAAACgQJQ3AAAAAAAABaK8AQAAAAAAKBDlDQAAAAAAQIEobwAAAAAAAApEeQMAAAAAAFAgyhsAAAAAAIACUd4AAAAAAAAUiPIGAAAAAACgQJQ3AAAAAAAABaK8AQAAAAAAKBDlDQAAAAAAQIEobwAAAAAAAAqkrK6urq7UIQAAAAAAAHiLK28AAAAAAAAKRHkDAAAAAABQIMobAAAAAACAAlHeAAAAAAAAFIjyBgAAAAAAoECUNwAAAAAAAAVSUeoAwKYmT56cZ555Ju3atUtZWVk+9alPbfT82rVrc/vtt6djx455/fXXM3To0FRWVpYoLaX0fsfKY489lj/84Q9p1qxZkuTYY4/N0UcfXYqolNCSJUty5513Zvbs2fnRj360yfPOKbzt/Y4V5xSSZN68ebnzzjvTq1evvPHGG2nbtm1OP/30jdZxXqEUfIZufO83xuPHj8+SJUvSoUOHzJw5M2eccUZ22223EqXddr3fOL/tiSeeyC9+8YvcdtttadGixVZOuW17vzGuq6vLQw89lCSpqanJypUrc/7555ci6jbr/cZ4wYIFue2229KnT5/MmjUrRx55ZAYMGFCitNsm87zG935j7H1vy3i/cX5bU3zfc+UNFMyaNWsyZsyYjBo1KsOHD8/s2bPzwgsvbLTOgw8+mF122SWnnXZaPv7xj+f6668vUVpKqSHHSpJ89atfzXe+85185zvf8T9Zm6hp06ZlwIABqaure9fnnVN42/sdK4lzCsmKFStyxBFHZMiQIfnMZz6TP/3pT5k5c+ZG6zivsLX5DN34GjLGq1evzqhRozJ06NAcdthhuf3220uUdtvV0M/4c+fOzdy5c0uQcNvXkDF+4okn0rp165x88skZNWpUTjnllBKl3TY1ZIzvvffe7LXXXhk6dGg+8YlP5LbbbitR2m2XeV7je78x9r63ZTRkHtpU3/eUN1Aw06dPT6dOner/VfNee+2VZ599dqN1nn322fTt2zdJ0r1798yePTu1tbVbPSul1ZBjJUkefvjh3HffffnNb36TFStWbO2YFMBhhx2Wli1bbvZ55xTe9n7HSuKcQtKnT58MHDiw/nFdXV123HHHjdZxXmFr8xm68TVkjM8888yUlZUlSTZs2NBk/lXsltSQcV6zZk3uu+++zV6Rw3tryBg/8cQTWbFiRR588MHccccdjuUPqCFj3L59+yxbtixJsmzZsvTq1Wur59zWmec1vvcbY+97W8b7jXNTft9T3kDBLF26dKOTfcuWLbN06dJN1nnnSa1ly5b1H3poOhpyrPTr1y9Dhw7NkCFD0qtXr1x55ZVbOybbAOcUGso5hX/0zDPP5IADDtjk9hDOK2xtPkM3voaM8dvWr1+fxx9/PGeeeebWirfdaMg4/+pXv8onP/nJVFS4E/7/RkPGeOHChVm1alVOPvnkDBo0KD/84Q+zYcOGrR11m9WQMf74xz+eV155Jbfeemt+85vfZNCgQVs55fbP+97W432vcTXl9z3lDRRM+/bts3r16vrHq1atSvv27TdZZ9WqVRut065du62WkWJoyLHSuXPn+mNj3333zYsvvmjSwSacU2go5xTe6e9//3v+/ve/Z9SoUZs857zC1uYzdONryBgnb/0PrDFjxuTTn/50unTpsjUjbhfeb5wXLlyYlStX5s9//nPGjx+fJPntb3+bGTNmbO2o26yGHMstW7ZMnz59kiSVlZWpra3NwoULt2rObVlDxvjaa6/Nsccem1GjRuWSSy7Jz372M1d1b2He97YO73uNq6m/7ylvoGD69u2bmpqarFu3Lslb933s379/VqxYUX95a//+/TN9+vQkSVVVVXr06JFWrVqVLDOl0ZBj5Y477sibb76Z5K0vmO7cuXPKy536iXMKDeacwrt59tln8/zzz+czn/lMlixZkunTpzuvUFI+Qze+hozx2rVr88tf/jIf//jH06tXrzz99NOljLxNer9x3mWXXXLBBRdk6NChGTp0aJK3rmDo3bt3CVNvWxpyLO+7775ZsGBBkqS2tjYbNmxIhw4dShV5m9OQMX7jjTey0047JUlat26dsrIy/yhoC/C+1/i8720d3vfeUlb3Xt8EBJTE5MmT8/TTT6ddu3bZYYcd8qlPfSpjx45NmzZtMnTo0Kxduza33XZbdtppp8ybNy+nnXZaKisrSx2bEni/Y+XBBx9MVVVVOnfunKqqqpx88sn197yl6XjxxRfz+OOP57nnnssJJ5yQU089NePGjXNOYRPvd6w4p5AkM2fOzKWXXlo/YVqzZk3+6Z/+KXPnznVeoaR8hm587zfGV1xxRebMmVP/P2TXrFmTH/3oRyVOve15v3FO3vqOkD/84Q/5r//6r3zyk5/M8ccfn44dO5Y2+Dbk/ca4trY2Y8eOzS677JL58+fn0EMPTf/+/Usde5vyfmM8bdq0PPDAA9ljjz2yYMGC9OrVKyeccEKpY29TzPMa3/uNsfe9LeP9xjlpuu97yhsAAAAAAIACcZ8LAAAAAACAAlHeAAAAAAAAFIjyBgAAAAAAoECUNwAAAAAAAAWivAEAAAAAACgQ5Q0AAAAAAECBKG8AAAAAAAAKRHkDAAAAAABQIMobAAAAAACAAlHeAAAAAAAAFIjyBgAAAAAAoECUNwAAAAAAAAWivAEAAAAAACgQ5Q0AAAAAAECBKG8AAAAAAAAKRHkDAAAAAABQIMobAAAAAACAAlHeAAAAAAAAFIjyBgAAAAAAoECUNwAAAAAAAAWivAEAAAAAACgQ5Q0AAAAAAECBKG8AAAAAAAAKRHkDAAAAAABQIMobAAAAAACAAlHeAAAAAAAAFIjyBgAAAAAAoECUNwAAAAAAAAWivAEAAAAAACgQ5Q0AAAAAAECBKG8AAAAAAAAKRHkDAAAAAPD/s3fnYVaVZ76wf1UUyDzJWMogEJzF4BA1TlG0jVEDRFFRhqgxUWMGc9Imns4X7RyT7o4no1OCA0baGOKAGscoKhocQtRgQERAKBWBQmYKZarvD0+qQxBBGfYquO/r8rrYa+291rP3+1q1n/rt9W6AAhHeAAAAAAAAFIjwBgAAAAAAoECENwAAAAAAAAUivAEAAAAAACgQ4Q0AAAAAAECBCG8AAAAAAAAKRHgDAAAAAABQIMIbAAAAAACAAhHeAAAAAAAAFIjwBgAAAAAAoECENwAAAAAAAAUivAEAAAAAACgQ4Q0AAAAAAECBCG8AAAAAAAAKRHgDAAAAAABQIMIbAAAAAACAAhHeAAAAAAAAFIjwBgAAAAAAoECENwAAAAAAAAUivAEAAAAAACgQ4Q0AAAAAAECBCG8AAAAAAAAKRHgDAAAAAABQIMIbAAAAAACAAhHeAAAAAAAAFIjwBgAAAAAAoECENwAAAAAAAAUivAEAAAAAACgQ4Q0AAAAAAECBCG8AAAAAAAAKRHgDAAAAAABQIMIbAAAAAACAAhHeAAAAAAAAFIjwBgAAAAAAoECENwAAAAAAAAUivAEAAAAAACgQ4Q0AAAAAAECBCG8AAAAAAAAKRHgDAAAAAABQIMIbAAAAAACAAhHeAAAAAAAAFIjwBgAAAAAAoECENwAAAAAAAAUivAEAAAAAACgQ4Q0AAAAAAECBCG8AAAAAAAAKRHgDAAAAAABQIMIbAAAAAACAAhHeAAAAAAAAFIjwBgAAAAAAoECENwAAAAAAAAUivAEAAAAAACgQ4Q0AAAAAAECBCG8AAAAAAAAKRHgDAAAAAABQIMIbAAAAAACAAhHeAAAAAAAAFIjwBgAAAAAAoECENwAAAAAAAAUivAEAAAAAACiQilIXQP0we/bsUpdAwVVWVponfChzhI0xR9gYc4QNqaysLHUJFJyfHfWLn/f1i/Gqf4xZ/WK86h9jVr8UYbw21M+48gYAAAAAAKBAhDcAAAAAAAAFIrwBAAAAAAAoEOENAAAAAABAgVSUugDqh7e/fV6pS6Dg3i51AQXQ+cc3lLoEAAA+wPbYz3jvCQCwfXPlDQAAAAAAQIEIbwAAAAAAAApEeAMAANuZm266KX/605+SJHPmzMnTTz9dt+8vf/lLrrvuulKVBgAA8KH0M+/znTcAALCd+eIXv5iysrIk/9PsHH744UmSAw44IH379i1leQAAABukn3mf8AYAAArk4Ycfzi9/+cucddZZWbFiRaZPn56vfvWrmT9/fh5++OHssssuqaqqyrnnnpt27drl5z//eVq3bp333nsv7dq1y6c//en88pe/TK9evXLWWWfloYceyrRp0zJy5Mgcc8wxue+++/Laa6/lZz/7WdasWZPrr78+LVu2zNKlS9OlS5ecfPLJuf3223PLLbfkggsuyOTJk7No0aJceeWVadCgQalfHgAAoMD0M1uOZdMAAKBA/uVf/iXNmzfPkUcemXPOOSfHHntsfvWrX+Xf//3fc9555+XMM8/MQQcdlOuuuy5Lly7N+PHjc+KJJ+b8889P796907Fjx7pPpTVs2DAnnHBCevXqleHDh6dr1675whe+UHeu+++/P6tXr86QIUNy4YUX5q677sqsWbNyxhlnpFWrVtl///3zne98J0kybdq0krweAABA/aGf2XKENwAAUECdO3dOkuyyyy55/fXXU1NTk9atW9dtmz59elq0aJGvfvWrueqqq/KNb3wj77333kc6x4wZM+rO8/dzvv7663W3u3TpkiRp3bp1VqxYsZnPCAAA2FHoZzaf8AYAAAro7bffTpK8+eab6datW5o1a5aFCxcmSd5666306tUry5YtS+vWrfOf//mf+frXv55rr712veOUl5entrY27733XqqqqtbZ17Nnz8yePXudc/bo0aPu9t/XmQYAAPgo9DObz3feAABAAf3lL3/Jgw8+mGnTpuXiiy/OggULMmLEiFRWVuaNN97IBRdckDVr1uSOO+7IxIkTs3jx4nzhC1/IvHnzMn78+CxbtiwzZ85M9+7dU11dnWuvvTaHHXZYXnzxxcydOzfPPfdcTjzxxFx33XUZOXJkli5dmoEDB6Zr16554oknsnz58jzwwAPp1atXZsyYkUceeST77LNPKiq0EAAAwIfTz2y+stra2tpSF0Hx/eWsE0tdAhRe5x/fUOoSCq2ysnKdT0PAPzNH2JgdaY6cccYZuf3220tdRr1RWVlZ6hIouO2xn9me33vuSD/vtwfGq/4xZvWL8ap/jFn96meKMF4b6mcsmwYAAAXyxz/+McuXL8+YMWNKXQoAAMBHop/ZcurPNUIAALADOO6443LccceVugwAAICPTD+z5bjyBgAAAAAAoECENwAAAAAAAAUivAEAAAAAACgQ4Q0AAAAAAECBVJS6AAAAKLq3v33eFj1e5x/fsEWPtz156aWX0rx58/Tq1avUpQAAwHZBP7PtbMl+xpU3AABAYbz00kuZNm1aqcsAAAD4yLZkP+PKGwAAKKAHH3wwI0aMyKBBgzJjxowsXrw4J5xwQv785z/nrbfeyg9/+MM8+uijmTlzZtq0aZO5c+fmkksuSU1NTX7wgx+kvLw8PXv2zOTJk3PsscfmpJNOyooVK3LFFVekT58+qaqqSr9+/XLAAQckSX7xi19kzZo1adeuXZ577rnsuuuuufjiizN9+vQ8+OCD6datW954442cf/75Wbp0af7zP/8znTt3TvPmzfPqq6/m1FNPzeTJkzNlypQMHjw4hx56aNasWZOrr746rVu3zvLly9OrV68cf/zxuf3223PLLbfkggsuyOTJk7No0aJceeWVmT17dt0n1ebMmZPBgwenUaNGJR4JAADgo6ov/UynTp3yl7/8pZD9jCtvAACggD772c+ma9eu+cQnPpHLLrssDRs2TE1NTf71X/81vXr1yoQJE9K+fftcfPHFGTp0aHbaaac8//zzadGiRQYPHpylS5fmS1/6Ur7//e/nrrvuSpKUlZXltNNOy5lnnpkLLrggI0aMSJI888wzeeutt/LNb34zQ4YMSVlZWU444YQ0bdo0P/jBD3LOOefkjDPOyL777ptRo0Zl1113zec+97kkyde+9rWceeaZufvuu3PRRRfla1/7Wu67774kyf33359Vq1Zl2LBhueCCCzJq1KgsXLgwZ5xxRlq1apX9998/3/nOd5Ik06ZNS5cuXbL//vvn8MMPz/DhwwU3AABQT9WXfubf/u3fCtvPuPIGAAAKbJdddkmSNG/evO7fLVq0yIoVK9K8efP86le/SqtWrTJr1qz07t277nG77rprkqR169apqalJktTW1uall17KpEmTUlFRkUWLFiVJZs6cWXfsJOncuXOSZPHixVmyZEn++Mc/JkmWLFmS8vL/+fxXZWVlXW1//3eLFi3qzjdjxowsWLAgt912W5Jkt912y4IFC9KmTZskSZcuXepqXLFixRZ5vQAAgOLQz3x8whsAAKinLr/88txwww3p2LFjli9fvs6+srKy9e5///33Z/78+bn00kuzevXq3HvvvUmS7t2758UXX6y739tvv50kadWqVVq3bp2TTz45LVq0yOLFizN58uRNrq9nz55p2LBhBg8enCR56qmn0qlTpw+tsby8PLW1tamurk7Dhg3TunXrTT4fAABQf+hnPpzwBgAACmjChAmZO3duHnrooRx22GGZMWNGHnnkkey8886ZOHFiZsyYkWOOOSY///nPs++++2by5Ml54403cvDBB+eRRx7JjBkz8uqrr+b111/P8uXL8+STT+bggw/OuHHjcv3116dFixZ124888sg899xzueqqq1JZWZmGDRsmeb8Z+d73vpdf/epX6dChQ+bNm5fTTjstCxYsyPjx47Ns2bK88cYbdeebOnVqxo8fn7lz52bChAk58cQT86tf/SojR47MqlWrstNOO+WII47IE088keXLl+eBBx5Ir1696p7bPvvsk/322y933HFHJkyYkK985SslHgUAAODjqC/9zOuvv17Yfqastra2dksMRpFMmzYto0aNyurVqzN06NB1LrfaHFdeeWW++tWvplWrVpt0/6eeeiozZ85M48aNs2TJkixfvjyDBg1aJ537Ry+88EJuvPHGfP/730+HDh22SM1byl/OOrHUJUDhdf7xDaUuodAqKysze/bsUpdBgZkjbIw5snX97W9/yz777JMkueSSS3LppZemY8eOJa5q0/x9iYPthX5my9se+5nt+b2nn/f1i/Gqf4xZ/WK86h9jVhoft58pwnhtqJ/ZLq+86dWrV/baa6+8++67W6zRSZLLLrvsAy+F+iBPPPFEZsyYkXPOOadu26hRo1JVVbXBZqdv3751l3oBAMC2NHLkyPTt2zc1NTU57LDD6k1wsz3SzwAAwEezPfYz22V482H+/gVDXbp0yZw5c3LcccelVatW+dnPfpYWLVrkwgsvzJ///OdMmzYtX/rSl/L73/8+M2bMyMknn5ybb745w4cPz957750bb7wxLVu2zMqVK9O2bdt89rOfXec89913X77xjW+ss23QoEFZu3ZtkuTRRx/N7Nmz06xZsyxZsiTDhg1b58uSkuT555/PSy+9lA4dOmT+/PkZOnRoZs6cmREjRmTPPffMmjVrMnPmzJxyyimZNGlSpk+fnnPOOSc9e/bM1KlT88ADD2S33XbLzJkzc9ZZZ6Vdu3YZNWpU/vSnP+WEE07I9OnT07hx41x44YVb9TUHAKD4rrrqqlKXwCbQz+hnAABY3/bYz+xw4c1vfvObHHjggTn88MMzb968XHXVVfmv//qvDBw4MH/605/SvHnzvP7663nxxRezdu3atGjRIsOGDUunTp3SvXv3JMmyZcsyYcKEXHnllWnbtm1effXV9c4zZ86c9b6MqFGjRkmSN998Mw899FDdhBoxYkTGjh2bfv361d132bJlueGGG3L11VenUaNGGT16dB599NGceOKJOeigg7J27dqcccYZuf/++/P888/n4osvzvPPP58nn3wyPXv2TOPGjTN48OB06NAhzz33XB588MEMGTIkZ599dh588MEcd9xx+fznP59LLrkkS5cuTYsWLT70ddueL8lnyyjCJYYAANs7/Yx+BgCAHcMOF95UVVWlVatWmT9/fmpra9OqVausXbs2++67b2688ca888472XnnndOzZ8/87W9/y5w5c9ZbFqB58+b54he/mOuvvz4rV67MwIED1zvPzjvvnEWLFn1gE/HGG2+kffv2dbc7deqUmTNnrnOfOXPmpKysLA888ECS95ufxo0br/OYJGnWrFndJWDNmjXLihUrkrzfWD300ENp0aJF5s2bl9WrV9c9tlWrVmnatGmSpGXLllmxYsVGmx0AAKD09DP6GQAAdgw7THhTVVWVxYsXp1u3btl3331z4IEHpra2Nm3btk15eXnKy8uzzz775Prrr8+5556bjh075r777kufPn3WO9by5cvTsmXLXHbZZXnjjTfy85//fL3Lsk4++eQ89thjGT58eN22X/3qVzniiCPStWvXzJs3r27722+/nR49eqzz+E6dOqVhw4Y5+eST06BBg8yZMycLFy7c5Od766235uCDD85RRx2Vv/71r3n66afr9m3qOtcAAEAx6Gf0MwAA7Fi2y/Bm+vTpeeWVV7J69erceeedSZJ58+Zlzz33zJAhQzJ69OhUVVVl0aJF2Xvvvesed9hhh+W3v/1tOnXqlLZt2+a6667Ll7/85STJlClTUlVVlXHjxqVz5865//7788orr2Tp0qU58cQT16vhuOOOy7hx4zJq1Kg0atQoS5YsSc+ePbPXXnslST772c9m5MiRadq0aSoqKnLMMcfkhRdeSHV1df74xz/mrLPOyrBhw3LzzTendevWeeedd3L66adn9uzZeeWVV1JVVZXevXtnwoQJWb58eWbPnp1x48alqqoq06ZNyxFHHJGHHnoo8+bNyzvvvJOqqqpMnz49M2fOTE1NTZ599tk0b9481dXVefzxx3P66advg5EBAAA2Rj+jnwEAgLLa2traUhdB8fkuEzbGd96wMeYIG2OOsDGlnCPDb3lmix5v5LBDt+jxNmTevHm5+uqr06NHj3WuoNgUTz/9dHr16rXekltFVFlZWeoSKDi/X+oX7wnqF+NV/xiz+sV41T9FHDP9zIYVYbw21M+Ub+M6AACAbaRDhw457LDDPtZjn3766cyZM2cLVwQAALBpdvR+ZrtcNg0AAOq7FStW5IorrkifPn1SVVWVfv36Zd68eRkxYkROO+20zJ49O1VVVfnhD3+YZs2a5Z577snMmTPTpk2bzJ07N5dcckkaNGhQd7xXX301/+f//J/ss88+ufTSS/PQQw/lD3/4Q7797W/nd7/7XTp37pyFCxemT58+6dChQ6ZNm5aHHnookydPzuDBg0v4SgAAAPWNfmbzufIGAAAKqKysLKeddlrOPPPMXHDBBRkxYkQ++9nPpmvXrunZs2e+9a1vZbfddsuECROSJO3bt8/FF1+coUOHZqeddsrzzz+/zvF23333nHnmmWnUqFGSpEGDBvnyl7+cVatWZdq0afn85z+fCy64IJ06dcqee+6ZXr165YQTTqi3jQ4AAFA6+pnN58obAAAooNra2rz00kuZNGlSKioqsmjRorp9Xbp0SZK0bt06K1asSJLstNNO+dWvfpVWrVpl1qxZ6d2793rH7NevX2699dYsW7YsL7/8co477rgkyec///lcfvnlqaioyHnnnbf1nxwAALBd089sPlfeAABAAd1///2ZP39+hg4dmkGDBq2zr6ysbL37X3755Rk4cGAGDx6cPfbY4wOP2ahRo/Tr1y9XXXVV9t577yTJ22+/nb322is/+clPMmDAgNxyyy1JkvLy8tTW1uatt96qa6gAAAA2hX5m8wlvAACggA4++OC89dZbuf766/O73/0uy5cvz9ixYzN37tw88MADmT17diZOnJjx48dn0aJFOeWUU/Lzn/88v/3tbzN58uSMHz8+8+bNy/jx4zNx4sTMnDkzyfufSps8eXI+85nPJElWrVqVW2+9Nb/97W/z3HPP5aSTTkqSHHDAAbn//vtz0003fWBzBQAAsCH6mc1XVltbW1vqIii+2bNnl7oECq6ystI84UOZI2yMOcLGmCObb9WqVVm0aFEeeuihDBkypNTlbDGVlZWlLoGC87OjfvHzvn4xXvWPMatfjFf9Y8y2nq3RzxRhvDbUz/jOGwAA2AG8++67ueyyy9K1a9d88YtfLHU5AAAAm2xH7GeENwAAsANo3LhxfvKTn5S6DAAAgI9sR+xnfOcNAAAAAABAgQhvAAAAAAAACkR4AwAAAAAAUCDCGwAAAAAAgAIR3gAAAAAAABSI8AYAAAAAAKBAhDcAAAAAAAAFIrwBAAAAAAAoEOENAAAAAABAgQhvAAAAAAAACkR4AwAAAAAAUCDCGwAAAAAAgAIR3gAAAAAAABSI8AYAAAAAAKBAhDcAAAAAAAAFIrwBAAAAAAAoEOENAAAAAABAgQhvAAAAAAAACkR4AwAAAAAAUCDCGwAAAAAAgAIR3gAAAAAAABSI8AYAAAAAAKBAhDcAAAAAAAAFIrwBAAAAAAAoEOENAAAAAABAgQhvAAAAAAAACqSi1AVQP7z97fNKXQJbUOcf31DqEgAAYJvRz9Qvb2+l4+qDAID6xJU3AAAAAAAABSK8AQAAAAAAKBDhDQAAAAAAQIEIbwAAAAAAAApEeAMAAAAAAFAgwhsAAAAAAIACEd4AAAAAAAAUiPAGAAAAAACgQCpKXQBsz95dW5v3aktdxfoaL1y4xY/ZqFGjLNwKx/27xo0bp0mTJlvt+AAAwP8oai+zObZGH1QU+iUA2P4Ib2ArGrd8TR5dvqbUZazva18rdQUf2YABAzJw4MBSlwEAADuEwvYym6Me9kGbSr8EANsfy6YBAAAAAAAUiPAGAAAAAACgQIQ3AAAAAAAABSK8AQAAAAAAKBDhDQAAAAAAQIEIbwAAAAAAAAqkotQFwPbsyGYN8qmmDUpdxno6fu+qLX/Mjh0zd+7cLX7cv2vcuPFWOzYAALCuovYym2Nr9EFFoV8CgO2P8Aa2osblZSniW+g2bdps8WO2a9cuK1eu3OLHBQAAtr2i9jKbY2v0QQAAW4tl0wAAAAAAAApEeAMAAAAAAFAgwhsAAAAAAIACEd4AAAAAAAAUyA4Z3kyePDmXX355LrzwwqxevXqdfaNGjcqXv/zlPPbYYx/pmC+88EIuuuiizJs3b4P3Wbx4ca655pp8+ctfzujRo3PrrbfmBz/4QebOnbvBx4wdOzYPPvjgBvcvX748TzzxxEeqFQAAqL/0MwAAsP3bIcObvfbaK3vttVdatWq1TlOzZMmSTJ8+PW3atMmxxx77kY7Zt2/ftG/f/kPv06pVqxx99NFp06ZNBg0alCFDhmSPPfbIQw89tMHHHHPMMTnhhBM2uF+zAwAAOxb9DAAAbP8qSl1AKZ166qm54YYbcswxx6Rhw4Z56KGHcvzxx+eee+6pu8/111+ftm3b5t13302bNm1y8sknZ+rUqRkxYkR69OiRZs2aZdy4cfn5z39e95jJkyfnxhtvzJFHHpnPf/7zH1rDkiVL0rZt2yTJT3/608ybNy/77rtvpkyZkv3226/uU2wXXXRRnnvuubz88stp3759pk+fnksuuSSPPvpoqqurM3r06Oy///7p0qVLbr311nTo0CHz589Pnz59su++++anP/1p3nvvvVxwwQWprq7Ovffem8suuyxPPPFEHn/88VxyySVp1arVVniVAQCArUE/o58BAGD7tUOHN126dEnv3r3z6KOP5tBDD015eXlatmy5zn0OOOCAHHTQQUmSb3/72+nXr1969+6dgw46KCtXrszZZ5+do446KjvttFOSpKamJs8991y+973vpXXr1h943kWLFmXMmDFZuHBhXn/99QwcODBJctZZZ+V73/teBg0alFWrVmXhwoVZuHBh3SfRnnzyyRx88ME5+uij8+qrryZJ+vXrl6lTp2bQoEFJkttuuy2dOnXKKaecklWrVuXiiy/OVVddlSFDhmTEiBHp2LFjHnvsscyePTtLly5N8+bNc+qpp2600en84xs+1msMAABsHfoZ/cz2qrKyMrNnzy51GQAAJbVDLpv2j0477bTce++9ue+++3L88cevt3/hwoW57bbbMmbMmKxYsSJLly6t27fLLrskSbp165aKivdzsHvvvTcTJ06su/1BWrdunf79++eLX/xihg4dmh/+8Id1+zp16pSKioo0adIklZWV6zxu2LBhmTJlSr7zne/kpZdeSm1t7XrHnjVrVjp27JgkadiwYZo1a5Y5c+Zk1113TU1NTaqrq5MkBx98cJ577rlMnjw5e++996a+XAAAQIHoZ/QzAABsn3b48GbXXXfNnnvumYqKivU+pTZz5szce++9GTx4cPr377/eJ8/KysrWO94ZZ5yRU045Jddee+0mnb9169ZZsGDBhx7z795444185Stfyf/5P/8nL7/8cl5//fWUl5fXNT0zZ85Mt27d6pYmWLVqVZYvX57OnTsnSQ499ND8+te/zr777ptPf/rTefLJJ1NRUZHy8h1+GgAAQL2kn9HPAACwfdohl02bPn16Xnnllbz77rsZPHhwvva1ryV5f73mcePGZeHChXnqqafyqU99Krvsskuuv/76VFZWZsGCBXn88cdzxBFH5JVXXklVVVW6dOmSnj17ZuLEiamurs7YsWNz2GGH5fbbb8+1116bM888M23atFnv+HfeeWeS5M0338z555+fJBk7dmzdMY455pisWLEi48aNS1VVVV599dVMnTo1r732Wnbaaad06dIlXbt2TVlZWRo1apRbbrklu+66awYMGJBbbrkld955Z+bPn59zzz03zZo1S5IcdthhefDBB7P33nunvLw8ixcvTt++fUswAgAAwMeln9HPAACw/Sur/aBr1eGfWG+YjbEuNRtjjrAx5ggbY46wIf+8PBf8Mz876hc/7+sX41X/GLP6xXjVP8asfinCeG2on3F9OQAAAAAAQIEIbwAAAAAAAApEeAMAAAAAAFAgwhsAAAAAAIACEd4AAAAAAAAUiPAGAAAAAACgQIQ3AAAAAAAABSK8AQAAAAAAKBDhDQAAAAAAQIEIbwAAAAAAAApEeAMAAAAAAFAgwhsAAAAAAIACEd4AAAAAAAAUiPAGAAAAAACgQIQ3AAAAAAAABSK8AQAAAAAAKBDhDQAAAAAAQIEIbwAAAAAAAApEeAMAAAAAAFAgwhsAAAAAAIACEd4AAAAAAAAUiPAGAAAAAACgQIQ3AAAAAAAABSK8AQAAAAAAKBDhDQAAAAAAQIEIbwAAAAAAAApEeAMAAAAAAFAgwhsAAAAAAIACEd4AAAAAAAAUiPAGAAAAAACgQIQ3AAAAAAAABSK8AQAAAAAAKBDhDQAAAAAAQIEIbwAAAAAAAApEeAMAAAAAAFAgwhsAAAAAAIACEd4AAAAAAAAUiPAGAAAAAACgQIQ3AAAAAAAABSK8AQAAAAAAKBDhDQAAAAAAQIEIbwAAAAAAAApEeAMAAAAAAFAgwhsAAAAAAIACEd4AAAAAAAAUiPAGAAAAAACgQIQ3AAAAAAAABSK8AQAAAAAAKBDhDQAAAAAAQIEIbwAAAAAAAApEeAMAAAAAAFAgwhsAAAAAAIACEd4AAAAAAAAUiPAGAAAAAACgQIQ3AAAAAAAABSK8AQAAAAAAKBDhDQAAAAAAQIEIbwAAAAAAAApEeAMAAAAAAFAgwpv/p6amJkOGDMmMGTOSJFOmTMmll16aSZMmfejjfve732XChAkf6VwrV67MnXfemdGjR+f3v/99RowYkV/+8pdZtmzZBh+zqfX83dixY/Pggw9+6H1GjRqVyy+//KOUDgAAFJB+BgAAti8VpS6gKJ5++ukcdNBBefTRR3P++ednjz32SNeuXTf6uEGDBqWsrOwjneuGG27IAQcckE996lN120aOHJlly5alefPmH/iYTa3n74455pjU1tZ+6H2OP/74TJs2bZOPCQAAFJN+BgAAti/Cm//n7bffzrBhw3LJJZdk6NChady48Tr7b7/99qxevToVFRVZtWpVhgwZkvnz5+emm25K9+7dM2jQoPz0pz9NdXV19t9//0yfPj09e/bMoEGD1jnO0qVL88ILL+TCCy9cZ/vw4cPr/n399denbdu2effdd9OmTZucfPLJdftefPHFTJ06Na+99lqOP/747L///vnpT3+aefPmZd99982UKVOy3377Ze7cuUmSiy66KDU1NRk5cmQ6d+6cd955JwceeGD233//j/T6DL/lmY90fzbNyGGHlroEAAC2A/qZD6efKQ39DgDAx2fZtCSvvfZa9txzz7Rq1Sp9+vTJ008/vd59evbsmbPPPjtnnHFGZs+enTfeeCPt2rXLwQcfXHefs846KwsXLsypp56aSy+9NI899th6x5k7d25atWpVd7u2tjZjxozJ1VdfnT//+c9JkgMOOCCDBg3K0KFDM27cuKxYsaLu/p07d86AAQNy/vnn55prrkltbW3OOuusLFiwIIMGDcp3v/vdHHbYYTn66KPrHjNmzJh06tQpAwYMyNChQ/PrX/86a9as2RIvHQAAUGL6GQAA2P648ibJ+PHjs9NOO2XmzJlp2LBh/vjHP6Zfv37r3Gf16tUZNWpUmjdvngULFmTJkiUfeKwOHTqkvPz9TKyiYv2Xt2PHjlm0aFHd7bKysvTv3z/XXHNN3nnnnSTJwoULc9ttt6Vp06ZZsWJFli5dmiZNmtQ9Pklat26d9957r66OTp06paKiIhUVFWnSpEkWLlxYd45Zs2alRYsWGTNmTJKka9euH7oeNQAAUH/oZwAAYPuzw4c3NTU1adasWU499dS6bRdffHHdF30myfLly3P11VfnlltuSUVFRWbNmrXB421svegWLVrkgAMOyPjx43PYYYfVbf/7J8dmzpyZe++9N1dffXWSrPfloXPnzs0+++yThQsXZqeddkrLli1TXV39oeft1q1bWrdunRNPPDFJMm7cuLRo0SLvvffeh9YKAAAUm34GAAC2Tzt0eLNq1aqMGDFinU+UvfXWW2nevHluvfXWzJw5M+Xl5enZs2cOPfTQXH311enRo0fefPPNjBs3Lh07dsyECROyfPnyvPnmm3n66adTXV2dl19+OStWrEhNTU3Gjh2bY445Zp3znnfeebn33ntz++23p7y8PIsXL06jRo3yyU9+Mm3atMkuu+yS66+/PpWVlVmwYEEef/zx9OnTJ1VVVWnYsGHeeeedTJ8+PRdeeGHKysoyduzYVFdX151rxYoVGTduXKqqqvLqq69mwIABGTVqVO68887U1NSkY8eOKS8vzyOPPJLq6uq8+OKL+eQnP7mtX34AAGAz6Gf0MwAAbL/Kamtra0tdBMV3/I/uLHUJ26Xt6Qs8KysrM3v27FKXQYGZI2yMOcLGmCNsSGVlZalLoOD0M6XxcfsdP+/rF+NV/xiz+sV41T/GrH4pwnhtqJ8p38Z1AAAAAAAA8CGENwAAAAAAAAUivAEAAAAAACgQ4Q0AAAAAAECBVJS6ANgUtatXJmtWlbqMLW7hwoWlLmGLadSo0cd6Po0bN06TJk22QkUAAPC+2veWl7qEHdLH7Xc+bm9BaXzQeOnzAGDzCW+oF2pnvZTa1yeUuowt7mtP3VLqEkpuwIABGThwYKnLAABgO7bW++6S0O/suPR5ALD5LJsGAAAAAABQIMIbAAAAAACAAhHeAAAAAAAAFIjwBgAAAAAAoECENwAAAAAAAAUivAEAAAAAACiQilIXAJuirNv+Kdt171KXscX97LQDSl3CFtOxY8fMnTv3Iz+ucePGW6EaAAD4H+VHDCt1CTukj9vvfNzegtL4oPHS5wHA5hPeUC+UVTRKKhqVuowtrk2bNqUuYYtp165dVq5cWeoyAABgPWU7NSt1CTukj9vv6C3qF+MFAFuHZdMAAAAAAAAKRHgDAAAAAABQIMIbAAAAAACAAhHeAAAAAAAAFIjwBgAAAAAAoECENwAAAAAAAAUivAEAAAAAACiQilIXQP0wctihpS4BAADgY9HPAABQ37jyBgAAAAAAoECENwAAAAAAAAUivAEAAAAAACgQ4Q0AAAAAAECBCG8AAAAAAAAKRHgDAAAAAABQIMIbAAAAAACAAhHeAAAAAAAAFIjwBgAAAAAAoECENwAAAAAAAAUivAEAAAAAACgQ4Q0AAAAAAECBVJS6AOqHt799XqlLoODeLnUBfKjOP76h1CUAAAAAAJvIlTcAAAAAAAAFIrwBAAAAAAAoEOENAAAAAABAgQhvAAAAAAAACkR4AwAAAAAAUCDCGwAAAAAAgAIR3gAAAAAAABSI8AYAAAAAAKBAKkpdAPXD4jW1pS4B2AyNFy4sdQlp1KhRFhagDorLHGFjzJFiaty4cZo0aVLqMgAAALYrwhs2yZXVK0tdArA5vva1UlcAwHZqwIABGThwYKnLAAAA2K5YNg0AAAAAAKBAhDcAAAAAAAAFIrwBAAAAAAAoEOENAAAAAABAgQhvAAAAAAAACkR4AwAAAAAAUCAVpS6A+uF/t29U6hKAzdDxe1eVuoR07Ngxc+fOLXUZFJg5wsaYI8XUuHHjUpcAAACw3RHesElaNSgrdQnAZmjTpk2pS0i7du2ycuXKUpdBgZkjbIw5AgAAwI7CsmkAAAAAAAAFIrwBAAAAAAAoEOENAAAAAABAgQhvAAAAAAAACkR4AwAAAAAAUCBbPbyZNm1aLr/88vzbv/1bRo8enRtuuCE33XRT1q5du8HHPP/885k3b96HHvfKK6/M4sWLN7j/qaeeyhe/+MWN1vf888/n2muvzejRo/PrX/86V199dZLkhRdeyEUXXbTROv7Z/fffv8Hbm1rTljRz5sxMmjQpSbJixYpcd911ueaaa7ZpDQAAUF/pZ/QzAABQCls9vOnVq1f22muv9O7dO4MGDcp5552XWbNm5aWXXtrgY/785z+nurr6Q4972WWXpVWrVhvcf8QRR6Rp06Ybre9Xv/pVhg8fnkGDBuX8889PRUVFkqRv375p3779Rh//zx544IEN3t7Umrakf2x2mjRpkiOPPHKbnh8AAOoz/Yx+BgAASqFiW59wzZo1Wbp0aVq2bJnrr78+bdu2zbvvvps2bdrk5JNPzrRp0zJz5sw88cQTee2117LXXntlxIgR6dGjR5o1a5Zx48blkksuyc0335zhw4dn7733zpQpU/LEE0+ksrIy06ZNyymnnJJevXrVnXP8+PG57777cuyxx6Zfv37r1NO6devcddddOfHEE9O2bdt85StfWWf/M888k7lz5+att97KpZdempUrV+bXv/51unfvnkGDBuW2227L1KlTc/nll2f8+PFZvnx5Ro8enV122SVlZWXr3P70pz+9zrEfeeSRzJ49Oy1atEhNTU3OPvvsPPHEE7nllltywQUX5FOf+lQuvvji/Pu//3uWL1+e6667LoMGDUqXLl0yevTodO7cOW+//XaOPvro7LHHHvnpT3+aefPmZd99982UKVNywAEH5NVXX01NTU1Gjx6d448/PkmyZMmS3HbbbXnttdfy6U9/er3XBAAA+GD6mf+hnwEAgK1nm4U3U6dOzejRo7Ns2bIMHDgwvXr1ysKFC3PQQQclSb797W+nX79+6dWrV7p3756jjz46e++9d5LkoIMOysqVK3P22WfnqKOOyi677JLu3bsnSWpra/Ozn/0s//Ef/5HWrVunqqoq7733Xt15FyxYkFdffTX/3//3/6VJkybr1fXd7343d999d7773e+mVatWOfnkk3PEEUfU7d9tt93y+c9/PjfeeGMmTpyYQw45JAcffHDd8gP9+vXL1KlTkySHHXZY/vu//zuDBg2qe/w/3/67N998Mw8++GB+8pOfpKysLNdcc00mTJiQz3zmM/njH/+Ybt26ZerUqWncuHGeeeaZnHDCCdl9993Tp0+f/OxnP8shhxySQw45JIsWLcp3vvOdXHfddTnrrLPyve99L4MGDcqqVauycOHCtGrVKvPmzaur4a233kpNTU0GDx6cJUuW5IorrtikZqfzj2/Y6H3YsVVWVmb27NmlLgMAYKvQz6yrvvUzAABQ32yz8Obvywz8o4ULF+a2225L06ZNs2LFiixduvQDG5Ik2WWXXZIk3bp1W2f70qVLs2LFirRu3TpJ0rVr13X233777XnzzTfTsGHDDzxuu3bt8qUvfSnnnXdeJk2alKuuuirdunWrO06nTp2SJC1atMi777770Z70h3jjjTdSVlaWe+65J0nSoEGDrFixIsn7TdMzzzyT9957L1/5ylcycuTI7Lrrrtlnn32SJFVVVTnllFOSvP9Ju5qamixdurSu3oqKilRUVKRJkyZ1jdg/6tixY5KkZcuWW/Q5AQDA9ko/sy79DAAAbF1b/TtvNmTmzJm59957M3jw4PTv37+uWUmS8vLy1NbWZs6cOXVvxsvKyj7wOC1atEjTpk3rvuxz1qxZefXVV+v2X3DBBdl///1z6623fuDj//3f/73u+Pvss0923nnnrF69+kNrb9y4cV1jMn/+/HX2/b32119//QNv/13Xrl3TqFGj9O/fP/3798/xxx9f9+m7Qw89NOPHj8/q1avTs2fPrFixImPHjs1+++2X5P2Gb+7cuUmSRYsWpVmzZmnRosUHvk7l5e8P8bJly+pq3dBrCQAAbBr9jH4GAAC2pq1+5c306dPzyiuvZPXq1Xn22WdzyCGHJHl/iaVddtkl119/fSorK7NgwYI8/vjjOf3007Pvvvtm7NixWbt2bQYMGJBXXnklVVVV6dKlS3r27JkpU6akqqoq48aNS8+ePfP1r389t912Wzp37pwFCxbkjDPOyDPPPJOampqMHTs2++yzT/7jP/4j5eXlOfPMM9OoUaO6+po3b54bbrghLVu2zMKFC3PooYemR48emThxYqqrq/P444/n6KOPrquhb9++2W+//TJ27NiMGTMmDRs2THV1dV588cV88pOfzCc/+cnceuutWbt2bXbbbbd1br/55pupqanJI488kuOPPz79+vXLLbfckiZNmmTp0qU566yzkiQ777xzGjdunL322ivJ+81PdXV13ZePDhkyJLfffnvefvvtzJkzJ1//+tdTVlaWsWPHprq6OmPHjs0xxxyT5P0vWH3qqafym9/8Jscdd1zGjRuXqqqqTJ8+PW+88UZqamrWGRcAAOB/6Gf0MwAAUApltbW1taUuguLzXSZsjO+8YWPMETbGHGFjzBE2pLKystQlUHB+dtQvft7XL8ar/jFm9Yvxqn+MWf1ShPHaUD9TsmXTAAAAAAAAWJ/wBgAAAAAAoECENwAAAAAAAAUivAEAAAAAACgQ4Q0AAAAAAECBCG8AAAAAAAAKZJPDm8mTJ2fmzJlbsRQAAICtQz8DAADUJ5sc3vzwhz/MW2+9tTVrAQAA2Cr0MwAAQH2yyeHN3nvvnU9/+tPrbZ80adIWLQgAAGBL088AAAD1ySaHN3379s1dd92VqqqqzJ8/v+6/3/72t1uzPgAAgM2mnwEAAOqTik2940033ZQk+d3vfrfVigEAANga9DMAAEB9ssnhzV577ZXvf//7622/8sort2hBAAAAW5p+BgAAqE82edm0//2///dH2g4AAFAU+hkAAKA+2eQrbyoqKvL0009n3Lhxqa2tzde//vXcfffdOf3009OoUaOtWSMAAMBm0c8AAAD1ySZfeXPHHXfk4YcfTp8+fbJs2bI0b948u+66a379619vzfoAAAA2m34GAACoTzY5vHn55ZdzxRVX5HOf+1waN26cJPnMZz6TBQsWbLXiAAAAtgT9DAAAUJ9scnizdu3alJeXr7ftvffe2+JFAQAAbEn6GQAAoD7Z5O+86d27d37wgx/kqKOOyvLly/Pss8/m6aefzt5777016wMAANhs+hkAAKA+2eQrbwYPHpy99947d955Z2bPnp3bb789PXv2zBlnnLE16wMAANhs+hkAAKA+2eQrbxYsWJCBAwdm4MCB62x//PHH85nPfGaLFwYAALCl6GcAAID6ZJOvvLn22mvX2zZ79uzccccdW7QgAACALU0/AwAA1CebHN5MmzYtTz75ZJKktrY299xzT7773e9mxYoVW604AACALUE/AwAA1CebvGzagAEDsmDBgtx5552ZMGFCkuQHP/hBpkyZstWKAwAA2BL0MwAAQH2yyVfeDBw4MAMGDEiDBg3SvHnzXHnllenatWtWrVq1NesDAADYbPoZAACgPvnQK28+aF3oJJk1a1Z+8YtfpFGjRvnrX/+az33uc1ulOAAAgI9LPwMAANRXHxreTJo0KUcfffR624877rj/OUDFJq+8BgAAsM3oZwAAgPrqQzuVAQMGpF+/fh96gM6dO2/RggAAALYE/QwAAFBffeh33mys0UmSv/71r1usGAAAgC1FPwMAANRXm7xGwKJFizJq1Ki8/vrree+999bZftFFF22V4gAAALYE/QwAAFCfbHJ486tf/Sqf+tSnUlVVlQsvvDCrV6/OSy+9tE7jAwAAUET6GQAAoD750GXT/tHKlStz9NFHp0mTJtlrr72y3377ZejQoVm0aNFWLA8AAGDz6WcAAID65COFN0lSXl6eGTNmJEnmzJmTWbNmbZ3KAAAAthD9DAAAUJ9s8rJp+++/fx566KGceOKJ+bd/+7c0bdo0y5cvz4ABA7ZmfQAAAJtNPwMAANQnmxzefOELX6j7909+8pO8/vrr6dSpU3bbbbetUhgAAMCWop8BAADqk00Ob/7utddey9KlS3PwwQenpqZma9QEAACwVehnAACA+mCTv/Nm9uzZ+cY3vpErr7wyt9xyS1auXJkrr7wyL7744tasDwAAYLPpZwAAgPpkk8ObG2+8MUOHDs3IkSPTtm3bNGnSJJdffnnuueeerVkfAADAZtPPAAAA9ckmhzdr1qxJ375919nWuHHjlJWVbfGiAAAAtiT9DAAAUJ9scnhTW1ubyZMnr7Nt+vTpW7wgAACALU0/AwAA1CcVm3rHYcOG5Yc//GGaNGmSpUuX5lvf+laWLVuW73znO1uzPgAAgM2mnwEAAOqTTQ5vevTokV/84hd54YUX8s4772TnnXfOAQcckCZNmmzN+gAAADabfgYAAKhPNjm8SZKmTZtmzz33zMKFC9OmTRuNDgAAUG/oZwAAgPpik8Ob6urq/OIXv8jUqVPrtvXu3TsXX3xxOnTosFWKAwAA2BL0MwAAQH2yyeHN1Vdfnb59++Yb3/hGWrRokSVLluTJJ5/MNddckyuuuGJr1ggAALBZ9DMAAEB9Ur6pd1yzZk0GDBiQnXfeOY0aNUq7du3yhS98IWvWrNma9QEAAGw2/QwAAFCfbHJ406FDhyxevHidbYsWLUplZWXd7bvvvnvLVQYAALCF6GcAAID6ZJOXTVu5cmW+8Y1vZK+99kqzZs2ybNmyTJ06Nfvss0+uvfbaJMlf//rXDBgwYKsVCwAA8HHoZwAAgPpkk8Ob119/PSeeeGLd7fbt22e33XZb5z4NGzbccpUBAABsIfoZAACgPtnk8OZzn/tcDj744Oy8886pra3NuHHjsnbt2hx11FFp0KBBkqRNmzZbrVAAAICPSz8DAADUJ5v8nTdVVVUZOXJk1qxZkzFjxuTuu+/OU089lRtvvLHuPv369dsqRQIAAGwO/QwAAFCfbPKVN3Pnzs33v//91NbW5tFHH83ll1+eDh065LLLLtua9QEAAGw2/QwAAFCfbPKVN2vXrk2SvPzyy+ncuXM6dOiQJGnSpMnWqQwAAGAL0c8AAAD1ySZfedOlS5f86Ec/SlVVVb785S9n5cqVefTRR32pJwAAUHj6GQAAoD7Z5PDm3HPPzUsvvZRmzZqld+/eqampSdOmTTN06NCtWR8AAMBm088AAAD1ySaHN2VlZfnkJz9Zd7tp06Y5+uijt0ZNAAAAW5R+BgAAqE82+TtvAAAAAAAA2PqENwAAAAAAAAUivAEAAAAAACgQ4c0/qampyZAhQzJjxoxtfu7Vq1dn5MiROfvsszN69Ojcdttt+fd///dMmzZts4778MMP56KLLtpCVQIAAEWlnwEAgO2D8OafPP300znooIPy6KOPbvNzV1RU5MQTT8xOO+2UQYMGZfDgwTnyyCMzZsyYzTruv/zLv2yZAgEAgELTzwAAwPahotQFFM3bb7+dYcOG5ZJLLsnQoUNTVVWVESNGZPfdd09FRUVee+21nHPOOenZs2eee+65vPzyy2nfvn2mT5+eSy65JCtWrMitt96aDh06ZP78+enTp08OOuigjBo1Kn/6059ywgknZPr06WncuHEuvPDCjdazZMmStGzZMknqjnHsscdm2rRp6dSpU0455ZSMHj06nTt3zttvv52jjz46e+yxR+bNm5ebb745u+22W9q2bVt3vHfffTc//elPs+eee2b27Nk5/PDDs99++2211xMAANh29DMAALB9EN78g9deey177rlnWrVqlT59+uTpp59Ov379ctBBB2X16tUZPHhwnnnmmTz55JPp2bNnnnzyyRx88ME5+uij8+qrryZJ7r777romZNWqVbn44ouz55575uyzz86DDz6Y4447Lp///OdzySWXZOnSpWnRosV6daxcuTJjxozJ8uXL8/LLL9ctEfD3Y5xwwglp2rRpqqqq8pvf/CaHHHJIDjnkkCxatCjf+c53ct1112XUqFE54ogjcthhh2XOnDm5++67kyRlZWX53Oc+l/322y/Lli3LlVdeuUnNzvBbntmCr/TGjRx26DY9HwAA1Hf6mQ3b1v0MOw69KwCwtVg27R+MHz8+M2bMyOjRo9OwYcP88Y9/rNvXuXPnJEnLli2zYsWKJMmwYcMyZcqUfOc738lLL72U2trazJo1Kx07dkySNGzYMM2aNcucOXOSJK1atUrTpk3XO84/a9SoUfr375+zzjor//qv/5of/OAHWbVqVd0xmjdvnvLy8nTv3j1VVVXp0KFDkqR169apqanJ0qVL88Ybb6RTp05JUrc/SWprazN58uTccccdefTRR7NkyZIt9voBAAClo58BAIDthytv/p+ampo0a9Ysp556at22iy++uO6LPsvKytZ7zBtvvJGvfOUrWb16dS6//PIcdNBB6datW+bOnZskWbVqVZYvX17XKH3QMTamRYsWqampyerVq9OwYcP1jvH38/Xo0SOLFi1Ks2bN0qJFi+y66655++2306NHj8ybN6/u/mPHjs2CBQty4YUXZvXq1es0dAAAQP2knwEAgO2L8CbvNyUjRoxIRcX/vBxvvfVWmjdvnltvvTVJUlVVlT59+mTcuHGpqqrK9OnTM3Xq1Lz22mvZaaed0qVLl3Tt2jWdO3fOLbfckjvvvDPz58/Pueeem2bNmuWxxx5LTU1Nnn322TRv3jzV1dV5/PHHc/rpp9edc/Xq1XnooYeycuXK3HnnnSkrK8vbb7+doUOHpkmTJnXH+MMf/pCTTjopSTJkyJDcfvvtefvttzNnzpx8/etfT1lZWc4666zcfPPNmTVrVpo2bZqampo89dRT6dOnT5599tnceuutad68eV1NhxxyyLZ90QEAgC1CP6OfAQBg+1NWW1tbW+oiKL7jf3TnNj2fdYPrn8rKysyePbvUZVBg5ggbY46wMeYIG1JZWVnqEii4bd3PsOPQu/r9XB8Zs/rFeNU/xqx+KcJ4baif8Z03AAAAAAAABSK8AQAAAAAAKBDhDQAAAAAAQIEIbwAAAAAAAApEeAMAAAAAAFAgwhsAAAAAAIACEd4AAAAAAAAUiPAGAAAAAACgQIQ3AAAAAAAABSK8AQAAAAAAKBDhDQAAAAAAQIEIbwAAAAAAAApEeAMAAAAAAFAgwhsAAAAAAIACEd4AAAAAAAAUiPAGAAAAAACgQIQ3AAAAAAAABSK8AQAAAAAAKBDhDQAAAAAAQIEIbwAAAAAAAApEeAMAAAAAAFAgFaUugPph5LBDS10CAADAx6KfqV8qKysze/bsUpcBAFBSrrwBAAAAAAAoEOENAAAAAABAgQhvAAAAAAAACkR4AwAAAAAAUCDCGwAAAAAAgAIR3gAAAAAAABSI8AYAAAAAAKBAhDcAAAAAAAAFIrwBAAAAAAAoEOENAAAAAABAgQhvAAAAAAAACkR4AwAAAAAAUCDCGwAAAAAAgAIR3gAAAAAAABSI8AYAAAAAAKBAhDcAAAAAAAAFIrwBAAAAAAAoEOENAAAAAABAgQhvAAAAAAAACkR4AwAAAAAAUCDCGwAAAAAAgAIR3gAAAAAAABSI8AYAAAAAAKBAhDcAAAAAAAAFIrwBAAAAAAAoEOENAAAAAABAgQhvAAAAAAAACkR4AwAAAAAAUCDCGwAAAAAAgAIR3gAAAAAAABSI8AYAAAAAAKBAhDcAAAAAAAAFIrwBAAAAAAAoEOENAAAAAABAgQhvAAAAAAAACkR4AwAAAAAAUCAVpS6g1BYuXJj77rsvTZs2zdq1azN79ux06NAhgwcP3mLnmDRpUpo1a5bu3bt/4PlvvfXWdOzYMWvXrs2MGTMyZMiQdO3adYudHwAA2D7pZwAAYPu0Q4c3q1atyn/913/lW9/6Vtq1a5ckWb16dX7+859v0fNMmjQpHTp0+MBm57777kuvXr1y4oknJkmeeOKJ1NTUbNHzAwAA2x/9DAAAbL926PDmL3/5S9q3b1/X6CRJRUVFvvWtbyVJHn/88dx22205/vjj884772TWrFn5xje+kVtuuSW77757qqqqcvLJJ6d79+6599578/vf/z5DhgzJa6+9liVLluTSSy/NnDlzMnny5MycOTPz5s1L//7906hRo7rztW7dOk899VR69eqVT3ziEzn66KOTJLNmzcrNN9+c1q1bp2vXrnn99ddz4IEH5qijjsqKFSty6623pkOHDpk/f3769OmTgw46KKNGjcqf/vSnHHvssZk2bVo6deqUhQsXZt68edl3330zZcqUfOpTn8p+++2Xe+65J127ds1bb72VgQMHpmPHjtv0tQcAADaPfkY/AwDA9muHDm/mzZuX1q1b192urq7On/70p0yZMiXnnHNOPvOZz+TJJ59Mz549c9ppp2X69OmpqKjIqaeemh49emTGjBm56667cskll+SUU07Jww8/nH322SfHH398fvSjH2XmzJnp0aNH9tprr3To0KGukflHJ510Uho2bJgbb7wxCxYsyGGHHZYzzjgj3bp1y1577ZW1a9dm4MCBWbVqVS666KL07ds39913Xzp16pRTTjklq1atysUXX5w999wzZ599dh588MGccMIJadq0aaqqqtK0adN873vfy6BBg7Jq1aosXLgw11xzTYYOHZrdd989kyZNym9+85t8+9vf/tDXavgtz2zhVx+2TyOHHVrqEgCAHYR+Rj8DRfDId79Q6hIAYLtUXuoCSqljx45ZuHBh3e327dunf//+eeONN/Luu+/Wbd91112TJD179kyDBg0yfvz43HXXXRk/fnyWLFmyzjE7d+6cJGnZsmVWrFix0RrKy8vz2c9+Nv/5n/+Z//iP/8js2bPz+9//vm5/hw4dkiQNGzZMixYtMnfu3MyaNavuk2UNGzZMs2bNMmfOnCRJq1at0rx585SXl9cta9CpU6dUVFSkSZMmqaysTFVVVf76179mzJgxmTRpUho3bvxRXzoAAKDE9DP6GQAAtl87dHjTt2/fVFdXZ968eetsX7t27QYfM2bMmDRu3DgDBw7MMcccs97+srKy9baVl5entrY2CxYsWK85uuaaazJ//vwkyc4775z99tsvq1evrtv/99pWrlyZJUuWpGPHjunWrVvmzp2b5P11rpcvX17XZH3Q+f95W7du3fKpT30q/fv3z4ABA9K3b98NPl8AAKCY9DP6GQAAtl879LJpDRs2zKWXXpp77rknzZo1y9q1azNnzpwcddRR6dChQyZOnJjq6uo89NBD6d+/f1q2bJlDDjkkt912W1atWpXVq1enuro6L7/8cpYtW5aampqMHTs23bt3T1VVVcaNG5fdd989e+21V/7whz9k4sSJGTJkyDo17Lnnnhk5cmS6du2aVatWpbq6OsOHD6/bv3jx4tx1112ZNm1aBg8enBYtWmTAgAG55ZZbcuedd2b+/Pk599xz06xZszz22GOpqanJH/7wh5x00klJkrFjx6a6ujpjx46ta86+8pWv5A9/+EPdGtNHHnnkNnvNAQCALUM/o58BAGD7VVZbW1tb6iL4YKNHj97g2tLb2vE/urPUJUC94DtvNqyysjKzZ88udRkUmDnCxpgjbEhlZWWpS+AD6Gdgx/DId7/g93M94z1V/WK86h9jVr8UYbw21M/s0MumFVlVVVVeeeWVTJgwoW4ZAgAAgPpAPwMAAJtnh142rci6du2a73//+6UuAwAA4CPTzwAAwOZx5Q0AAAAAAECBCG8AAAAAAAAKxLJpwHpqV69M1qwqdRn10sKFC0tdQmE1atTI67OZGjdunCZNmpS6DACod2rfW17qEmC7NX/+fO/z6xm9Wf1ivOofY1a/tG7dutQlbJDwBlhP7ayXUvv6hFKXUS997albSl0C27EBAwZk4MCBpS4DAOqdtd6jwVZzuv+/AKjHhg4dmuOOO67UZXwgy6YBAAAAAAAUiPAGAAAAAACgQIQ3AAAAAAAABSK8AQAAAAAAKBDhDQAAAAAAQIEIbwAAAAAAAAqkotQFAMVT1m3/lO26d6nLqJd+dtoBpS6hsDp27Ji5c+eWuox6rXHjxqUuAQDqpfIjhpW6BNhu/farJ3qfX8/ozeoX41X/GLP6ZbfddsuiRYtKXcYHEt4A6ymraJRUNCp1GfVSmzZtSl1CYbVr1y4rV64sdRkAwA6obKdmpS4Btlve59c/xqx+MV71jzGrX5o2bVrY8MayaQAAAAAAAAUivAEAAAAAACgQ4Q0AAAAAAECBCG8AAAAAAAAKRHgDAAAAAABQIMIbAAAAAACAAhHeAAAAAAAAFIjwBgAAAAAAoEAqSl0A9cPIYYeWugQKrrKyMrNnzy51GQAAsB79TP2itwAAcOUNAAAAAABAoQhvAAAAAAAACkR4AwAAAAAAUCDCGwAAAAAAgAIR3gAAAAAAABSI8AYAAAAAAKBAhDcAAAAAAAAFIrwBAAAAAAAoEOENAAAAAABAgQhvAAAAAAAACkR4AwAAAAAAUCDCGwAAAAAAgAIR3gAAAAAAABSI8AYAAAAAAKBAhDcAAAAAAAAFIrwBAAAAAAAoEOENAAAAAABAgQhvAAAAAAAACkR4AwAAAAAAUCDCGwAAAAAAgAIR3gAAAAAAABSI8AYAAAAAAKBAhDcAAAAAAAAFIrwBAAAAAAAoEOENAAAAAABAgQhvAAAAAAAACkR4AwAAAAAAUCDCGwAAAAAAgAIR3gAAAAAAABSI8AYAAAAAAKBAhDcAAAAAAAAFIrwBAAAAAAAoEOENAAAAAABAgQhvAAAAAAAACkR4AwAAAAAAUCDCGwAAAAAAgALZocObv/3tb/mv//qvfPOb38yECRM2eL8nnngiy5cvr7t95ZVXZvHixZt8nhdeeCEXXXRR5s2bt1n1rly5MnfeeWdGjx6d3//+9xkxYkR++ctfZtmyZR/5WFOmTMmll16aSZMmbVZNAABAaehn9DMAAGy/KkpdQCnts88+mT9/fv7yl7/kwAMP3OD9nnjiiey1115p1qxZkuSyyy5LWVnZJp+nb9++uffeeze73htuuCEHHHBAPvWpT9VtGzlyZJYtW5bmzZt/pGPtscce6dq162bXBAAAlIZ+Rj8DAMD2a4cOb/7Zj3/84/Ts2TMLFizI7rvvniOOOCJ//etfU11dnQceeCCVlZXZddddc/PNN2f48OFp27Ztrr322rRv3z5t2rTJ1KlTM2DAgPTt2zerVq3Kddddl9atW6dNmzZZsWJF3Xmef/75vPTSS+nQoUPmz5+foUOHZubMmRkxYkR69OiRZs2aZdy4cfn5z39e12AtXbo0L7zwQi688MJ1ah4+fHjdv//85z9n4sSJ2XnnnTN37twMHTo0TZo0+cDzNWrU6CO9NsNveebjv7Afw8hhh27T8wEAQH2nnwEAgO2H8OYfHH300TnooIOydu3afPOb38wRRxyRPn36pH379jnxxBPToUOHJEn37t2TJJ07d86xxx6bl156KUOGDMm0adNyxx13pG/fvnnsscfSpEmTDB06NGvXrs0DDzyQJFm2bFluuOGGXH311WnUqFFGjx6dRx99NCeeeGIOOuigrFy5MmeffXaOOuqo7LTTTnW1zZ07N61ataq7XVtbm3vuuSdvvvlmPvWpT2XPPffMjTfemKuvvjoVFRUZM2ZM7r777pxyyikbPB8AALD90M8AAMD2Q3jz/6xZsyZvvvlmXn/99TRq1ChLlizZ5MdWVlYmSVq2bJl33303SfLmm2+mc+fOSZLy8vK6RmnOnDkpKytbp/lp3Lhx3bF22WWXJEm3bt3WOUfHjh2zaNGiuttlZWXp379/rrnmmrzzzjuZM2dOmjdvnoqK94e0U6dOefzxxzd6PgAAoP7TzwAAwPZFePP/vPDCC5k4cWK+//3vJ0kefPDBun3l5eVJkqqqquy6666bdLxdd901VVVVSZK1a9fWfblnp06d0rBhw5x88slp0KBB5syZk4ULF9Y9bkNrT7do0SIHHHBAxo8fn8MOO6xu+5o1a+qOu2zZsqxevToVFRWZM2dOunfvvtHzAQAA9Z9+BgAAti/Cm7zfYPTu3Tv3339/brrpprRt2zbvvfdexo4dm2OOOSb7779/xowZk5UrV6Zfv36pqqrKuHHj0qFDh0yYMCHLly/PnDlzMm7cuFRXV+fll1/OMccck+uuuy433XRTmjdvnsaNG+eRRx7J2WefnWHDhuXmm29O69at88477+T000/P7Nmz88orr6SqqipdunRJz54916vzvPPOy7333pvbb7895eXlWbx4cRo1apRPfvKTad68ec4999zcdNNN2XnnnVNdXZ1hw4alSZMmH3i+KVOm1D2Pnj17+vQaAADUU/oZ/QwAANufstra2tpSF1EKEydOzH777Zf7778/c+fOzTnnnFPqkgrt+B/duU3PN3LYodv0fGy+ysrKzJ49u9RlUGDmCBtjjrAx5ggb8vdlv3Yk+pmPxs+O+sXP+/rFeNU/xqx+MV71jzGrX4owXhvqZ3bYK28efvjh/O1vf8ubb76Zs846q9TlAAAAbDL9DAAAbN922PDm29/+dqlLAAAA+Fj0MwAAsH0rL3UBAAAAAAAA/A/hDQAAAAAAQIHssMum8dHUvrd8m55v4cKF2/R8pdK4ceM0adKk1GUAAAAAAFAgwhs2ydqnbtmm5/vaNj5fqQwYMCADBw4sdRkAAAAAABSIZdMAAAAAAAAKRHgDAAAAAABQIMIbAAAAAACAAhHeAAAAAAAAFIjwBgAAAAAAoECENwAAAAAAAAVSUeoCqB/Kjxi2Tc/3s9MO2KbnK5XGjRuXugQAAAAAAApGeMMmKdup2TY9X5s2bbbp+QAAAAAAoCgsmwYAAAAAAFAgwhsAAAAAAIACEd4AAAAAAAAUiPAGAAAAAACgQIQ3AAAAAAAABSK8AQAAAAAAKBDhDQAAAAAAQIFUlLoA6oeRww4tdQkAAAAAALBDcOUNAAAAAABAgQhvAAAAAAAACkR4AwAAAAAAUCDCGwAAAAAAgAIR3gAAAAAAABSI8AYAAAAAAKBAhDcAAAAAAAAFIrwBAAAAAAAoEOENAAAAAABAgQhvAAAAAAAACkR4AwAAAAAAUCDCGwAAAAAAgAIR3gAAAAAAABSI8AYAAAAAAKBAhDcAAAAAAAAFIrwBAAAAAAAoEOENAAAAAABAgQhvAAAAAAAACkR4AwAAAAAAUCDCGwAAAAAAgAIR3gAAAAAAABSI8AYAAAAAAKBAhDcAAAAAAAAFIrwBAAAAAAAoEOENAAAAAABAgQhvAAAAAAAACkR4AwAAAAAAUCDCGwAAAAAAgAIR3gAAAAAAABSI8AYAAAAAAKBAhDcAAAAAAAAFIrwBAAAAAAAoEOENAAAAAABAgQhvAAAAAAAACkR4AwAAAAAAUCDCGwAAAAAAgAKpKHUB29q0adMyatSorF69OkOGDMnuu++eZ599Nrfeemt69+6ds846K+3atdsi57ryyivz1a9+Na1atVpn+8KFC3PrrbemY8eOWbt2bWbMmJEhQ4aka9euW+S8AADA9kk/AwAAO4YdLrzp1atX9tprr7z77rvZfffdkySHHHJIHnrooRx++OFbrNFJkssuuyxlZWXrbb/vvvvSq1evnHjiiUmSJ554IjU1NVvsvAAAwPZJPwMAADuGHS682RQ1NTUZOXJkOnfunHfeeScHHnhg9t9//4waNSp/+tOfcsIJJ2T69Olp3LhxLrzwwkydOjUjRoxIjx490qxZs4wbNy6XXHJJbr755gwfPjx77733Osdv3bp1nnrqqfTq1Suf+MQncvTRRydJZs2alZtvvjmtW7dO165d8/rrr+fAAw/MUUcd9ZFrSpI///nP+etf/5r27dtn6tSpGTZsWHbeeeeMHDkyrVq1Sk1NTbp3754jjzxyW7/EAADAVqKfAQCA+m+HDW8mTZqUkSNH1t2eM2dO3b/HjBmTTp06ZcCAAVm5cmW+8Y1v5Je//GXOPvvsPPjggznuuOPy+c9/PpdcckmWLl2a3r1756CDDsrKlStz9tln56ijjsouu+yS7t27f+C5TzrppDRs2DA33nhjFixYkMMOOyxnnHFGunXrlr322itr167NwIEDs2rVqlx00UXp27dv7rvvvo9UU1lZWW688cb88pe/TMOGDTNp0qSsXbs2Y8eOzerVq3PqqaemtrY23/zmN9OnT5/1lkIAAACKSz+jnwEAYPu2w4Y3e++9d4YOHVp3e+bMmXX/njVrVlq0aJExY8YkSbp27Zply5alVatWadWqVZo2bZokadmyZVasWJEWLVokSXbZZZckSbdu3T703OXl5fnsZz+bz372s3nnnXdy/fXX5/e//31dPR06dEiSNGzYMC1atMjcuXM/ck1LlixJ8+bN07Bhw7rnmyR/+MMfsnDhwrrjdOnSJYsWLdLsAABAPaKfef84+hkAALZXO2x482G6deuW1q1b163hPG7cuLqG5oPWfP67D9v3j6655pqcfvrpadeuXXbeeefst99+qa6urts/b968JMnKlSuzZMmSdOzY8SPX1KlTpyxbtiyrV69ORUVFJk2alNatW6d79+5p2LBh+vfvnyR5/vnn0759+02qGwAAKD79DAAA1H87XHgzffr0vPLKK1m9enWmTp2a3r175/nnn091dXXGjx+fbt26ZcCAARk1alTuvPPO1NTUpGPHjikvL89jjz2WmpqaPPvss2nevHmqq6vz+OOP54gjjsgrr7ySqqqqdOnSJT179syUKVNSVVWVcePGpWfPnmncuHFdDXvuuWdGjhyZrl27ZtWqVamurs7w4cPr9i9evDh33XVXpk2blsGDB6dFixYfuabTTz895557bm666aa0b98+y5Yty5lnnpnOnTtn1KhRGT16dFavXp1GjRrl4IMPLsFIAAAAH5V+Rj8DAMCOoay2tra21EXwP0aPHp0OHTrUfelnUcyePbvUJVBwlZWV5gkfyhxhY8wRNsYcYUMqKytLXQL/j36GLcHP+/rFeNU/xqx+MV71jzGrX4owXhvqZ8q3cR18iKqqqrzyyiuZMGFC5s+fX+pyAAAANpl+BgAAtpwdbtm0IuvatWu+//3vl7oMAACAj0w/AwAAW44rbwAAAAAAAApEeAMAAAAAAFAgwhsAAAAAAIACEd4AAAAAAAAUiPAGAAAAAACgQIQ3AAAAAAAABSK8AQAAAAAAKBDhDQAAAAAAQIEIbwAAAAAAAApEeAMAAAAAAFAgwhsAAAAAAIACEd4AAAAAAAAUiPAGAAAAAACgQIQ3AAAAAAAABSK8AQAAAAAAKBDhDQAAAAAAQIEIbwAAAAAAAApEeAMAAAAAAFAgwhsAAAAAAIACEd4AAAAAAAAUiPAGAAAAAACgQIQ3AAAAAAAABSK8AQAAAAAAKBDhDQAAAAAAQIEIbwAAAAAAAApEeAMAAAAAAFAgZbW1tbWlLgIAAAAAAID3ufIGAAAAAACgQIQ3AAAAAAAABSK8AQAAAAAAKBDhDQAAAAAAQIEIbwAAAAAAAApEeAMAAAAAAFAgwhsAAAAAAIACqSh1ARTHxIkT8/zzz6dly5YpKyvLaaedts7+lStX5tZbb03btm3z9ttvp3///qmsrCxRtZTCxuZIkowfPz6//e1vM3z48BxwwAElqJJS2tgcGTNmTBYtWpTWrVtnxowZOf3007PLLruUqFpKZWPzZPz48fnzn/+c7t27Z/r06TnyyCNz4IEHlqhaSmFTft8kyVNPPZVf/vKX+c1vfpPGjRtv4yqBIticHmbcuHGZOXNmysvL07Fjxxx33HGleAo7lI87XtOmTcsDDzyQ7t27Z/bs2enVq1f69etXomexY9ncvxMsXrw4//qv/5oBAwbkhBNO2Nbl73A2Z7ymTp2aiRMnpry8PJMmTcoFF1yQdu3aleJp7FA2Z8xuueWWNGjQILW1tXnvvfdyzjnnpLzc5/S3ps35u5j3HaXxccesKO89/B9NkuS9997LiBEjMmzYsAwaNCizZs3Kyy+/vM59HnjggbRr1y4DBgzISSedlOuvv75E1VIKmzJH5s2bl5YtW2bnnXcuUZWU0qbMkXfffTfDhg1L//79c8ghh+TWW28tUbWUyqbMk5UrV+ass87K5z//+QwYMCC/+c1vSlQtpbApcyRJ3nzzzbz55pslqBAois3pYd55553cd999GTJkSM4+++yMHTs2b7/9dimexg5jc8Zr0aJFOfHEE3PKKafkvPPOy3//939nyZIlpXgaO5TN/TvB2rVr89vf/jY9e/bc1qXvkDZnvGpqanLvvffm1FNPzcCBA3P++eenefPmpXgaO5TNGbPXXnstf/vb33L22WdnyJAhefXVVzN16tRSPI0dxub8Xcz7jtLYnDErynsP4Q1J3v+ERfv27dOwYcMkyR577JEXXnhhnfu88MIL6d27d5Kka9eumTVrVmpqarZ5rZTGpsyRDh06ZJ999ilFeRTApsyRM844I2VlZUneb+Z8Un7Hsynz5Oijj677lN+cOXOy6667bvM6KZ1NmSPvvfde7r333g1ekQPsGDanh/nrX/+aHj161L0v+cQnPpEXX3xx2z6BHczmjNeBBx6YXr161d2vvLw8FRUWEtnaNvfvBPfcc0+OPfbYNGvWbNsWvoPanPF68cUX07hx4/zhD3/IHXfckddff12vtg1szpi1aNEi7777btasWZM1a9Ykef9vMmw9m/N3Me87SmNzxqwo7z282yHJ+5cy/+Mv5iZNmmTx4sXr3adJkybr3GfJkiVp2rTpNquT0tmUOcKO7aPMkdWrV+fJJ5/Mueeeu63KoyA2dZ6sXLkyo0ePzuTJk/O1r31tW5ZIiW3KHPntb3+bL3zhC/5wBzu4zelh/nl706ZNXcmxlW2pnvOhhx7KgAED9KHbwOaM2YwZM7LTTjvlE5/4RB555JFtVvOObHPGq7q6OtOmTctXvvKVlJeX54orrkjz5s19OHMr25wx69SpU4499tj85Cc/SVlZWfbdd9+0bNlym9W+I9qcv4t531EaW+pvmaV87+HKG5IkrVq1yrvvvlt3e8WKFWnVqtV691mxYsU69/GLYcexKXOEHdumzpHVq1dnxIgROfPMM9OpU6dtWSIFsKnzpFGjRjn77LPzta99LVdccUVWr169LcukhDY2R+bPn5/ly5fnmWeeyZgxY5Ikf/jDHzJ9+vRtXSpQYpvTw/zz9pqaGr3NVrYles6nn3467733Xk466aStXzCbNWYTJkzIypUrM2bMmFRVVWXixIl5/PHHt1ntO6LNGa+mTZume/fuqaioSHl5eXr37p3Jkydvs9p3VJv7/9ikSZPy7W9/O//rf/2vzJs3L4899tg2q31HtDl/F/O+ozS2xN8yS/3eQ3hDkqR3796prq7OqlWrkiRTpkxJ3759s2zZsrpLnvv27Vu3fmZVVVW6devm0047kE2ZI+zYNmWOrFy5Mr/+9a9z0kknpUePHnn22WdLWTIlsCnz5N57701tbW2SpG3btlmyZElWrlxZsprZtjY2R9q1a5eLLroo/fv3T//+/ZMkJ510kvX0YQe0OT1Mnz59MmPGjLrfN6+99lo++clPluaJ7CA2t+d87LHHsnjx4nzhC19IVVVVZs+eXZonsgPZnDEbPnx43e/qrl27Zr/99stnPvOZkj2XHcHmjNfee++d6urqumNVV1ensrJy2z+JHczmjNn8+fPTunXrumO1adOm7jhsHZvzdzHvO0pjc/+WWYT3HmW1f5817PAmTpyYZ599Ni1btkyDBg1y2mmnZdSoUWnevHn69++flStX5je/+U3atGmTOXPmZMCAAX6Z72A2Nkdqa2tz1113ZezYsdljjz1yxBFHZP/99y912WxDG5sjV111Vd544420adMmyfvfW/GjH/2oxFWzrW1sntx1111ZsGBB2rVrlzfffDN77LFH+vXrV+qy2YY2NkeSZMmSJfnjH/+Y3/3ud/nCF76Q4447Lm3bti1t4cA2tzk9zLhx4zJjxoyUl5enc+fOOe6440r8bLZ/H3e8/vznP+fqq6/ObrvtliRZunRpzjnnnOy9994lfkbbv839O8HYsWPz8MMPp02bNvmXf/kXf6zcyjZnvB5++OFUV1enQYMGWblyZYYMGZLycp/53to+7pi9++67+fWvf5327dunvLw88+bNy5e+9CXfVbSVbc7fxbzvKI2PO2ZFee8hvAEAAAAAACgQEToAAAAAAECBCG8AAAAAAAAKRHgDAAAAAABQIMIbAAAAAACAAhHeAAAAAAAAFIjwBgAAAAAAoECENwAAAAAAAAUivAEAAAAAACiQilIXAADbizvuuCMPP/xwDjjggCxZsiQLFy5My5Ytc9FFF6Vly5Z56aWXcscdd6RBgwZp1KhRzj333HTq1Clr167NjTfemKqqqpSXl6dz584ZPnx4GjduXOqnBAAA7AAeffTR3H333fnEJz6Rpk2bZvr06WndunW+9a1vpVGjRnnppZfy+9//Pg0bNkzjxo1z/vnnp23btkmSF198Mf/93/+dZs2aZc8998xTTz2Vpk2b5stf/nJ69epV4mcGUH+58gYAtpBTTz01+++/fyZNmpSLL744P/rRj9K2bdvcfPPNmTt3bv7v//2/ufDCC3PFFVfkiCOOyH/8x39kzZo1eemll1JdXZ0f/OAHueKKK7J06dIsWbKk1E8HAADYQfTr1y9HHXVUXnnllQwePDg/+tGPMn/+/Dz//POZN29efvKTn+Siiy7K5Zdfnv333z/XXHNNkmTJkiX5yU9+ki996Uu54oor0qtXr8yfPz/Dhw8X3ABsJuENAGxhffv2TZMmTZIkRx55ZJ599tn86U9/Sq9evVJZWZkkOfzww1NdXZ1XX301zZs3T1VVVSZOnJi1a9fm61//etq1a1fKpwAAAOyAPvGJT6R58+YpLy9Ply5dMm/evDz99NPp2bPnOr3Myy+/nIULF+aFF15I69ats/vuuydJDjzwQCsIAGwhlk0DgC2sWbNmdf9u0aJF1qxZk3feeSctW7as215eXp7mzZtnwYIFOfzww3P++efnnnvuyXXXXZd+/fplwIABpSgdAADYgf39Q2hJ0rBhw6xevTqLFy/Om2++mcsvv7xuX/v27bN48eIsWrQoLVq0WOcYzZs331blAmzXhDcAsIUtW7as7t9LlixJgwYNsvPOO2f27Nl129euXZtly5albdu2qampyd57752+fftmzpw5+eEPf5i2bdvmM5/5TCnKBwAAqLPzzjunR48e+e53v1u3bdmyZWnatGlmzpy53pLP/9gPAfDxWTYNALawiRMnZsWKFUmScePG5ZBDDsnhhx+eGTNmZM6cOUmS8ePHp3379tl9993z/PPP59FHH02SdOrUKTvvvHPWrl1bsvoBAAD+7vDDD8+0adNSXV2dJFm8eHEuv/zyrF27Nn379s3ixYszZcqUJMmECROycuXKUpYLsN1w5Q0AbGH77LNPrr322syfPz8tW7bMRRddlJYtW+aSSy7JNddck/Ly8jRq1CiXXnppGjRokN69e+eWW27JhAkT8u6776Zbt2456qijSv00AACAHcTTTz+dJ598MitXrswjjzyS8vLyvPTSS2nUqFEqKyvzta99Lb/4xS/SoEGDlJWV5fzzz09FRUVatmyZb37zmxkxYkRatGiRPn36pE2bNikrKyv1UwKo98pqa2trS10EAGwvrrnmmrRv3z6DBg0qdSkAAABb3bJly9b5npshQ4bkRz/6UXbdddcSVgVQ/1k2DQAAAAD4WH784x/XLZX23HPPpXXr1uncuXOJqwKo/yybBgBbyB133FG3tEC7du1yzDHHlLokAACAreoTn/hEvv/976dRo0ZJkm9961tp0KBBiasCqP8smwYAAAAAAFAglk0DAAAAAAAoEOENAAAAAABAgQhvAAAAAAAACkR4AwAAAAAAUCDCGwAAAAD4/zcKRsEoGAWjYBQMIgAAoFxjuqWjsqQAAAAASUVORK5CYII=",
      "text/plain": [
       "<Figure size 1728x1440 with 4 Axes>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "vader_sentiment_graph(data12)"
   ]
  }
 ],
 "metadata": {
  "interpreter": {
   "hash": "378f15a9c99c0eadcbb489acac60c4a0019363beb3b4f0d5307afa7c06af9fb8"
  },
  "kernelspec": {
   "display_name": "workspace",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.8.8"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 5
}
